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9Gastrointestinal bacterial pathogens
Symptomatic gastrointestinal infections are frequently diagnosed illnesses, and an im-
portant cause of morbidity and mortality worldwide. In the Netherlands about 4.5 mil-
lion episodes of symptomatic gastroenteritis per year are diagnosed with an estimated 
incidence of 11 cases per 1000 people per year in a general practitioner’s population1. In 
developed countries gastrointestinal infections are mostly caused by bacterial patho-
gens, such as Campylobacter, Salmonella, Shigella and Yersinia species and viral patho-
gens such as Norwalk-like virus, Rotavirus, Adenovirus and Astrovirus1,2. Campylobacter, 
Salmonella, Shigella and Yersinia are rod-shaped bacteria of the Enterobacteriaceae fami-
ly. Parasitic infections are also responsible for a large burden of gastrointestinal disease, 
but occur mainly in developing countries3. Typhoidal Salmonella species are bacterial 
gastrointestinal pathogens, endemic in many developing countries with poor hygiene 
and sanitation4,5. In contrast with other bacterial gastrointestinal pathogens, which are 
usually self-limiting diseases, typhoidal Salmonella infections usually require antimicro-
bial treatment. In the past decades, antimicrobial treatment options have been compli-
cated by emergence of antimicrobial resistance5,6. This thesis concerns studies on risk 
factors for gastroenteritis and antimicrobial resistance, and focusses on epidemiology 
and antimicrobial resistance of typhoidal Salmonella species.
Risk factors for gastroenteritis
Gastroenteritis is mostly associated with foodborne transmission. Risk factors for Cam-
pylobacter infections include travelling abroad, eating undercooked chicken, environ-
mental sources, and direct contact with farm animals7. Travel, eating raw eggs, and 
eating in restaurants have been associated with Salmonella infection8. An association 
between proton pump inhibitor (PPI) therapy and bacterial gastroenteritis has been 
suggested as well as contradicted9-17.
There is also an increased incidence of gastroenteritis in patient with HIV18. HIV-in-
fected patients also have an increased risk of more severe disease course of bacterial 
gastroenteritis18. For example, long term carriage or bacteremia after gastroenteritis 
caused by Campylobacter of Salmonella species are more often observed in patient with 
HIV18,19. HIV infection does not seem to be a risk factor for Shigella bacteremia20. More-
over, since 1994 remarkable outbreaks of Shigella infection have been observed in HIV-
infected men who have sex with men, as a sexual transmitted disease21.
1
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Risk factors for antimicrobial resistance
The emergence of bacteria resistant to antimicrobial agents is an emerging global prob-
lem, resulting in limited options for oral treatment, and consequently an increasing 
number of hospital admissions for intravenous treatment22,23. The most important risk 
factors for acquisition of antimicrobial resistance are use of antibiotics and admission 
to health care facilities23. However, multidrug resistant organisms are also often ob-
served in patients without previous hospital contacts or use of antibiotics. Therefore, 
we need a broader approach to study community-acquired risk factors for antimicrobial 
resistance to combat infections caused by these multidrug resistant organisms. Inter-
national travel is considered to be an important risk factor for acquisition of multidrug-
resistant bacteria24-34.
Of all gastrointestinal infections caused by the usual bacterial pathogens (Salmonella, 
Campylobacter, Shigella and Yersinia) typhoidal Salmonella species are the only patho-
gens requiring antimicrobial treatment in immunocompetent patients. Therefore, stud-
ies on antimicrobial resistance, management and epidemiology are most clinically rel-
evant for these species.
Enteric fever
Epidemiology
Enteric fever is the illness caused by Salmonella enterica serotype Typhi (S. Typhi), also 
called typhoid fever5,6. Enteric fever, can also be caused by Salmonella enterica serotype 
Paratyphi A, B and C, sometimes called paratyphoid fever35,36. The bacillus suspected 
to cause enteric fever was first describes by Karl Joseph Eberth in 188037. Until the mid-
twentieth century, enteric fever was endemic in developed countries such as the Neth-
erlands38. Nowadays enteric fever is mainly a disease of developing countries and is 
occasionally diagnosed in ill returned travellers in developed countries3,4. Enteric fever 
has an estimated worldwide yearly incidence of 26.9 million episodes and the highest 
incidence in Southern Asia35. In contrast with other Salmonella species which have a 
strictly zoonotic reservoir, typhoidal Salmonella species only have human transmission. 
Transmission occurs by feco-oral route and therefore infections are mostly foodborne, 
due to poor sanitation and lack of clean water.
Clinical presentation
Enteric fever is a systemic febrile disease. The symptoms vary widely and therefore it is 
difficult to define a classical presentation of the disease. Abdominal complains are most 
frequently reported, such as abdominal pain accompanied by diarrhoea and (counterin-
tuitively) often constipation6,36.
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Enteric fever has been associated with relative bradycardia (pulse-temperature dissocia-
tion), which may also be caused by other tropical infectious diseases such as malaria39. 
This might therefore not be a very useful feature for clinical use. Typical laboratory 
abnormalities in typhoid fever are decreased or normal leukocyte count with aneosino-
philia, moderate thrombocytopenia, increased C-reactive protein, increased liver en-
zymes. Newer diagnostics such as procalcitonin have not been shown to have additional 
value compared to these traditional laboratory values in the diagnosis of enteric fever40.
Risk factors
There is conflicting evidence regarding the risk of enteric fever in HIV-positive patients. 
Patient who are infected with HIV might have an increased risk of infection with typhoi-
dal Salmonella41. However, a more recent publication observed a protective effect on ac-
quiring a typhoidal Salmonella infection42,43. This in great contrast to non-typhoidal Sal-
monella infections which are the most important cause of bacteraemia in HIV positive 
patients in sub-Saharan Africa19. Another possible risk factor for typhoidal Salmonella 
infections is proton pump inhibitor therapy. Use of PPIs probably leads to an increased 
risk of enteric infections, because diminishing gastric acid leads to increased survival of 
Salmonella species. This has only been demonstrated for non-typhoidal Salmonella spe-
cies, but based on the biological effect this will probably hold for typhoidal Salmonella 
species as well44,45.
Diagnostics and treatment
To confirm the diagnosis of enteric fever, a positive blood culture is considered as the 
gold standard46,47. Typhoidal Salmonella species can be isolated from stool, urine or ce-
rebral fluid as well. The Widal test is an old serologic assay for detecting IgM and IgG 
to the antigens of Salmonella. The test is unreliable but is still widely used in most de-
veloping countries because of its low cost46,47. Further, it is possible to detect typhoidal 
Salmonella species using other diagnostics, such as polymerase chain reaction (PCR) or 
Maldi-Tof48-50. A new serological assays (TPTest) is currently under research, but not yet 
used in clinical practice in the Netherlands51.
As a result of the wide presence of multidrug-resistant (MDR) Salmonella strains (de-
fined as resistance against chloramphenicol, amoxicillin and trimethoprim) in the 80s 
and 90s, infections caused by typhoidal Salmonella strains are now treated with fluo-
roquinolones, third generation cephalosporins or azithromycin6,52. Treatment has been 
complicated by the emergence of fluoroquinolone resistance in Asian countries6,52. Be-
cause of cases of treatment failure in systemic infections caused by Salmonella spp with 
low-level ciprofloxacin resistance (MIC 0.125–1.0 mg/L), it is now stated by the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) that all Salmonella isolates 
with an MIC >0.06 mg/L should be considered ciprofloxacin resistant and should be 
treated otherwise53. In the majority of the cases enteric fever is acquired in Asia, where 
12
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third generation cephalosporines and azithromycin are the only treatment options left. 
Typhoidal Salmonella strains expressing extended-spectrum beta-lactamases have been 
sporadically described from Asian countries54-55. Cases of azithromycin resistance in 
typhoidal Salmonella infection are still very uncommon56-57.
Aim of the thesis
The overall aim of this thesis was to study risk factors and treatment options in gastro-
intestinal infections, especially in typhoidal Salmonella isolates.
Primary research questions
1 To study risk factors of gastrointestinal infections and antimicrobial resistance
2 What are the most important mechanisms involved in antimicrobial resistance in 
typhoidal Salmonella isolates?
3 Can a new rapid diagnostic methodology be developed to identify antimicrobial re-
sistance in typhoidal Salmonella isolates?
Outline of this thesis
To avoid treatment challenges it is best to prevent gastrointestinal infection. PPIs are 
among the most frequently prescribed drugs worldwide and in many cases the indica-
tion is doubtful. In Chapter 2 we studied the association between proton pump in-
hibitor therapy and Campylobacter, (non-typhoidal) Salmonella, Yersinia or Shigella in-
fection in community-dwelling non-hospitalized individuals in The Rotterdam Study, a 
population-based cohort study. Another possible cause of emergence of antimicrobial 
resistance is introduction of multi-drug resistant microorganisms in the community 
as a result of international travel. In Chapter 3 a systematic review was performed to 
study the available evidence of the association of international travel and asymptomatic 
fecal carriage of multidrug-resistant Enterobacteriaceae.
Chapter 4 describes the different mechanisms involved in reduced susceptibility 
to ciprofloxacin of S. Typhi and S. Paratyphi A isolates from travellers to South-East 
Asia. In all of these cases, resistance to fluoroquinolone-based antibiotics is associated 
with genetic mutations in the quinolone resistance-determining region (QRDR) of the 
bacterial DNA gyrase gene, gyrA. Though these mutations are invariably detected by 
sequencing of the gyrA gene, phenotypically important QRDR mutations also result in 
amino acid substitutions in the GyrA protein of typhoidal Salmonellae, which could po-
tentially be detected using high resolution mass spectrometry techniques. In Chapter 
13
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5 we demonstrate the development and evaluation of a liquid chromatography-mass 
spectrometry (LC-MS) methodology for the detection of amino acid substitutions in the 
GyrA protein of the 23 typhoidal Salmonella isolates used in Chapter 4. In the same 
travellers of the previous two chapters we studied the impact of decreased ciprofloxacin 
susceptibility on the fate of travellers returning with enteric fever in Chapter 6. Possible 
alternative treatment options based on pharmacokinetic parameters of different fluoro-
quinolones were also determined in Chapter 6. In many countries azithromycin is the 
only antibiotic left for oral treatment of enteric fever. In Chapter 7 we analysed trends 
in susceptibility to azithromycin among typhoidal Salmonella isolates in isolates already 
possessing increased MICs for ciprofloxacin in an epidemiological study, using all avail-
able typhoidal Salmonella isolates collected in the Netherlands during 1999-2012. Re-
sistance to azithromycin is still very rare in gastrointestinal pathogens. Chapter 8, a 
case report of Shigella flexneri infection with treatment failure due to azithromycin re-
sistance, acts as an example of a future problem, namely occurrence of antimicrobial 
resistance to this “last resort” antimicrobial drug.
Chapter 9 outlines and reflects on the main findings of the thesis. Limitations and 
methodological considerations will be discussed as well as clinical implications and fu-
ture research.
14
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Abstract
Background  An association between proton pump inhibitor (PPI) therapy and bacte-
rial gastroenteritis has been suggested as well as contradicted. The aim of this study 
was to examine the association between the use of PPIs and occurrence of bacterial 
gastroenteritis in the prospective Rotterdam Study.
Methods  The Rotterdam Study is a population-based cohort study among 14 926 
subjects aged 45 years and older with up to 24 years of follow-up. Analyses were per-
formed with a generalized estimating equations method in participants who handed-in 
a diagnostic stool sample. Furthermore, a nested case-control analysis was performed 
using the total cohort as a reference group.
results  A bacterial microorganism was isolated in 125 samples, whereas 1174 samples 
were culture negative. In the generalized estimating equations analysis, we found that 
participants with a bacterial gastroenteritis were more likely than controls to be current 
users of PPIs (adjusted OR, 1.94; 95% CI 1.15-3.25). Different sensitivity analyses did not 
change this result. A considerably higher effect was observed (adjusted OR 6.14; 95% CI 
3.81-9.91), using the total cohort as a reference in a nested case-control analysis.
conclusions  Current PPI therapy is associated with an increased risk of bacterial gas-
troenteritis. However, by reducing the risk of selection and information bias in our study 
design, we demonstrated that the effect is lower than previously assumed.
22
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Introduction
Proton pump inhibitors (PPIs) are among the most frequently prescribed drugs world-
wide, but seem to be associated with an increased risk of bacterial gastroenteritis1-9. 
As a result warnings are introduced for people using PPIs, such as avoiding raw meat 
consumption and antibiotic treatment on demand for travels to the tropics, to prevent 
food borne infections. This cohort study was designed to asses if the magnitude of this 
risk, warrants preventive recommendations.
Common indications for PPIs are dyspepsia, peptic ulcer disease, reflux esophagitis, and 
Barrett’s oesophagus10. PPIs reduce gastric acid production by up to 99% by irreversible 
blocking of H+/K+ ATPase of parietal cells in the stomach11. They have a maximal effect 
within 4 days and the effect may persist up to three days after stopping use12. Associa-
tions between PPIs and infectious adverse events such as pneumonia, Clostridium diffi-
cile-associated diarrhoea and bacterial gastroenteritis have often been described1-9,13-17. 
An increased risk of gastroenteritis might be explained by the strong reduction in gastric 
acid resulting in increased susceptibility to bacterial infections. Exogenous bacteria are 
usually destroyed in the stomach when the pH is less than 3.0. For species such as Vibrio 
cholerae and Campylobacter jejuni it has been shown in vitro that they are very sensitive 
to pH18. However, Salmonella species have been found to respond to low pH by develop-
ing adaptive mechanisms that allow survival in acid environments19. Furthermore, PPIs 
change the gut flora, which provides a homeostatic protection against ingested patho-
gens20,21. PPIs also reduce the antibacterial activity of neutrophils which may facilitate 
Salmonella and Campylobacter infection22,23. Several case-control studies have shown an 
increased risk of acquiring gastrointestinal infections caused by Campylobacter or Sal-
monella species in patients using PPIs1-8. In these case-control studies, a relatively high 
adjusted odds ratio (aOR) or relative risk was observed, ranging from 2.9 to 11.7. In one 
nested case-control study, in which participants with a gastroenteritis prior to first PPI 
prescription were excluded, a considerably lower effect was observed (aOR 1.6)9. It has 
even been stated that there is no evidence that PPIs are associated with gastrointestinal 
infections based on outcomes adjusted for pre-treatment susceptibility to bacterial gas-
trointestinal infections and time-dependent confounding factors24, which observation 
suggests that previous case-control studies have suffered from selection or information 
bias. Therefore, we designed a nested case control study within The Rotterdam Cohort, 
a prospective cohort study, to examine the association between the use of PPIs and oc-
currence of bacterial gastroenteritis. To minimize the risk of information bias we used 
participants with negative stool samples as a control group. To test the hypothesis that 
an incorrect control group will influence the study results we also analysed the associa-
tion using the total cohort as a control group.
23
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Materials and methods
Study population
The study was performed in The Rotterdam Study, a prospective population-based co-
hort study in 14,926 people aged ≥45 years, from one district (Ommoord) in the city 
of Rotterdam, the Netherlands25. In short, from 1990 through 1993, 7983 participants 
were included (cohort I). In 2000 an additional 3011 participants who had become 55 
years old or older or who had moved into the district, were enrolled (cohort II). In 2006 
another 3932 participants, aged 45 years and older were included (cohort III). Follow-
up examinations are conducted every four to five years. Participants are continuously 
monitored through linkage of records from general practitioners.
The Rotterdam Study was approved by the medical ethics committee according to the 
Wet Bevolkingsonderzoek ERGO (Population Study Act Rotterdam Study) executed by 
the Ministry of Health, Welfare and Sports of the Netherlands. All study participants 
provided written informed consent.
Definition of outcome
A case was defined as a community-dwelling non-hospitalized individual with a posi-
tive stool sample for Campylobacter, Salmonella, Yersinia or Shigella species. A control 
was defined as an individual with a negative stool sample. Stool sample results were 
obtained from Star Medisch Diagnostisch Centrum (Star-MDC), a centre for medical 
diagnostics for outpatients in the city of Rotterdam. The majority of all laboratory 
tests, including microbiology tests, of patients from general practitioners within the 
Ommoord district of Rotterdam are performed at Star-MDC. Of all participants of The 
Rotterdam Study, of whom informed consent was obtained for requesting medical in-
formation, positive and negative microbiology tests between 1999 and April 2013 were 
obtained. Stool samples were selected and samples in which parasites were isolated 
were excluded. Detection of bacterial enteric pathogens in stool samples at Star-MDC 
is performed by Multiplex polymerase chain reaction (PCR), followed by culture and 
microscopy in case of a positive result. Until December 2010, when PCR was introduced 
at Star-MDC, detection of bacterial enteric pathogens was performed by conventional 
culture and microscopy only.
Assessment of exposure and covariables
Participants were considered as current user of PPI if the calendar date of the stool 
sample fell within a prescription episode of a PPI. Prescription episodes were calculated 
by dividing the total number of supplied pills by the recommended daily number. Ad-
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ditional covariables assessed were age, sex, cohort, calendar date (year), BMI, house-
hold status, past use of proton pump inhibitors, current or past use of H2-receptor 
antagonists, current use of chronic medication (antidiabetic medication, antihyper-
tensive medication, or statins), intestinal anti-inflammatory agents, corticosteroids, 
immunosuppressant medication, meat consumption, red meat consumption, chicken 
consumption, egg consumption and alcohol consumption (for all dietary variables: yes/
no and gram/days).
BMI and household status was obtained from baseline characteristics of The Rotterdam 
Study. Medication use was obtained through automated linkage with pharmacy filled 
prescription data, available from January 1st, 1991 until April 2013. Dietary data were 
available from one week food consumption questionnaires obtained at the first visit 
of cohort I and cohort III and at the third visit of cohort II. Multiple imputation (10x) of 
missing dietary data and BMI was performed using all covariables.
Statistical analyses
Model design
To assess the association between current use of PPIs and gastrointestinal infections 
generalized estimating equations (GEE) was used to adjust for correlation between re-
peated measurements in the same participants, using a varying between-measurement 
time window26,27. The working correlation matrix in which the model had the lowest 
quasi likelihood under independence model criterion was selected. The model was ad-
justed for age and sex and additionally for covariables changing the point estimate (β) of 
current PPI use by more than 10% or if considered clinically relevant.
Sensitivity analyses
Different sensitivity analyses were performed. To exclude confounding by indication 
or protopathic bias we recoded PPI use started within 14 days before a positive stool 
sample as non-use. To take into account that in many occasions PPIs are not used on a 
daily basis, and therefore the actual period of exposure will probably exceed the period 
calculated based on the pharmacy data, we also included use during the past 14 days 
and 30 days as potentially exposed cases in sensitivity analyses. To exclude confound-
ing by contra-indication we censored every participant at the first case in a sensitivity 
analysis. Participants receiving medication from other sources than the pharmacy, such 
as nursing home residents, might introduce information bias. Therefore we did a sensi-
tivity analysis excluding participants without pharmacy prescriptions during the last 90 
days because nursing home residents do not obtain medication through a community 
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pharmacy. Furthermore, we performed a sensitivity analysis for Campylobacter species 
and Campylobacter or Salmonella species only. Different analyses were stratified on sex.
Additional analysis
We also analysed the exposure of PPIs in a nested case-control analysis to assess the 
association between PPIs and gastrointestinal infections in the total population of The 
Rotterdam Study. The use of PPIs was used as a time-varying determinant of exposure 
as previously described28. To use the total population of The Rotterdam Study every 
case (participant with a positive stool sample) was matched to every other participant 
alive and eligible at the same calendar date (day). Each time a case was identified, ex-
posure in this case was compared with exposure in the other participants (cases might 
become controls, and controls might become cases). The model was adjusted for age 
and sex and additionally for covariables used in the final model.
A two-sided p-value below 0.05 was considered statistically significant. Statistical anal-
yses were performed using SPSS version 21.0 (IBM Corp., Somers, NY, USA).
Results
During the study period, 1329 stool cultures of participants of The Rotterdam Study were 
identified at Star-MDC. We excluded 30 stool samples because of isolation of a parasite, 
resulting in 1299 stool samples for the study. A bacterial microorganism was isolated 
in 125 samples, whereas 1174 samples were culture negative. In total 105 (84.0%) Cam-
pylobacter species, 16 (12.8%) Salmonella species, 3 (2.4%) Yersinia species and 1 (0.8%) 
Shigella sonnei were isolated. All 125 positive stool samples were collected from 118 dif-
ferent participants and all 1174 negative stool samples from 903 different participants. 
The percentage of missing data of BMI was 7.6% and of dietary data 28.6%. Character-
istics of cases and controls are shown in table 1.
Model design
For the generalized estimating equations, the independent working correlation struc-
ture had the best fit. Designing the final model, past use of H2-receptor antagonists 
increased the point estimate (β) of current PPI use, adjusted for age and sex, by more 
than 10%, whereas current use of chronic medication, all decreased the effect by more 
than 10%. We included age, sex, cohort, calendar date, past use of proton pump inhibi-
tors, past use of H2-receptor antagonists, and current use of chronic medication in the 
final model (model 2). In the final model we found that participants with a bacterial 
gastroenteritis were more likely than control participants to be current users of PPIs, 
with an aOR of 1.94 (95% CI 1.15-3.25) [table 2].
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Table 1 Baseline characteristics of participants with stool sample
Participants with  
positive stool sample
Participants with 
negative stool sample
Total 118* 903
Age - yr (SD) 65.1 ±10.3 68.1 ±12.8
Male sex – no. (%) 49 (41.5) 301 (33.3)
Cohort (%)
 – I
 – II
 – III
34 (28.8)
35 (29.7)
49 (41.5)
325 (36.0)
227 (25.1)
351 (38.9)
Household alone – no. (%) 20 (16.9) 229 (25.4)
BMI‡ (SD) 25.2 ±4.2 24.5 ±4.3
Use of proton pump inhibitors – no. (%)
 – Current use for 14 days or more
 – Including use during past 14 days
 – Including use during past 30 days
 – >1 Defined Daily Dose/day
 – Past use only
43 (36.4)
32 (27.1)
50 (42.4)
55 (46.6)
13 (30.2)
33 (28.0)
242 (26.8)
152 (16.8)
269 (29.8)
288 (31.9)
76 (31.4)
289 (32.0)
Medication use – no. (%)
 – H2-receptor antagonists
 – H2-receptor antagonists – past use
 – Antidiabetic medication
 – Antihypertensive medication
 – Statins
 – Antidiabetic, antihypertensive medication or statins
 – Intestinal anti-inflammatory agents
 – Corticosteroids
 – Immunosuppressant medication
3 (2.5)
37 (31.4)
12 (10.2)
50 (42.4)
27 (22.9)
55 (46.6)
1 (0.8)
3 (2.5)
0
22 (2.4)
312 (34.6)
93 (10.3)
316 (35.0)
151 (16.7)
376 (41.6)
4 (0.4)
15 (1.7)
6 (0.7)
Dietary – no. (%)
 – No meat consumer†
 – No red meat consumer∏
 – No chicken consumer∏
 – No egg consumer∏
 – Alcohol$
 – Dietary – gram/days (SD)
 – Meat†
 – Red meat∏
 – Chicken∏
 – Eggs∏
 – Alcohol$ 
2 (2.4)
2 (2.4)
15 (18.3)
5 (6.1)
72 (61.0)
110.9 ±60.4
91.7 ±55.0
17.1 ±18.1
15.0 ±11.1
13.0 ±15.7
6 (0.7)
11 (1.2)
105 (11.6)
48 (5.3)
558 (61.8)
103.3 ±54.4
85.5 ±50.0
16.4 ±16.5
15.7 ±12.9
13.4 ±15.2
* out of total 125 positive isolates
† Patients with positive stool sample N = 82, negative stool sample N = 644
‡ Patients with positive stool sample N = 111, negative stool sample N = 839
∏ Patients with positive stool sample N = 82, negative stool sample N = 646
$ Patients with positive stool sample N = 93, negative stool sample N = 712 
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Sensitivity analyses
Different sensitivity analyses did not result in a significant change of the effect [table 
2]. A sensitivity analysis including use during the past 14 days and 30 days resulted in 
aORs of 2.14 (95% CI 1.35-3.38) and 2.28 (95% CI 1.46-3.55), respectively. Excluding cur-
rent use of PPIs for 14 days or more, to exclude confounding by indication or protopathic 
bias, resulted in an aOR of 1.99 (95% CI 1.19-3.35). Censoring at the first case, to exclude 
confounding by contra-indication, resulted in an aOR of 2.02 (95% CI 1.19-3.42) and ex-
cluding participants without prescriptions during the last 90 days in an aOR of 1.78 (95% 
CI 1.05-3.01). An aOR of 1.93 (95% CI 1.11-3.36) and 2.05 (95% CI 1.20-3.49) was observed in 
sensitivity analyses for including only Campylobacter and Campylobacter or Salmonella, re-
spectively (table 2). After stratifying on sex a difference was observed between male (aOR 
3.28; 95% CI 1.44-7.49) and female (aOR 1.31; 95% CI 0.66 ; 2.60) participants [table 2].
Additional analysis
In a matched case-control analysis, adjusting for the same covariables of the final mod-
el, but using all other participants of The Rotterdam Study as control group, a consider-
Table 2 Association of use of proton pump inhibitors with bacterial gastrointestinal infections Generalized 
estimating equations method , negative stool cultures as control group
Number 
of cases
Number 
in cohort 
Use of 
PPI (%)
Cases
N = 125
OR (95% CI)
P value
Current use of proton pump inhibitor:
Univariate analysis
Adjusted analysis – model 1
Adjusted analysis – model 2
125
125
125
1299
1299
1299
375 (28.9)
375 (28.9)
375 (28.9)
1.50 (1.01 ; 2.23)
1.62 (1.09 ; 2.43)
1.94 (1.15 ; 3.25)
0.047
0.018
0.013
Sensitivity analyses – model 2:
Only including current use for 14 days  
or more
Including use during past 14 days
Including use during past 30 days
Censored at first case
Excluding no medication for >90 days
125
125
125
118
124
1299
1299
1299
1246
1223
242 (18.2)
422 (32.5)
453 (34.9)
353 (28.3)
375 (30.7)
1.99 (1.19 : 3.35)
2.14 (1.35 : 3.38)
2.28 (1.46 ; 3.55)
2.02 (1.19 ; 3.42)
1.78 (1.05 ; 3.01)
0.009
0.001
<0.001
0.009
0.032
Campylobacter only
Campylobacter and Salmonella
105
121
1279
1295
368 (28.8)
375 (29.0)
1.93 (1.11 ; 3.36)
2.05 (1.20 ; 3.49)
0.019
0.008
Male only
Female only
53
72
436
863
131 (30.0)
244 (28.3)
3.28 (1.44 ; 7.49)
1.31 (0.66 ; 2.60)
0.005
0.45
Model 1: adjusted for sex, age
Model 2: adjusted for sex, age, cohort, calendar date, past use of proton pump inhibitors, current use of chronic medi-
cation, past use of H2-receptor antagonists
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ably higher aOR of 6.14 ( 95% CI 3.81-9.91) was observed compared to the GEE analysis 
using negative stool samples as control group [table 3].
Discussion
PPIs have been associated with an increased risk of bacterial gastroenteritis in previous 
studies1-9. In this population based cohort study we found that current PPI therapy was 
associated with a strongly increased risk of bacterial gastroenteritis, with an aOR of 
more than six. However, this risk decreased to 1.94 after restriction to the subgroup with 
stool samples. Therefore, we suspect that information bias inflated the risks in other 
population based studies which have shown an association between PPI therapy and 
an increased risk of Campylobacter and Salmonella infections before. Although, people 
using PPIs still should be careful consuming food which could be contaminated, such 
as beef, poultry or processed food, the risk of gastroenteritis is probably less than previ-
ously assumed.
One of the strengths of our study is that we tried to use a comparable control group by 
only using participants with negative stool samples. In most of the previous population 
based studies the magnitude of the effect may have been overestimated as a result of 
the use of incomparable control groups. Typically, case control studies regarding use of 
PPIs may suffer from a “healthy control” bias. We further tried to avoid healthy control 
Table 3 Association of use of proton pump inhibitors with bacterial gastrointestinal infections.Nested 
case-control analysis – all other participants of The Rotterdam Study as control group
Total cohort N = 12515
Number 
of cases
Number 
in cohort
Use of 
PPI (%)
Infections N = 125
OR (95% CI)
P value
Current use of proton pump inhibitor
Univariate analysis
Adjusted analysis – model1
Adjusted analysis – model2
125
125
125
12515
12515
12515
11.7*
11.7*
11.7*
3.35 (2.31;4.87)
4.03 (2.77;5.87)
6.14 (3.81;9.91)
<0.001
<0.001
<0.001
Male only – model2
Female only – model2
53
72
5113
7402
10.2†
12.7‡
11.07(5.51;22.24)
3.83 (1.96;7.47)
<0.001
<0.001
Model 1: adjusted for sex, age
Model 2: adjusted for sex, age, cohort, calendar date, past use of proton pump inhibitors, current use of chronic medi-
cation, past use of H2-receptor antagonists
* percentage over 125 strata
† percentage over 53 strata
‡ percentage over 72 strata
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bias by correcting for the use of chronic medication. Some of the previous studies used 
a random sample of population registries, or volunteering friends or relatives of the 
cases as control group2,4-6. These participants are probably healthier and will therefore 
differ considerably from the cases. But also commonly used strategies, such as using 
matched controls, obtained from general practitioner databases, will not prevent infor-
mation bias1. Studies considering self-limiting diseases such as gastroenteritis, might 
select a “help seeking” and therefore biased population. As a consequence, people us-
ing a PPI will be more inclined to consult medical help in case of gastroenteritis com-
pared to randomly selected controls, even if they are matched.
Residual confounding might also have influenced previous study results, because di-
etary pattern, which has been shown to be the most important risk factors for Cam-
pylobacter and Salmonella infections has not been included in these studies29,30. An as-
sociation with dietary data was not observed in our study. Unfortunately, the number of 
missing dietary data in our study was rather high with as a consequence a large number 
of imputed data.
Observational studies may always suffer from bias and residual confounding. We had no 
data on other important risk factors for bacterial gastroenteritis, such as foreign travel-
ling, eating in a restaurant, or contact with animals29,30.
We believe we used a comparable control group using participants with negative stool 
samples. However, results from a test-negative study design may also underestimate 
the risk, since a number of the controls with negative stool cultures may be false-nega-
tives. They can be false-negative either because of low diagnostic sensitivity against the 
four bacterial species (e.g., too little material received, long transportation time, stool 
collected many days after onset of gastroenteritis) or because the patient suffered from 
other causes of bacterial gastroenteritis (diarrheagenic Escherichia coli or Clostridium 
difficile). 
Furthermore, in elderly gastric acid secretion is impaired compared to younger aged 
individuals31. If gastric acid secretion is already impaired, PPIs will have a smaller effect. 
Therefore, the smaller risk estimate in our study might be explained by the fact that 
our population mainly consisted of elderly, in which gastric acid secretion is already 
impaired.
Because Salmonella species are less susceptible to pH, the association between PPI 
therapy and gastroenteritis might be smaller for Salmonella species19. Unfortunately, 
however, the number of Salmonella infections in this study was too small to draw con-
clusions on this association.
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During the study period the method of detection of enteric pathogens changed by the 
introduction of PCR, resulting in an increased sensitivity. To correct for an increased risk 
of false negative stool samples in the earlier years of the study, we included calendar 
date and cohort in the assessment of model design.
Although male gender has been shown to be an independent risk factor for bacterial 
gastroenteritis, it has not been shown before that the association between PPI therapy 
and bacterial gastroenteritis is much higher for males32. We were unable to explain this 
result by other covariables. Possibly there are unmeasured (hygiene related) behavioural 
aspects to explain this difference. In experimental studies a gender difference was ob-
served between male and female neutrophils. Male neutrophils show higher respon-
siveness to stimulation with lipopolysaccharide and interferon-Υ33. Neutrophils play an 
important role in Salmonella and Campylobacter infections22,23. The harmful effect of 
PPIs may therefore be greater for male than for female subjects. Of course, studies are 
needed to test this rather speculative hypothesis.
In conclusion, current PPI therapy was associated with an increased risk of bacterial 
gastroenteritis. We demonstrated that the effect is lower than previously assumed, by 
reducing the risk of information bias in our study design.
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Abstract
International travel is considered to be an important risk factor for acquisition of multi-
drug-resistant Enterobacteriaceae (MRE). The aim of this systematic review was to deter-
mine the effect of international travel on the risk of post-travel faecal carriage of MRE. 
Secondary outcomes were risk factors for acquisition of MRE. A systematic search for 
relevant literature in seven international databases was conducted according to Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 
Articles needed to report on (I) foreign travel, (II) screening in asymptomatic partici-
pants, (III) antimicrobial susceptibility data and (IV) faecal Enterobacteriaceae carriage. 
Two researchers independently screened the abstracts, assessed the full article texts for 
eligibility and selected or rejected them for inclusion in the systematic review. In case 
of disagreement, a third researcher decided on inclusion. Eleven studies were identified. 
In all studies, a high prevalence (>20%) of carriage of MRE after international travel was 
found. The highest prevalence was observed in travellers returning from Southern Asia. 
Foreign travel was associated with an increased risk of carriage of MRE. Further research 
is needed to assess if this leads to an increase in the number of infections with MRE. 
Systematic review registration number: PROSPERO CRD42015024973.
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Introduction
Rationale
Worldwide, the number of international travellers has grown from 25 million in 1950 
to 1087 million in 20131. According to the World Tourism Organization, this number is 
expected to increase by an average of 3.3% a year1. Of the international travellers visit-
ing the developing countries, 22-64% have self-reported health problems, and about 
8% require medical care during or after travel2,3. Healthy travellers may be exposed to a 
broad range of microorganisms while travelling, including drug-resistant Enterobacteria-
ceae, which may subsequently be introduced into their home country4,5.
Enterobacteriaceae are Gram-negative bacteria that are part of the human body’s nor-
mal commensal flora, called microbiota. Enterobacteriaceae, such as Escherichia coli and 
Klebsiella species, are capable of causing both healthcare-associated, and community-
acquired infections6. Multidrug-resistant Enterobacteriaceae (MRE), including extended 
spectrum beta-lactamase (ESBL) producing Enterobacteriaceae (ESBL-E) and plasmid-me-
diated Amp-C producing Enterobacteriaceae (pAmp C-E) are emerging worldwide7. Cases of 
carbapenemase-producing Enterobacteriaceae (CPE) are also reported more frequently8.
Since 2003, community carriage rates of MRE have increased dramatically in various re-
gions, such as South-East Asia, the Western Pacific and the Eastern Mediterranean7. Dur-
ing visits to such areas, travellers might acquire MRE and become asymptomatic carriers 
of MRE. In their home country, they may cause spread in the community and contribute 
to worldwide emerging antimicrobial resistance6,9,10. Acquired MRE in the digestive tract 
are considered apathogenic, however carriage of such Enterobacteriaceae have resulted in 
clinically relevant infections8. International travel has been reported as a risk factor for uri-
nary tract infections caused by ESBL-E11,12. The question arises if these observations war-
rant clinicians being aware for MRE in recently returned otherwise healthy, international 
travellers who seek medical attention even for unrelated conditions.
Objectives
The aim of this systematic review was to determine the effect of international travel on 
the risk of acquisition of faecal carriage of MRE. A secondary objective was to determine 
risk factors for acquisition of drug resistance.
Methods
Protocol and registration
A specific protocol was designed and used to conduct the study. The study is registered 
in the International prospective register of systematic reviews (PROSPERO) under regis-
tration number CRD42015024973.
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Search strategy and selection criteria
The systematic review was conducted according to Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) guidelines13. The following databases 
were searched, attempting to identify all relevant studies: Embase, MEDLINE, Web of 
Science, Scopus, Cochrane Library, PubMed publisher and Google Scholar. The latest 
search was conducted on 17 August 2015.
The topic search terms used for searching the databases were “Gram negative bac-
teria”, “Gram negative bacterial infections”, “Enterobacteriaceae”, “Escherichia”, “Kleb-
siella”, “Campylobacter”, “Salmonella”, “Shigella”, “Yersinia”, “travel”, “traveller”, “tour-
ist”, “tourism”, “turista”, “aviation”, “air transport”, “airport”, “colonisation”, “carriage”, 
“carrier”, “susceptibility” and “(multiple) drug resistance”.
The queries differed per database searched and were developed with help of a biomedi-
cal information specialist (Supplement 1). Articles written in English, German, French 
and Dutch were included.
For inclusion the article needed to fulfil the following criteria: (1) it needed to be related 
to foreign travel (2), report on screening in asymptomatic participants (3), present an-
timicrobial susceptibility data and (4) report on faecal Enterobacteriaceae carriage. We 
used the following exclusion criteria: case reports, reviews, meta-analysis, veterinary 
medicine, in vitro studies, and studies regarding symptomatic patients. The reference 
list of reviews were screened to identify studies possibly missed by the search.
Two researchers (R.H. and J.A.) independently performed the screening of the abstracts. 
Any discordant result was discussed in consensus meetings. After screening the ab-
stracts, the full text of the articles was assessed for eligibility by the same two research-
ers and selected or rejected for inclusion in the systematic review. In case of disagree-
ment a third researcher (A.V.) decided on inclusion.
Data collection process
The following data (if available) were extracted from each article: year of publication, 
country of the study, study period, study design, microorganism studied, study popula-
tion, study size, age, sex, sample time before and after travel, duration of travel, travel-
ling in pairs or groups, symptoms during travel, countries visited, MRE prevalence before 
travel, MRE prevalence after travel, MRE resistance acquired during travel, resistance to 
other antibiotic drugs of acquired MRE, risk factors for acquisition (among which travel 
to predefined United Nations geographical region: southern Asia, Asia except southern 
Asia, Africa, South and Central America, North America, Europe and Oceania14), method 
of MRE susceptibility determination, phenotypic approaches, genotypic characteriza-
tion of post-travel MRE isolates, molecular typing of post-travel MRE isolates, duration 
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of MRE colonisation and MRE transmission to household contacts. To obtain missing 
data, authors of the article were contacted.
Quality assessment
We assessed the methodological quality and the risk of bias in individual studies that 
may affect the cumulative evidence, using tools for assessing quality and susceptibility 
to bias in observational studies as recommended in the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) Statement15,16.
Data synthesis and analysis
As a result of the design of the studies (cohort studies) and the heterogeneity in patient 
populations (e.g. travellers, healthcare workers and healthcare students) a formal meta-
analysis was not possible. Therefore, the study results were summarised to describe the 
main outcomes of interest. The principle summary measure was percentage of MRE 
acquisition during travel, defined as ESBL-E or pAmp C-E. Furthermore, risk factors for 
acquisition of drug resistance were assessed. If possible, percentages not presented in 
the articles were calculated from available data.
Results
Study selection
A total of 2398 studies were identified through database searching after duplicates had 
been removed [figure 1]. After screening of titles and summaries, 36 articles were se-
lected for full-text assessment. Eleven articles were included in qualitative synthesis of 
the systematic review [see figure 1 for reasons for exclusion]17-27.
Study characteristics
Eleven prospective cohort studies, conducted in northern and western Europe, Australia 
and the United States (US) were included17-27. Characteristics of these studies are shown 
in table 1. Nine studies investigated travellers visiting a travel or vaccination clinic, one 
study hospital staff and contacts, and one study healthcare students working or study-
ing abroad. The number of study participants ranged from 28 to 574. The median age of 
travellers in the individual studies varied between 25 and 66 years, with the youngest 
group being healthcare students. In all studies, the majority of travellers were female 
(range: 55-78%). The proportion of participants who were lost to follow up varied from 
3.8% (4/106)18 to 30% (12/40)21. The mean duration of travel was similar in all studies 
(14–21 days). In the study of Angelin et al. on healthcare students, median length of stay 
was 45 days (range: 13-365 days)22. In four studies, follow-up samples of MRE carriers 
were collected at six months after returning from travel, and in one of these studies, 
samples were collected monthly in the first three months with further follow-up until 12 
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months after return25. Ten studies used a phenotypic method for susceptibility testing, 
with genotypic confirmation of ESBL positivity by PCR17-22,24-27. One study used a PCR-
based approach23. In one study, only isolated E. coli were included, whereas the other 
studies included all isolated Enterobacteriaceae, which mainly consisted of E. coli17-27.
Figure 1 Flowchart for literature search on the acquisition of multidrug-resistant Enterobacteriaceae in 
international travel (n=4,989)
Articles identified in Embase, 
MEDLINE, Web of Science, Scopus, 
The Cochrane Library, PubMed and 
Google Scholar (n=5189)
Articles identified by 
searching references in 
published articles  
(n=0)
Duplicates removed 
(n=2791)
Articles ineligible based 
on title and/or abstract 
(n=2362)
Studies excluded for the following reasons (n=25)
Letter to the editor (n=2)
Review (n=4)
Study design (n=1)
Oral or poster presentation (n=3)
No ESBL- Enterobacteriaceae (n=6)
Symptomatic patients (n=7)
No travel (n=1)
Results of a follow-up study (n=1)
Articles screened 
(n=2398)
Articles retrieved for 
further evaluation (n=36)
Articles included in 
systematic review (n=11)
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Table 1 Characteristics of prospective cohort studies included for systematic review of the acquisition  
of multidrug-resistant Enterobacteriaceae in international travel (n=11)
Study Country Study period Population
Characteristics
Study 
sizea
Median Age 
in years 
(range or SD)
Proportion 
of women 
in %
Identification of MRE-
positive organisms in 
post-travel isolates
Sample 
method 
used
Sample time 
(range) before/
after travel
Mean duration 
of travel in 
days (range)
Total number 
of co-travellers 
participating in 
study
Follow-up 
of resistant 
isolates
Tängdén17 Sweden November 2007 - 
31 January 2009
Travel clinic 100 43 (2-84) 55 Enterobacteriaceae  
100% (24/24) E.coli
Stool Unknown 14 (1-26) 23 6 months
Kennedy18 Australia January 2008 – 
April 2009
Hospital staff 
and contacts
102 45 (17-77) 62 E.coli Rectal or 
perianal 
swab
Within 2 weeks  
before and after
21 (9-135) Unknown 6 months
Östholm-
Balkhed19
Sweden September 2008 - 
April 2009
Vaccination clinic 231 54 (18-76) 59 Enterobacteriaceae
90% (104/116) E.colib
Stool 
sample
15 (1-114) days /  
3 (0-191) days
16 (4-119) Unknown None
Kantele20 Finland March 2009 - 
February 2010
Travel clinic 430 40 (0-77) 61 Enterobacteriaceae
97% (94/97) E. colib
Stool 
sample
Before and first (or 
second) stool after
19 (4-133) 83 None
Weisenberg21 United States July 2009 - 
February 2010
Travel clinic 28 66 (41-83) 68 Enterobacteriaceae
100% (7/7) E. colib
Stool 
sample
1 week before /
1 week after
16 (8-24) Unknown None
Angelin22 Sweden April 2010 - 
January 2014
Healthcare 
students
99 25 (20-15) 78 Enterobacteriaceae
100% (36/36)) E. colic
Stool 
sample
Close to departure /
1 to 2 weeks after 
returning
45 (13-365)d Unknown None
von 
Wintersdorff23
The Netherlands November 2010 - 
August 2012
Travel clinic 122 43 (18-72) 58 Not done Stool 
sample
Before and  
immediately after
21 (5-240) Unknown None
Paltansing24 The Netherlands March 2011 - 
September 2011
Travel clinic 370 33 (19-82) 63 Enterobacteriaceae
92% (146/158) E. colic
Rectal 
swab
Immediately before 
and after
21 (6-90) None 6 months
Ruppé25 France February 2012 - 
April 2013
Vaccination 
Centres
574 36 (SD 13) 61 Enterobacteriaceae
93% (491/526) E. colib
Stool 
sample
Within 1 week  
before and after
20 (15-30) None 12 months
Kuenzli26 Switzerland December 2012 - 
October 2013
Travel clinic 170 41 (30-53) 56 Enterobacteriaceae
98% (157/161) E. colib
Rectal 
swab
1 week before /  
directly after
18 (5-35) Unknown None
Lübbert27 Germany May 2013 –  
April 2014
Travel clinic 205 34 (3-76) 57 Enterobacteriaceae  
92% (58/63) E. colib
Stool 
sample
Before/ within  
1 week after
21 (3-218) 22 6 months
E.coli: Escherichia coli; MRE: multidrug-resistant Enterobacteriaceae; SD: standard deviation.
a Number of travellers who provided pre- and post-travel swab.
b Data of MRE-positive isolates newly acquired during travel.
c Data of MRE-positive isolates post-travel.
d Healthcare students, median duration of stay.
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Table 1 Characteristics of prospective cohort studies included for systematic review of the acquisition  
of multidrug-resistant Enterobacteriaceae in international travel (n=11)
Study Country Study period Population
Characteristics
Study 
sizea
Median Age 
in years 
(range or SD)
Proportion 
of women 
in %
Identification of MRE-
positive organisms in 
post-travel isolates
Sample 
method 
used
Sample time 
(range) before/
after travel
Mean duration 
of travel in 
days (range)
Total number 
of co-travellers 
participating in 
study
Follow-up 
of resistant 
isolates
Tängdén17 Sweden November 2007 - 
31 January 2009
Travel clinic 100 43 (2-84) 55 Enterobacteriaceae  
100% (24/24) E.coli
Stool Unknown 14 (1-26) 23 6 months
Kennedy18 Australia January 2008 – 
April 2009
Hospital staff 
and contacts
102 45 (17-77) 62 E.coli Rectal or 
perianal 
swab
Within 2 weeks  
before and after
21 (9-135) Unknown 6 months
Östholm-
Balkhed19
Sweden September 2008 - 
April 2009
Vaccination clinic 231 54 (18-76) 59 Enterobacteriaceae
90% (104/116) E.colib
Stool 
sample
15 (1-114) days /  
3 (0-191) days
16 (4-119) Unknown None
Kantele20 Finland March 2009 - 
February 2010
Travel clinic 430 40 (0-77) 61 Enterobacteriaceae
97% (94/97) E. colib
Stool 
sample
Before and first (or 
second) stool after
19 (4-133) 83 None
Weisenberg21 United States July 2009 - 
February 2010
Travel clinic 28 66 (41-83) 68 Enterobacteriaceae
100% (7/7) E. colib
Stool 
sample
1 week before /
1 week after
16 (8-24) Unknown None
Angelin22 Sweden April 2010 - 
January 2014
Healthcare 
students
99 25 (20-15) 78 Enterobacteriaceae
100% (36/36)) E. colic
Stool 
sample
Close to departure /
1 to 2 weeks after 
returning
45 (13-365)d Unknown None
von 
Wintersdorff23
The Netherlands November 2010 - 
August 2012
Travel clinic 122 43 (18-72) 58 Not done Stool 
sample
Before and  
immediately after
21 (5-240) Unknown None
Paltansing24 The Netherlands March 2011 - 
September 2011
Travel clinic 370 33 (19-82) 63 Enterobacteriaceae
92% (146/158) E. colic
Rectal 
swab
Immediately before 
and after
21 (6-90) None 6 months
Ruppé25 France February 2012 - 
April 2013
Vaccination 
Centres
574 36 (SD 13) 61 Enterobacteriaceae
93% (491/526) E. colib
Stool 
sample
Within 1 week  
before and after
20 (15-30) None 12 months
Kuenzli26 Switzerland December 2012 - 
October 2013
Travel clinic 170 41 (30-53) 56 Enterobacteriaceae
98% (157/161) E. colib
Rectal 
swab
1 week before /  
directly after
18 (5-35) Unknown None
Lübbert27 Germany May 2013 –  
April 2014
Travel clinic 205 34 (3-76) 57 Enterobacteriaceae  
92% (58/63) E. colib
Stool 
sample
Before/ within  
1 week after
21 (3-218) 22 6 months
E.coli: Escherichia coli; MRE: multidrug-resistant Enterobacteriaceae; SD: standard deviation.
a Number of travellers who provided pre- and post-travel swab.
b Data of MRE-positive isolates newly acquired during travel.
c Data of MRE-positive isolates post-travel.
d Healthcare students, median duration of stay.
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Table 2 Risk of multi-drug-resistant Enterobacteriaceae in travellers (n=11 studies)
Study Method of MRE 
determination
Phenotypic 
approaches
Results genotypic 
characterisation  
post-travel MRE isolates
Results  
molecular  
typing of  
post-travel  
MRE isolates
MRE 
prevalence 
pre-travel 
% (ratio)
MRE 
prevalence 
post-travel 
% (ratio)
New MRE 
acquisition 
during 
travel % 
(ratio)a
Persistent newly 
acquired MRE carriage 
6 months after travel % 
(ratio)
Results univariate
/multivariable risk 
factor analysis for 
MRE acquisition
MRE in  
non-travelling 
household 
contacts % 
(ratio)
Tängdén17 Phenotypic approach 
with genotypic 
confirmation by PCR
Enrichment broth, 
selective media, 
AST: Etest, MRE 
confirmation: disc 
diffusion
TEM (n=11) , SHV (n=3), CTX-M 
group 1 (n=14) of which 
CTX-M-15 (n=13), CTX-M-1 
(n=1), CTX-M group 4 (n=10) 
of which CTX-M-9 (n=3), 
CTX-M-14 (n=5), CTX-M-27 
(n=2)b
No data 1
(1/105)
No data 24
(24/100)
24
(5/21)
Gastroenteritis
travel to Indiac
No data
Kennedy18 Phenotypic approach 
with genotypic 
confirmation by PCR
Enrichment broth, 
selective media, 
AST: Vitek2, MRE 
confirmation: disc 
diffusion
TEM or SHV (n=4), CTX-M 
group 1 (n=12), CTX-M group 
9 (n=6), and pAmp C genes 
(n=4)d
No data 2
(2/106)
22
(22/102)
21
(21/100)
6
(1/18)
Gastroenteritis
Use of antibiotics
travelling to Asia,  
South America and/or 
Middle East/Africae,c
No data
Östholm-
Balkhed19
Phenotypic approach 
with genotypic 
confirmation by PCR
Selective media, 
AST: Etest, MRE 
confirmation: Etest
TEM-19 (n=1), SHV (n=6), 
CTX-M-15-like (n=36), CTX-
M-14-like (n=36), CTX-M-
27-like (n=5), CTX-M-53-like 
(n=5), CTX-M-1/61 like (n=3), 
CTX-M-2 like (n=2), CTX-M-3-
like (n=1), pAmpC genes (n=15), 
no genes detected (n=13)b 
No data 2
(6/251)
31
(72/231)
30
(68/226)
No data Age
Diarrhoea or other 
gastrointestinal 
symptoms, travel to 
Asia, Africa (north
of equator), Indian 
subcontinentf
No data
Kantele20 Phenotypic approach 
with genotypic 
confirmation by PCR
Selective media, 
AST: Vitek2, MRE 
confirmation: disc 
diffusion
79% CTX-M-type (CTX-M-1 
and CTX-M-9 most prevalent), 
other common strains TEM and 
OXA (data not published)b
No data 1
(5/430)
22
(93/430)
21
(90/430)
No data Traveller’s diarrhoea, 
age, use of antibiotics 
for traveller’s 
diarrhoeaf
No data
Weisenberg21 Phenotypic approach 
with genotypic 
confirmation by PCR
Selective media, 
AST: Vitek2, MRE 
confirmation: disc 
diffusion
SHV-12 (n=1), CTX-M-14 (n=3), 
CTX-M-15 (n=2), no gene 
detected (n=1)b
MLST typing
7 multidrug-resistant 
E. coli isolates: ST 
39, 8 (n=2), 37, 399, 
437, 83
4
(1/28)
25
(7/28)
26
(7/27)
No data No data No data
Angelin22 Phenotypic approach 
for detection of 
ESBL, pAmp C and 
phenotypic approach 
with genotypic 
characterization for 
detection of OXA-48/ 
OXA-181
Selective media, AST: 
disc diffusion, MRE 
confirmation: Etest 
(ESBL), disc diffusion 
(pAmpC)
No data No data 7
(7/99)
36
(36/99)
35
(35/99)
No data Travel to the  
South-East Asia 
region (India, Nepal, 
Vietnam, Indonesia, 
Sri Lanka), antibiotic 
treatment during 
travelg
No data
von 
Wintersdorff23
Metagenomic 
approach
(detection blaCTX-M)
No data blaCTX-M (n=41)d No data 9
(11/122)
34
(41/122)
32
(36/111)
No data Travel to Indian 
subcontinentf
No data
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Table 2 Risk of multi-drug-resistant Enterobacteriaceae in travellers (n=11 studies)
Study Method of MRE 
determination
Phenotypic 
approaches
Results genotypic 
characterisation  
post-travel MRE isolates
Results  
molecular  
typing of  
post-travel  
MRE isolates
MRE 
prevalence 
pre-travel 
% (ratio)
MRE 
prevalence 
post-travel 
% (ratio)
New MRE 
acquisition 
during 
travel % 
(ratio)a
Persistent newly 
acquired MRE carriage 
6 months after travel % 
(ratio)
Results univariate
/multivariable risk 
factor analysis for 
MRE acquisition
MRE in  
non-travelling 
household 
contacts % 
(ratio)
Tängdén17 Phenotypic approach 
with genotypic 
confirmation by PCR
Enrichment broth, 
selective media, 
AST: Etest, MRE 
confirmation: disc 
diffusion
TEM (n=11) , SHV (n=3), CTX-M 
group 1 (n=14) of which 
CTX-M-15 (n=13), CTX-M-1 
(n=1), CTX-M group 4 (n=10) 
of which CTX-M-9 (n=3), 
CTX-M-14 (n=5), CTX-M-27 
(n=2)b
No data 1
(1/105)
No data 24
(24/100)
24
(5/21)
Gastroenteritis
travel to Indiac
No data
Kennedy18 Phenotypic approach 
with genotypic 
confirmation by PCR
Enrichment broth, 
selective media, 
AST: Vitek2, MRE 
confirmation: disc 
diffusion
TEM or SHV (n=4), CTX-M 
group 1 (n=12), CTX-M group 
9 (n=6), and pAmp C genes 
(n=4)d
No data 2
(2/106)
22
(22/102)
21
(21/100)
6
(1/18)
Gastroenteritis
Use of antibiotics
travelling to Asia,  
South America and/or 
Middle East/Africae,c
No data
Östholm-
Balkhed19
Phenotypic approach 
with genotypic 
confirmation by PCR
Selective media, 
AST: Etest, MRE 
confirmation: Etest
TEM-19 (n=1), SHV (n=6), 
CTX-M-15-like (n=36), CTX-
M-14-like (n=36), CTX-M-
27-like (n=5), CTX-M-53-like 
(n=5), CTX-M-1/61 like (n=3), 
CTX-M-2 like (n=2), CTX-M-3-
like (n=1), pAmpC genes (n=15), 
no genes detected (n=13)b 
No data 2
(6/251)
31
(72/231)
30
(68/226)
No data Age
Diarrhoea or other 
gastrointestinal 
symptoms, travel to 
Asia, Africa (north
of equator), Indian 
subcontinentf
No data
Kantele20 Phenotypic approach 
with genotypic 
confirmation by PCR
Selective media, 
AST: Vitek2, MRE 
confirmation: disc 
diffusion
79% CTX-M-type (CTX-M-1 
and CTX-M-9 most prevalent), 
other common strains TEM and 
OXA (data not published)b
No data 1
(5/430)
22
(93/430)
21
(90/430)
No data Traveller’s diarrhoea, 
age, use of antibiotics 
for traveller’s 
diarrhoeaf
No data
Weisenberg21 Phenotypic approach 
with genotypic 
confirmation by PCR
Selective media, 
AST: Vitek2, MRE 
confirmation: disc 
diffusion
SHV-12 (n=1), CTX-M-14 (n=3), 
CTX-M-15 (n=2), no gene 
detected (n=1)b
MLST typing
7 multidrug-resistant 
E. coli isolates: ST 
39, 8 (n=2), 37, 399, 
437, 83
4
(1/28)
25
(7/28)
26
(7/27)
No data No data No data
Angelin22 Phenotypic approach 
for detection of 
ESBL, pAmp C and 
phenotypic approach 
with genotypic 
characterization for 
detection of OXA-48/ 
OXA-181
Selective media, AST: 
disc diffusion, MRE 
confirmation: Etest 
(ESBL), disc diffusion 
(pAmpC)
No data No data 7
(7/99)
36
(36/99)
35
(35/99)
No data Travel to the  
South-East Asia 
region (India, Nepal, 
Vietnam, Indonesia, 
Sri Lanka), antibiotic 
treatment during 
travelg
No data
von 
Wintersdorff23
Metagenomic 
approach
(detection blaCTX-M)
No data blaCTX-M (n=41)d No data 9
(11/122)
34
(41/122)
32
(36/111)
No data Travel to Indian 
subcontinentf
No data
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Study Method of MRE 
determination
Phenotypic 
approaches
Results genotypic 
characterisation  
post-travel MRE isolates
Results  
molecular  
typing of  
post-travel  
MRE isolates
MRE 
prevalence 
pre-travel 
% (ratio)
MRE 
prevalence 
post-travel 
% (ratio)
New MRE 
acquisition 
during 
travel % 
(ratio)a
Persistent newly 
acquired MRE carriage 
6 months after travel % 
(ratio)
Results univariate
/multivariable risk 
factor analysis for 
MRE acquisition
MRE in  
non-travelling 
household 
contacts % 
(ratio)
Paltansing24 Phenotypic approach 
with genotypic 
characterisation by 
microarray
Enrichment broth, 
selective media, 
AST: Vitek2, MRE 
confirmation: disc 
diffusion
SHV (n=1), CTX-M group 1 
(n=110) of which CTX-M-1-like 
(n=4), CTX-M-3-like (n=1), 
CTX-M-15-like (n=85), CTX-M-
32-like (n=20), CTX-M-group 9 
(n=42), CTX-M-group 2 (n=2), 
CTX-M-group 8/25 (n=1), 
pAmpC genes (n=3)d
MLST typing: 146 
multidrug-resistant 
E. coli isolates: most 
prevalent ST 38 
(n=17), ST10 (n=10), 
ST131 (n=9)
9
(32/370)
36
(133/370)
33
(113/338)
17
(19/113)
Travel to South  
or East Asiaf
18
(2/11)
Ruppé25 h Phenotypic approach 
with genotypic 
confirmation by PCR
Enrichment broth, 
selective media, AST: 
disc diffusion
Predominant CTX-M-type 
(95.4%) among which  
CTX-M-group 1 predominated 
(83.7% of all CTX-M), OXA-181 
(N=2), NDM-1 (n=1)b
No data 12
(81/700)
No data 51
(292/574)
After 1 month 34 (83/245),
after 2 months 19 (45/236),
after 3 months 10 (24/233),
after 6 months 5 (11/230),
after 12 months 2 (5/227)
Travel to Asia or  
sub-Saharan Africa, 
beta-lactam use 
during travel, 
diarrhoea during 
travel, type of travelf
No data
Kuenzli26 Phenotypic approach 
with genotypic 
screening by 
microarray and 
confirmation by 
PCR/DNA sequence 
analysis
Enrichment broth, 
selective media, 
AST: Vitek2, MIC for 
meropenem and 
ertapenem: Etest, 
MRE confirmation: 
disc diffusion, 
modified Hodge test
TEM-1-like (n=33), 
SHV238S/240K (n=7), 
SHV238S (n=1), SHV-5/12-like 
(n=1), SHV-2/3-like (n=1),  
CTX-M-15-like (n=48), CTX-M 
group 9 (n=1), CTX-M group 
1 (n=24), predominant ESBL 
gene was CTX-M-15 (80 
representative E. coli isolates 
analysed), NDM-1 (n=1)b 
80 representative  
E. coli isolates 
analysed by rep-PCR: 
not clonally related. 
MLST performed 
on 34 randomly 
selected
E. coli isolates: only 
3 pandemic strains 
found (ST131 n=2; 
ST648 n=1)
3
(5/175)
No data 70
(118/170)
No data Travel to India, 
Bhutan, or Nepal,
visiting friends and 
relatives,
consumption of ice 
cream and pastry, 
Length of stayf
No data
Lübbert27 Phenotypic approach 
with genotypic 
confirmation by PCR
Selective media,AST: 
microbroth dilution 
method, MRE 
confirmation:E-test
SHV-12 (n=1), CTX-M group 
1 (n=37), of which CTX-M-15 
(N=33), CTX-M-55 (n=4), 
CTX-M group 9 (n=19) of which 
CTX-M-14 (n=9), CTX-M-27 
(n=1), CTX-M-65 (n=1)b
7
(14/205)
31
(63/205)
30
(58/191)
9
(3/35)
Travel to India or 
South-East Asia,
Gastroenteritisc
No data
AST: antibiotic susceptibility testing; bla: beta-lactamase; CTX-M: cefotaximase; E. coli: Escherichia coli; ESBL: extended-
spectrum beta-lactamase; KPC: Klebsiella pneumoniae carbapenemase; MLST: Multilocus sequence typing; MRE multidrug-
resistant Enterobacteriaceae; NDM: New Delhi metallo-beta-lactamase; OXA: oxacillinase; pAmp C: plasmid-borne AMpC; 
PCR: polymerase chain reaction; PFGE: pulsed-field gel electrophoresis; rep-PCR: repetitive extragenic palindromic PCR; SHV:  
Sulphydryl variable; TEM: Temoniera.
a Percentage of MRE- positive post-travel samples in those travellers whose pre-travel sample was MRE-negative.
b Acquired genes detected in post-travel MRE isolates.
c Univariate statistics.
d Prevalent genes detected in post-travel MRE isolates.
e Risk factors for resistance to gentamicin, ciprofloxacin and/or third generation cephalosporins.
f Multivariable logistic regression analysis; participants ESBL-positive before travel were excluded.
g Binary regression analysis.
h Carbapenemase-positive isolates were included in the definition MRE.
Table 2 (sequel)
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Study Method of MRE 
determination
Phenotypic 
approaches
Results genotypic 
characterisation  
post-travel MRE isolates
Results  
molecular  
typing of  
post-travel  
MRE isolates
MRE 
prevalence 
pre-travel 
% (ratio)
MRE 
prevalence 
post-travel 
% (ratio)
New MRE 
acquisition 
during 
travel % 
(ratio)a
Persistent newly 
acquired MRE carriage 
6 months after travel % 
(ratio)
Results univariate
/multivariable risk 
factor analysis for 
MRE acquisition
MRE in  
non-travelling 
household 
contacts % 
(ratio)
Paltansing24 Phenotypic approach 
with genotypic 
characterisation by 
microarray
Enrichment broth, 
selective media, 
AST: Vitek2, MRE 
confirmation: disc 
diffusion
SHV (n=1), CTX-M group 1 
(n=110) of which CTX-M-1-like 
(n=4), CTX-M-3-like (n=1), 
CTX-M-15-like (n=85), CTX-M-
32-like (n=20), CTX-M-group 9 
(n=42), CTX-M-group 2 (n=2), 
CTX-M-group 8/25 (n=1), 
pAmpC genes (n=3)d
MLST typing: 146 
multidrug-resistant 
E. coli isolates: most 
prevalent ST 38 
(n=17), ST10 (n=10), 
ST131 (n=9)
9
(32/370)
36
(133/370)
33
(113/338)
17
(19/113)
Travel to South  
or East Asiaf
18
(2/11)
Ruppé25 h Phenotypic approach 
with genotypic 
confirmation by PCR
Enrichment broth, 
selective media, AST: 
disc diffusion
Predominant CTX-M-type 
(95.4%) among which  
CTX-M-group 1 predominated 
(83.7% of all CTX-M), OXA-181 
(N=2), NDM-1 (n=1)b
No data 12
(81/700)
No data 51
(292/574)
After 1 month 34 (83/245),
after 2 months 19 (45/236),
after 3 months 10 (24/233),
after 6 months 5 (11/230),
after 12 months 2 (5/227)
Travel to Asia or  
sub-Saharan Africa, 
beta-lactam use 
during travel, 
diarrhoea during 
travel, type of travelf
No data
Kuenzli26 Phenotypic approach 
with genotypic 
screening by 
microarray and 
confirmation by 
PCR/DNA sequence 
analysis
Enrichment broth, 
selective media, 
AST: Vitek2, MIC for 
meropenem and 
ertapenem: Etest, 
MRE confirmation: 
disc diffusion, 
modified Hodge test
TEM-1-like (n=33), 
SHV238S/240K (n=7), 
SHV238S (n=1), SHV-5/12-like 
(n=1), SHV-2/3-like (n=1),  
CTX-M-15-like (n=48), CTX-M 
group 9 (n=1), CTX-M group 
1 (n=24), predominant ESBL 
gene was CTX-M-15 (80 
representative E. coli isolates 
analysed), NDM-1 (n=1)b 
80 representative  
E. coli isolates 
analysed by rep-PCR: 
not clonally related. 
MLST performed 
on 34 randomly 
selected
E. coli isolates: only 
3 pandemic strains 
found (ST131 n=2; 
ST648 n=1)
3
(5/175)
No data 70
(118/170)
No data Travel to India, 
Bhutan, or Nepal,
visiting friends and 
relatives,
consumption of ice 
cream and pastry, 
Length of stayf
No data
Lübbert27 Phenotypic approach 
with genotypic 
confirmation by PCR
Selective media,AST: 
microbroth dilution 
method, MRE 
confirmation:E-test
SHV-12 (n=1), CTX-M group 
1 (n=37), of which CTX-M-15 
(N=33), CTX-M-55 (n=4), 
CTX-M group 9 (n=19) of which 
CTX-M-14 (n=9), CTX-M-27 
(n=1), CTX-M-65 (n=1)b
7
(14/205)
31
(63/205)
30
(58/191)
9
(3/35)
Travel to India or 
South-East Asia,
Gastroenteritisc
No data
AST: antibiotic susceptibility testing; bla: beta-lactamase; CTX-M: cefotaximase; E. coli: Escherichia coli; ESBL: extended-
spectrum beta-lactamase; KPC: Klebsiella pneumoniae carbapenemase; MLST: Multilocus sequence typing; MRE multidrug-
resistant Enterobacteriaceae; NDM: New Delhi metallo-beta-lactamase; OXA: oxacillinase; pAmp C: plasmid-borne AMpC; 
PCR: polymerase chain reaction; PFGE: pulsed-field gel electrophoresis; rep-PCR: repetitive extragenic palindromic PCR; SHV:  
Sulphydryl variable; TEM: Temoniera.
a Percentage of MRE- positive post-travel samples in those travellers whose pre-travel sample was MRE-negative.
b Acquired genes detected in post-travel MRE isolates.
c Univariate statistics.
d Prevalent genes detected in post-travel MRE isolates.
e Risk factors for resistance to gentamicin, ciprofloxacin and/or third generation cephalosporins.
f Multivariable logistic regression analysis; participants ESBL-positive before travel were excluded.
g Binary regression analysis.
h Carbapenemase-positive isolates were included in the definition MRE.
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Table 3 Proportion of travellers who acquired multidrug-resistant Enterobacteriaceae, by travel destination  
(n=11 studies)
Study Southern Asia % 
(ratio)
Asia except southern 
Asia % (ratio)
Northern Africa % 
(ratio)
Sub-Saharan  
Africa % (ratio)
South and Central 
America % (ratio)
North America %  
(ratio)
Europe %  
(ratio)
Oceania %  
(ratio)
Tängdén17 a,b 78
(7/9)
29
(10/34)
33
(4/12)
4
(1/23)
0
(0/7)
0
(0/2)
13
(2/16)
No data
Kennedy18 a,c 57
(8/14)
25
(21/85)
33
(1/3)
0
(0/2)
20
(1/5)
20
(2/10)
14
(3/21)
0
(0/2)
Östholm-Balkhed19 a,b 71
(10/14)
43
(26/60)
57
(17/30)
21
(15/71)
16
(5/31)
0
(0/15)
0
(0/15)
No data
Kantele20 b,d 46
(28/61)
32
(37/116)
67
(2/3)
12
(23/193)
0
(0/40)
0
(0/2)
0
(0/15) No data
Weisenberg21 b 29
(2/7)
25
(1/4)
33
(1/3)
13
(1/8)
33
(2/6)
No data No data No data
Angelin22 63
(25/40)
67
(6/9)
- 10
(4/40)
0
(0/5)
0
(0/4)
No data No data
von Wintersdorff23 c 58
(18/31)
20
(6/29)
31
(5/16)
29
(5/17)
0
(0/10)
No data 17
(1/6)
No data
Paltansing24 b,e 72
(18/25)
41
(62/161)
40
(4/10)
24
(20/82)
15
(9/60)
No data No data No data
Ruppé25 f 88
(53/60)
66
(61/93)
No data 49
(89/182)
31
(48/155)
No data No data 0
(0/2)
Kuenzli26 b 69
(118/170)
No data No data No data No data No data No data No data
Lübbert27 a,b 72
(13/18)g
33
(24/73)g
No data 24
(19/78)
8
(6/78)
0
(0/2)
20
(2/10)
No data
MRE: multidrug-resistant Enterobacteriaceae.
a Travellers visiting more than one region are categorised in all the visited geographical regions.
b Study reports data on MRE acquisition in travellers.
c Study reports data on MRE prevalence in travellers.
d Travellers visiting more than one region are categorised in the geographical region with the longest stay for this study.
e One traveller who visited Iran is categorised in Asia instead of Southern Asia.
f 42 travellers visited more than one country in Asia and may be represented in more than one column in the Table;  
28 of them acquired MRE.
g Exact numbers unpublished.
Southern Asia: Afghanistan, Bangladesh, Bhutan, India, Islamic Republic of Iran, Maldives, Nepal, Pakistan, Sri Lanka.
Asia (without southern Asia) Armenia, Azerbaijan, Bahrain, Brunei, Cambodia, China, Cyprus, Darussalam, Democratic 
People’s Republic of Korea, Georgia, Hong Kong, Indonesia, Iraq, Israel, Jordan, Japan, Kazakhstan, Kuwait, Kyrgyzstan, 
Laos, Lebanon, Mongolia, Malaysia, Myanmar, North Korea, Oman, Philippines, Qatar, Republic of Korea, Saudi Arabia, 
South Korea, Singapore, Palestine, Syrian, Tajikistan, Thailand, Timor-Leste, Turkey, Turkmenistan, United Arab Emirates, 
Uzbekistan, Viet Nam, Yemen.
Northern Africa: Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, Western Sahara.
Sub-Saharan Africa: Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, 
Chad, Comoros, Congo (Brazzaville), Côte d’Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, 
Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauri-
tius, Mozambique, Namibia, Niger, Nigeria, Réunion, Rwanda, Sao Tomé and Principe, Senegal, Seychelles, Sierra Leone, 
Somalia, South Africa, Sudan, Swaziland, Tanzania, The Gambia, Togo, Uganda, Western Sahara, Zambia, Zimbabwe.
South and Central America: Anguilla, Antigua and Barbuda, Argentina, Aruba, Bahamas, Barbados, Belize, Bolivia, Bo-
naire, Sint Eustatius and Saba, Brazil, British Virgin Islands, Cayman Islands, Chile, Colombia, Costa Rica, Cuba, Curaçao, 
Dominica, Dominican Republic, Ecuador, El Salvador, Falkland Islands, French Guiana, Grenada, Guadeloupe, Guate-
mala, Guyana, Haiti, Honduras, Jamaica, Martinique, Mexico, Montserrat, Nicaragua, Panama, Paraguay, Peru, Puerto, 
Rico, Saint Kitts and Nevis, Saint Lucia, Saint Martin, Saint Vincent and the Grenadines, Saint-Barthélemy, Sint Maarten, 
Suriname, Trinidad and Tobago, Turks and Caicos Islands, US Virgin Islands, Uruguay, Venezuela
North America: Bermuda, Canada, Greenland, Saint Pierre and Miquelon, United States.
Europe: Åland Islands, Albania, Andorra, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Channel Islands, 
Croatia, Czech Republic, Denmark, Estonia, Faeroe Islands, Finland, the former Yugoslav Republic of Macedonia, France, 
Germany, Gibraltar, Greece, the Holy See, Hungary, Iceland, Ireland, Isle of Man, Italy, Latvia, Liechtenstein, Lithuania, 
Luxembourg, Malta, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Moldova, Romania, Russia, San 
Marino, Serbia, Slovakia, Slovenia, Spain, Svalbard and Jan Mayen, Sweden, Switzerland, Ukraine, United Kingdom.
Oceania: American Samoa, Australia, Cook Islands, Fiji, French Polynesia, Guam, Kiribati, Marshall Islands, Microne-
sia, Nauru, New Caledonia, New Zealand, Niue, Norfolk Island, Northern Mariana Islands, Palau, Papua New Guinea, 
Pitcairn Islands, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu, Wallis and Futuna.
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Table 3 Proportion of travellers who acquired multidrug-resistant Enterobacteriaceae, by travel destination  
(n=11 studies)
Study Southern Asia % 
(ratio)
Asia except southern 
Asia % (ratio)
Northern Africa % 
(ratio)
Sub-Saharan  
Africa % (ratio)
South and Central 
America % (ratio)
North America %  
(ratio)
Europe %  
(ratio)
Oceania %  
(ratio)
Tängdén17 a,b 78
(7/9)
29
(10/34)
33
(4/12)
4
(1/23)
0
(0/7)
0
(0/2)
13
(2/16)
No data
Kennedy18 a,c 57
(8/14)
25
(21/85)
33
(1/3)
0
(0/2)
20
(1/5)
20
(2/10)
14
(3/21)
0
(0/2)
Östholm-Balkhed19 a,b 71
(10/14)
43
(26/60)
57
(17/30)
21
(15/71)
16
(5/31)
0
(0/15)
0
(0/15)
No data
Kantele20 b,d 46
(28/61)
32
(37/116)
67
(2/3)
12
(23/193)
0
(0/40)
0
(0/2)
0
(0/15) No data
Weisenberg21 b 29
(2/7)
25
(1/4)
33
(1/3)
13
(1/8)
33
(2/6)
No data No data No data
Angelin22 63
(25/40)
67
(6/9)
- 10
(4/40)
0
(0/5)
0
(0/4)
No data No data
von Wintersdorff23 c 58
(18/31)
20
(6/29)
31
(5/16)
29
(5/17)
0
(0/10)
No data 17
(1/6)
No data
Paltansing24 b,e 72
(18/25)
41
(62/161)
40
(4/10)
24
(20/82)
15
(9/60)
No data No data No data
Ruppé25 f 88
(53/60)
66
(61/93)
No data 49
(89/182)
31
(48/155)
No data No data 0
(0/2)
Kuenzli26 b 69
(118/170)
No data No data No data No data No data No data No data
Lübbert27 a,b 72
(13/18)g
33
(24/73)g
No data 24
(19/78)
8
(6/78)
0
(0/2)
20
(2/10)
No data
MRE: multidrug-resistant Enterobacteriaceae.
a Travellers visiting more than one region are categorised in all the visited geographical regions.
b Study reports data on MRE acquisition in travellers.
c Study reports data on MRE prevalence in travellers.
d Travellers visiting more than one region are categorised in the geographical region with the longest stay for this study.
e One traveller who visited Iran is categorised in Asia instead of Southern Asia.
f 42 travellers visited more than one country in Asia and may be represented in more than one column in the Table;  
28 of them acquired MRE.
g Exact numbers unpublished.
Southern Asia: Afghanistan, Bangladesh, Bhutan, India, Islamic Republic of Iran, Maldives, Nepal, Pakistan, Sri Lanka.
Asia (without southern Asia) Armenia, Azerbaijan, Bahrain, Brunei, Cambodia, China, Cyprus, Darussalam, Democratic 
People’s Republic of Korea, Georgia, Hong Kong, Indonesia, Iraq, Israel, Jordan, Japan, Kazakhstan, Kuwait, Kyrgyzstan, 
Laos, Lebanon, Mongolia, Malaysia, Myanmar, North Korea, Oman, Philippines, Qatar, Republic of Korea, Saudi Arabia, 
South Korea, Singapore, Palestine, Syrian, Tajikistan, Thailand, Timor-Leste, Turkey, Turkmenistan, United Arab Emirates, 
Uzbekistan, Viet Nam, Yemen.
Northern Africa: Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, Western Sahara.
Sub-Saharan Africa: Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, 
Chad, Comoros, Congo (Brazzaville), Côte d’Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, 
Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauri-
tius, Mozambique, Namibia, Niger, Nigeria, Réunion, Rwanda, Sao Tomé and Principe, Senegal, Seychelles, Sierra Leone, 
Somalia, South Africa, Sudan, Swaziland, Tanzania, The Gambia, Togo, Uganda, Western Sahara, Zambia, Zimbabwe.
South and Central America: Anguilla, Antigua and Barbuda, Argentina, Aruba, Bahamas, Barbados, Belize, Bolivia, Bo-
naire, Sint Eustatius and Saba, Brazil, British Virgin Islands, Cayman Islands, Chile, Colombia, Costa Rica, Cuba, Curaçao, 
Dominica, Dominican Republic, Ecuador, El Salvador, Falkland Islands, French Guiana, Grenada, Guadeloupe, Guate-
mala, Guyana, Haiti, Honduras, Jamaica, Martinique, Mexico, Montserrat, Nicaragua, Panama, Paraguay, Peru, Puerto, 
Rico, Saint Kitts and Nevis, Saint Lucia, Saint Martin, Saint Vincent and the Grenadines, Saint-Barthélemy, Sint Maarten, 
Suriname, Trinidad and Tobago, Turks and Caicos Islands, US Virgin Islands, Uruguay, Venezuela
North America: Bermuda, Canada, Greenland, Saint Pierre and Miquelon, United States.
Europe: Åland Islands, Albania, Andorra, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Channel Islands, 
Croatia, Czech Republic, Denmark, Estonia, Faeroe Islands, Finland, the former Yugoslav Republic of Macedonia, France, 
Germany, Gibraltar, Greece, the Holy See, Hungary, Iceland, Ireland, Isle of Man, Italy, Latvia, Liechtenstein, Lithuania, 
Luxembourg, Malta, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Moldova, Romania, Russia, San 
Marino, Serbia, Slovakia, Slovenia, Spain, Svalbard and Jan Mayen, Sweden, Switzerland, Ukraine, United Kingdom.
Oceania: American Samoa, Australia, Cook Islands, Fiji, French Polynesia, Guam, Kiribati, Marshall Islands, Microne-
sia, Nauru, New Caledonia, New Zealand, Niue, Norfolk Island, Northern Mariana Islands, Palau, Papua New Guinea, 
Pitcairn Islands, Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu, Wallis and Futuna.
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Acquisition of multidrug-resistant Enterobacteriaceae
Faecal carriage of MRE varied from 1 to 12% before travel and acquisition of MRE from 
21% to 51% [table 2]17-21, 23-27.
In the study of Kuenzli et al. on travellers to the Indian subcontinent only, a much higher 
MRE acquisition rate of 69% was demonstrated26. The risk of acquisition of MRE varied 
with geographical region [table 3]17-21,23-27. Travel to southern Asia posed the highest 
risk (range: 29–88%), followed by other Asian countries (18–67%) and Northern Africa 
(range: 31-57%). Acquisition of MRE after travelling to sub-Saharan Africa (range: 0–49%) 
or South and Central America (range: 0–33%) was less frequent, and three studies did 
not observe any acquisition MRE after travel to South or Central America [table 3]. 
 Acquisition of MRE after travel to North America, Europe and Oceania was rare. Results 
of the genotypic characterisation of MRE isolated after travel are presented in table 2, 
the majority of the genes belonged to the CTX-M type.
Risk factor for acquisition of multidrug-resistant Enterobacteriaceae
Besides travel destinations, other risk factors for acquiring MRE were age, use of an-
tibiotics during travel (beta-lactam use) and gastroenteritis or other gastro-intestinal 
symptoms [table 2]. The study of Kantele et al., designed to study these risk factors 
as primary outcome, showed that travel diarrhoea (adjusted odds ratio (AOR) 31.0; 95% 
confidence interval (CI): 2.7-358.1)) and antibiotic therapy for travel diarrhoea (AOR = 3.0; 
95% CI: 1.4-6.7) proved to be the most important risk factors for acquiring MRE (20). In 
the study of Kuenzli et al. in which only travellers to southern Asia were included, risk 
factors for MRE acquisition were length of stay, visit to family or friend and consumption 
of ice cream or pastry [table 2]26. Angelin et al. found a significant association for travel 
to the South-East Asia region (OR = 30; 95% CI: 6.3-147.2), and antibiotic treatment dur-
ing travel (OR = 5; 95% CI: 1.1-26.2), but found no association with travellers’ diarrhoea 
or patient-related healthcare work22.
Resistance of multidrug-resistant Enterobacteriaceae to other antibiotic drugs
Resistance of post-travel MRE isolates to various antibiotics was determined in nine 
studies [table 4]17-19,21-24,26, 27. In the study of Wintersdorff et al., a PCR-based approach 
was used, therefore it was not possible to determine which microorganism carried the 
resistance genes23. The resistance data to other antibiotic drugs in the study by Kennedy 
et al. were not part of the publication, but were provided on request18. Antimicrobial 
resistance was high for ciprofloxacin, varying from 31% to 57%, and for cotrimoxazole, 
varying from 49% to 86%17-19,21-24,26,27. Aminoglycoside resistance was high for gentami-
cin (range: 17-50%) and tobramycin (range: 18-59%) and low for amikacin (range: 2-5%)17-
19,21-24,26,27. Carbapenemase-producing Enterobacteriaceae were observed in four travellers 
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who had all visited India (in the study by Ruppé et al., two OXA-181 and one New Delhi 
metallo-beta-lactamase 1 (NDM-1), and in the study of Kuenzli et al., one NDM-1, but this 
strain was not included in the resistance results)25,26. Resistance to nitrofurantoin, colis-
tin and fosfomycin was only analysed in some of the studies [table 4]18,19,21-23,26.
Duration of multidrug-resistant Enterobacteriaceae carriage after return, risk 
factors for a long duration and rate of infection after travel
Five studies analysed MRE carriage six months after travel, and the persistence rate of 
acquired MRE after six months was 6-24% of travellers [table 2]17,18,24,25,27. Ruppé et al. 
analysed MRE carriage one, two, three, six and twelve months after travel, showing per-
sistence of carriage of an acquired MRE in 34, 19, 10, 5 and 2%, respectively25. Travellers 
to Asia showed longer carriage of MRE compared with other travel destinations. Carriage 
of multidrug-resistant E. coli had a lower risk for prolonged carriage than other multi-
drug-resistant species. No other risk factors were found for prolonged carriage of MRE. 
Eight travellers in this study reported an episode of urinary tract infection after their 
return, but no microbiological data were availabl25. In the study of Tängdén et al., five of 
21 travellers remained carriers of MRE after six months. However, none of these partici-
pants reported clinical infections17. In the study of Kennedy et al., one person developed 
a urinary tract infection with a travel-related organism18. Kantele et al. performed a 
one-year laboratory-based follow-up and did not find any clinical samples with MRE20.
Rate of transmission to household members
Only one study screened household contacts for MRE after return of the index traveller. 
Household contacts were defined as persons who shared the same household with a 
participant on a regular basis. Two of 11 contacts were found MRE-positive24. Both car-
ried a different ESBL-producing E. coli based on multilocus sequence typing (MLST) than 
the associated traveller.
Limitations of the studies
The quality of the studies and the susceptibility of bias between the studies were as-
sessed. In all but one study, participants constituted a non-random sample of the gen-
eral travelling population17-21,23-27. However, Angelin et al. studied healthcare students 
working or studying abroad22. Studies were performed on three different continents. 
Travel destinations and travel behaviour may differ considerably between different na-
tionalities and age groups. Including co-travellers, as done in all studies except Pal-
tansing et al. and Ruppé et al., can result in similar travel behaviour and therefore, simi-
lar risk factors. Overall, the main outcome was not influenced by recall or interviewer 
bias. For other outcomes such as risk factors, the risk of recall bias or interviewer bias 
was low because of the use of self-administered questionnaires.
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Every study had participants lost to follow-up for post-travel stool samples and follow-
up stool samples. Asymptomatic faecal carriage of MRE is probably not related to loss 
to follow up, therefore, the risk of information bias is small. Ruppé et al. calculated 
post-travel MRE carriage as those travellers with persisting MRE carriage divided by all 
travellers with MRE acquisition plus all travellers without MRE post-travel25. However, 
travellers without MRE were not included in the follow-up. As a result, local MRE acqui-
Table 4 Antibiotic drug resistance of newly acquired multidrug-resistant Enterobacteriaceae in travellers  
(n=11 studies)
Study Ciprofloxacin
% (ratio)
Cotrimoxazole
% (ratio)
Gentamicin
% (ratio)
Amikacin
% (ratio)
Tobramycin
% (ratio)
Carbapenem
% (ratio)
Nitrofurantoin
% (ratio)
Colistin
% (ratio)
Fosfomycin
% (ratio)
Tängdén17 a 50b 79
(19/24)
45b No data 38b 0b 0b No data 8b
Kennedy18 c 55
(12/22)
No data 50
(11/22)
No data 59
(13/22)
No data No data No data No data
Östholm-Balkhed19 a 31
(36/116)
70
(81/116)
41
(48/116)
2
(2/116)
46
(53/116)
0
(0/116)
7
(8/116)
No data 3
(3/116)
Kantele20 No data No data No data No data No data No data No data No data No data
Weisenberg21 a 43
(3/7)d
86
(6/7)
43
(3/7)
No data No data 0
(0/7)
No data No data No data
Angelin22 57
(28/49)
75b 30b No data No data 0
(0/49)
2b No data No data
von Wintersdorff23 e 37 (45/122) qnrB
56 (68/122) qnrS
No data 71
(86/122)
aac(6')-aph(2'')
71
(86/122)
aac(6')-aph(2'')
71
(86/122)
aac(6')-aph(2'')
0
(0/122)
blaNDM
No data No data No data
Paltansing24 f 36 67 35 No data 37 0 29 0 No data
Ruppé25 No data No data No data No data No data 0.6
(3/526)g
No data No data No data
Kuenzli26 a 41
(64/157)
49
(77/157)
No data 5
(7/157)
18
(28/157)
0
(0/157)
2
(3/157)
0
(0/157)
0.6
(1/157)
Lübbert27 a 43
(25/58)
83
(48/58)
17
(10/58)
2b 22b 0b No data 0b 16b
bla: beta-lactamase; CPE: carbapenemase-producing Enterobacteriaceae; ESBL: extended-spectrum beta-lactamase.
a Resistance among acquired ESBL-positive isolates detected in pot-travel samples
b Data extracted from bar chart, exact numbers of data unpublished.
c Resistance among prevalent ESBL-positive isolates detected in post-travel samples.
d Percentage of susceptibility to levofloxacin.
e Prevalent resistance genes in faecal samples post-travel.
f Resistance among prevalent ESBL-positive isolates detected in pre- and post-travel samples.
g Three acquired CPE detected in post-travel samples.
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sition was not included in the calculated post-travel MRE carriage prevalence. Therefore 
the true prevalence can be assumed to be higher.
In five studies, travellers visited multiple regions or even continents during their trip17-
20,27. In these travellers, it was not possible to attribute MRE prevalence or MRE acquisi-
tion to a certain geographical region. However, travellers in these studies were included 
Table 4 Antibiotic drug resistance of newly acquired multidrug-resistant Enterobacteriaceae in travellers  
(n=11 studies)
Study Ciprofloxacin
% (ratio)
Cotrimoxazole
% (ratio)
Gentamicin
% (ratio)
Amikacin
% (ratio)
Tobramycin
% (ratio)
Carbapenem
% (ratio)
Nitrofurantoin
% (ratio)
Colistin
% (ratio)
Fosfomycin
% (ratio)
Tängdén17 a 50b 79
(19/24)
45b No data 38b 0b 0b No data 8b
Kennedy18 c 55
(12/22)
No data 50
(11/22)
No data 59
(13/22)
No data No data No data No data
Östholm-Balkhed19 a 31
(36/116)
70
(81/116)
41
(48/116)
2
(2/116)
46
(53/116)
0
(0/116)
7
(8/116)
No data 3
(3/116)
Kantele20 No data No data No data No data No data No data No data No data No data
Weisenberg21 a 43
(3/7)d
86
(6/7)
43
(3/7)
No data No data 0
(0/7)
No data No data No data
Angelin22 57
(28/49)
75b 30b No data No data 0
(0/49)
2b No data No data
von Wintersdorff23 e 37 (45/122) qnrB
56 (68/122) qnrS
No data 71
(86/122)
aac(6')-aph(2'')
71
(86/122)
aac(6')-aph(2'')
71
(86/122)
aac(6')-aph(2'')
0
(0/122)
blaNDM
No data No data No data
Paltansing24 f 36 67 35 No data 37 0 29 0 No data
Ruppé25 No data No data No data No data No data 0.6
(3/526)g
No data No data No data
Kuenzli26 a 41
(64/157)
49
(77/157)
No data 5
(7/157)
18
(28/157)
0
(0/157)
2
(3/157)
0
(0/157)
0.6
(1/157)
Lübbert27 a 43
(25/58)
83
(48/58)
17
(10/58)
2b 22b 0b No data 0b 16b
bla: beta-lactamase; CPE: carbapenemase-producing Enterobacteriaceae; ESBL: extended-spectrum beta-lactamase.
a Resistance among acquired ESBL-positive isolates detected in pot-travel samples
b Data extracted from bar chart, exact numbers of data unpublished.
c Resistance among prevalent ESBL-positive isolates detected in post-travel samples.
d Percentage of susceptibility to levofloxacin.
e Prevalent resistance genes in faecal samples post-travel.
f Resistance among prevalent ESBL-positive isolates detected in pre- and post-travel samples.
g Three acquired CPE detected in post-travel samples.
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in the MRE prevalence or MRE acquisition rates of more than one geographical regions, 
which may have introduced information bias.
Seven studies used stool samples for detection of MRE17,19-21,23,25,27 and three studies 
used rectal or perianal swabs for detection of MRE18,24,26. This might have influenced 
detection of MRE carriage.
Discussion
In this systematic review we found a high prevalence of faecal carriage of MRE after 
international travel. The highest prevalence of MRE was observed in isolates from trav-
ellers returning from southern Asia, with up to 88% acquisition of MRE. In addition to 
the antibiotics not effective against MRE, an alarmingly high prevalence of resistance 
to other commonly used antibiotics such as cotrimoxazole (49-86%), ciprofloxacin (31-
57%) and aminoglycosides (gentamicin 17-71%) was observed in ESBL-positive isolates 
in travellers in all studies17-27.
Returning international travellers with MRE may introduce these microorganisms in 
their home countries. This may cause community-onset infections with MRE in patients 
without obvious risk factors transmitted by healthy carriers through food or person-to-
person contact9. Infections caused by MRE are associated with poorer outcome and a 
higher overall mortality rate than infections caused by susceptible bacteria28. In this 
review, all studies showed an increased prevalence of faecal carriage of ESBL after inter-
national travel. It is not possible to evaluate the proportion of travellers who will develop 
infection with these resistant bacteria. However, studies have demonstrated that inter-
national travel is a risk factor associated with developing an infection with an MRE11,12,29.
Many countries have infection prevention and control guidelines to detect and treat 
multidrug-resistant organisms (MDROs) including MRE30. In countries with low preva-
lence of MRE, infection prevention and control guidelines mainly include strategies for 
early identification and isolation strategies for patients recently hospitalised in foreign 
hospitals30,31. Patients with a recent history of travel to MRE-endemic areas but not ad-
mitted to healthcare facilities abroad are not normally considered at risk for carriage of 
MDROs. However, in hospitalised patients with a recent history of travel, increased rates 
of carriage of MRE have been observed10,29,30. Physicians should be aware of the risk that 
patients with recent travel to areas with high faecal carriage of MRE, as presented in this 
review, may introduce MRE to the hospital. Routine screening for MRE seems indicated 
in such patients. Furthermore, empiric antibiotic therapy may fail when an infection 
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by MRE is not taken into account. Therefore, careful recording of travel history needs 
to be incorporated in each patient evaluation. As shown in this review, there is also an 
increased risk of resistance against other antibiotics in travellers with MRE carriage. It 
is likely that this is caused by multiple genes, each encoding for resistance to different 
classes of antibiotics, which are often found on the same bacterial mobile genetic ele-
ment (e.g. a plasmid)32. As a result, other antibiotics, such as aminoglycosides, will also 
fail in many MRE-positive patients.
Of the MDROs, emergence of CPE is most worrisome because of the limited treatment 
options for these infections. NDM-1-producing Enterobacteriaceae have been found in 
environmental samples in endemic regions33. CPE (NDM-1) in patients from the United 
Kingdom with a recent history of travelling or medical tourism to India are already an 
important public health problem8. Case reports have also demonstrated acquisition of 
CPE in travellers without contact with medical healthcare facilities34,35. In this review, 
four travellers from India were carrying a carbapenemase-producing E. coli25,26. Pre-
liminary results of the Carriage Of Multiresistant Bacteria After Travel (COMBAT) study, a 
large-scale multicentre longitudinal cohort study conducted in the Netherlands among 
2001 travellers, show acquisition of CPE in four travellers36.
There are, besides the destination of travel, additional risk factors for acquisition of MRE 
during travel. Antibiotic therapy was found to increase the risk20,22. In five studies, travel-
ler’s diarrhoea or gastroenteritis were associated with an increased risk of MRE acquisition 
during travel17-20,25. Also, in one study, meticulous hand hygiene or strict consumption of 
bottled water did not lower the risk of acquiring MRE22. Therefore, it is not clear whether 
hygiene-related travel advice will decrease faecal carriage of MRE. Surprisingly, health-
care-related activities did not pose an increased risk of acquiring MRE in one study22.
MRE and CPE could also be carried by food. International spread of these bacteria by food 
supply has been reported37. In this review, only one study showed that food consump-
tion (ice cream and pastry) was associated with MRE carriage in travellers to southern 
Asia, whereas most of the studies did not focus on dietary patterns during travel.
One of the limitations of this review is the recruitment of travellers from travel clinics 
only, resulting in inclusion of very few travellers with European destinations. European 
countries such as Greece and Cyprus also are endemic for MRE and popular travel des-
tinations34. In addition, travellers visiting their country of origin, especially Morocco and 
Turkey usually do not ask for a pre-travel consultation, although these countries are en-
demic for MRE and CPE34. It is not clear whether not including these patients may have 
led to an under- or overestimation of MRE acquisition.
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Another limitation is the lack of sufficient data regarding the duration of carriage and 
the transmission among non-travelling household members. The study by Ruppé et al. 
suggests that three months after return, MRE carriage is comparable with the baseline 
prevalence before travelling. However, the study did not include baseline prevalence in 
the follow-up. The COMBAT study will address some of these questions38.
Conclusion
International travel is a major risk factor for acquisition of MRE. This risk is particu-
larly high after travelling to (southern) Asia and in persons with travel-related diarrhoea 
and antibiotic use. Carriage of MRE-positive isolates is also associated with a high risk 
of resistance to ciprofloxacin, cotrimoxazole and aminoglycosides. Further research is 
needed to assess duration of carriage, spread to household contacts and whether in-
troduction of MRE results in an increase of MRE infections. Our results, combined with 
the worldwide emergence of CPE, further stress the importance of infection prevention 
and control guidelines.
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Supplement I
eMBase.coM  (‘Gram negative bacterium’/exp OR ‘Gram negative infection’/de OR Enterobacteria-
ceae/de OR Escherichia/exp OR Klebsiella/exp OR Salmonella/exp OR Shigella/exp OR Yersinia/exp 
OR ‘Enterobacteriaceae infection’/exp OR (‘Gram negative’ OR Enterobacteri* OR (Enter* NEXT/1 bac-
teria*) OR Enterobacter* OR Escherichia* OR ‘e coli’ OR Klebsiella* OR Salmonell* OR Shigell* OR 
Yersinia*):ab,ti) AND (travel/de OR ‘traveller diarrhea’/de OR aviation/exp OR (travel* OR touris* OR 
turista OR aviation OR ‘air transport’ OR airport*):ab,ti) AND (‘antibiotic resistance’/exp OR ‘multidrug 
resistance’/de OR ‘drug resistance’/de OR ‘antibiotic sensitivity’/de OR ‘bacterial colonization’/exp OR 
‘bacterium carrier’/de OR (resistan* OR coloni* OR ((antibiotic* OR antimicrob*) NEAR/3 sensitivit*) OR 
susceptib* OR carriage* OR carrier*):ab,ti) NOT ([animals]/lim NOT [humans]/lim)
Medline (ovidsP)  (exp “Gram-Negative Bacteria”/ OR exp “Gram-Negative Bacterial Infections”/ 
OR Enterobacteriaceae/ OR exp Escherichia/ OR exp Klebsiella/ OR exp Salmonella/ OR exp Shigella/ 
OR exp Yersinia/ OR exp “Enterobacteriaceae infections”/ OR (“Gram negative” OR Enterobacteri* OR 
(Enter* ADJ bacteria*) OR Enterobacter* OR Escherichia* OR “e coli” OR Klebsiella* OR Salmonell* OR 
Shigell* OR Yersinia*).ab,ti.) AND (travel/ OR “Travel Medicine”/ OR exp aviation/ OR (travel* OR touris* 
OR turista OR aviation OR “air transport” OR airport*).ab,ti.) AND (exp “Drug Resistance, Microbial”/ 
OR exp “Drug Resistance, Multiple”/ OR “drug resistance”/ OR “bacterium carrier”/ OR (resistan* OR 
coloni* OR ((antibiotic* OR antimicrob*) ADJ3 sensitivit*) OR susceptib* OR carriage* OR carrier*).
ab,ti.) NOT (exp animals/ NOT humans/)
cochrane  ((‘Gram negative’ OR Enterobacteri* OR (Enter* NEXT/1 bacteria*) OR Enterobacter* OR 
Escherichia* OR ‘e coli’ OR Klebsiella* OR Salmonell* OR Shigell* OR Yersinia*):ab,ti) AND ((travel* OR 
touris* OR turista OR aviation OR ‘air transport’ OR airport*):ab,ti) AND ((resistan* OR coloni* OR ((an-
tibiotic* OR antimicrob*) NEAR/3 sensitivit*) OR susceptib* OR carriage* OR carrier*):ab,ti)
WeB-of-science  TS=(((“Gram negative” OR Enterobacteri* OR (Enter* NEAR/1 bacteria*) OR En-
terobacter* OR Escherichia* OR “e coli” OR Klebsiella* OR Salmonell* OR Shigell* OR Yersinia*)) AND 
((travel* OR touris* OR turista OR aviation OR “air transport” OR airport*)) AND ((resistan* OR coloni* 
OR ((antibiotic* OR antimicrob*) NEAR/3 sensitivit*) OR susceptib* OR carriage* OR carrier*)))
scoPus  TITLE-ABS-KEY(((“Gram negative” OR Enterobacteri* OR (Enter* W/1 bacteria*) OR Enterobac-
ter* OR Escherichia* OR “e coli” OR Klebsiella* OR Salmonell* OR Shigell* OR Yersinia*)) AND ((travel* 
OR touris* OR turista OR aviation OR “air transport” OR airport*)) AND ((resistan* OR coloni* OR ((anti-
biotic* OR antimicrob*) W/3 sensitivit*) OR susceptib* OR carriage* OR carrier*)))
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PuBMed PuBlisher  ((Gram negative[tiab] OR Enterobacteri*[tiab] OR Entero bacteria*[tiab] OR En-
teric bacteria*[tiab] OR Enterobacter*[tiab] OR Escherichia*[tiab] OR e coli[tiab] OR Klebsiella*[tiab] OR 
Salmonell*[tiab] OR Shigell*[tiab] OR Yersinia*[tiab])) AND ((travel*[tiab] OR touris*[tiab] OR turista[tiab] 
OR aviation[tiab] OR air transport*[tiab] OR airport*[tiab])) AND ((resistan*[tiab] OR coloni*[tiab] OR 
((antibiotic*[tiab] OR antimicrob*[tiab]) AND sensitivit*[tiab]) OR susceptib*[tiab] OR carriage*[tiab] OR 
carrier*[tiab])) AND publisher[sb]
google scholar  “Gram negative”|Enterobacteriaceae|Escherichia|Klebsiella|Salmonella|Shigella|Ye
rsinia travel|traveller|tourist|tourism resistance|resistant|colonization|colonisation|susceptibility|carria
ge|carrier
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Abstract
Owing to multidrug resistance, quinolones and third-generation cephalosporins are 
currently used as key antibiotics to combat Salmonella organisms. Therapy failure due 
to reduced ciprofloxacin susceptibility has been reported in endemic areas, but also 
in imported disease. Different bacterial resistance mechanisms may result in reduced 
ciprofloxacin susceptibility. In this study, the presence and expression of different resis-
tance mechanisms resulting in reduced minimum inhibitory concentrations (MICs) for 
ciprofloxacin were evaluated in 23 blood-culture-derived Salmonella enterica serotypes 
Typhi and Paratyphi A organisms from ill-returned travellers to Asia. The presence of 
mutations in the quinolone resistance-determining region (QRDR) of the gyrA gene as 
well as an activated efflux pump and plasmid-mediated quinolone resistance genes was 
determined. Resistance selection during therapy and the clonal relatedness of all iso-
lates were established. Efflux pump inhibition did not appear to affect the MICs of cip-
rofloxacin and activity of the efflux pump appeared to be specific for nalidixic acid. Re-
peated exposure of the isolates to ciprofloxacin did not result in a significant increase in 
the MICs for ciprofloxacin. Repetitive sequence-based polymerase chain reaction (rep-
PCR) profiles identified five different genotypes, but no correlation with resistance was 
observed. However, a significant relation was found with geographic region; reduced 
ciprofloxacin susceptibility was only found in travellers returning from India and Paki-
stan. All isolates with reduced ciprofloxacin susceptibility had a mutation at position 83 
in the QRDR region of the gyrA gene. Plasmid-mediated quinolone resistance was not 
found. These findings confirm that the reduced ciprofloxacin MIC in S. Typhi and S. Para-
typhi A is solely due to an amino acid substitution in the QRDR ‘cluster’ of the gyrA gene.
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Introduction
Resistance of Salmonella spp. to ampicillin, chloramphenicol and trimethoprim/sulfa-
methoxazole has been described during the last 20 years. Owing to this multidrug-
resistance, quinolones and third-generation cephalosporins are currently in use as key 
antibiotics to combat these multiresistant organisms1. As a consequence of the use of 
quinolones and cephalosporins, there have been reports describing clinical treatment 
failure following administration of ciprofloxacin to patients with typhoid fever owing to 
reduced ciprofloxacin susceptibility (defined as minimum inhibitory concentration (MIC) 
of 0.125-1 µg/mL). This reduced susceptibility is found not only in endemic areas but also 
in developed countries such as the USA and UK, reflecting a global problem2,3.
Bacterial resistance to quinolones in Salmonella spp. may result from different resis-
tance mechanisms. Quinolone resistance is usually associated with mutations in the 
target site (DNA gyrase), most commonly in the quinolone resistance-determining re-
gion (QRDR) of the GyrA subunit, conferring resistance to single-step mutants4. On the 
other hand, reduced susceptibility to quinolones is mostly due to mechanisms such as 
active efflux via efflux pumps as well as alterations in the expression of outer membrane 
proteins5. Plasmid-mediated quinolone resistance has also emerged in non-typhoidal 
Salmonella enterica strains resulting in reduced ciprofloxacin susceptibility; this mecha-
nism has not yet been observed in typhoidal Salmonella spp. Outer membrane protein-
deficient Salmonella spp. have only been described incidentally, resulting in increased 
MICs (>200 µg/mL) for chloramphenicol6.
Owing to increased travel to endemic areas as well as migrant workers originating from 
endemic countries, The Netherlands is also confronted with patients not responding to 
empirical therapy with ciprofloxacin. In this retrospective study, S. enterica serotypes 
Typhi and Paratyphi A isolates were systematically characterised with respect to the 
presence and expression of different mechanisms of resistance causing reduced sus-
ceptibility to fluoroquinolones in 23 consecutive patients (travellers and migrant work-
ers) diagnosed at the Institute for Tropical Diseases of Harbour Hospital-Rotterdam (The 
Netherlands) with blood culture-derived S. Typhi or S. Paratyphi A infection.
Materials and methods
Bacterial isolates
In total, 23 Salmonella isolates (S. Typhi from 11 individuals and S. Paratyphi A from 12 
individuals) were collected from consecutive patients attending the Institute for Tropi-
cal Diseases during the period January 2002 to August 2008. All isolates derived from 
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positive blood cultures. Isolates were initially identified biochemically, followed by con-
firmation using specific antisera. Serotype determination was performed at the National 
Institute for Public Health and the Environment (RIVM) (Bilthoven, The Netherlands).
Antimicrobial susceptibility
Susceptibility of the isolates was determined using the VITEK-2 system (bioMérieux sa, 
Marcy L’Etoile, France). MICs for nalidixic acid and ciprofloxacin were determined by the 
microbroth dilution technique. All tests were performed according to Clinical and Labo-
ratory Standards Institute (CLSI) guidelines where applicable. For in vitro detection of 
efflux pump expression, a two-step dilution series of the antibiotics nalidixic acid, cipro-
floxacin and chloramphenicol was made to detect the MIC in the absence and presence 
of the efflux pump inhibitor (EPI) phenylalanine β-naphthylamide (PAβN) (20 µg/mL). A 
reduction of the initial MIC by >3-step difference upon exposure to EPI is an indication 
for the presence of an activated efflux pump7.
Polymerase chain reaction (PCR) screening and sequence analysis
The QRDR of gyrA was amplified by PCR using the primers described by Kariuki et al.8. 
Products resulting from amplifications were subjected to sequencing using a 3100 ABI 
Prism Genetic Analyzer (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). 
Analysis and comparisons of nucleotide and amino acid sequence data were carried out 
using MegAlign software (DNAStar Inc., Madison, WI) and programs available at the Na-
tional Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov). Presence of 
the qnrA, qnrB, qnrS, and aac(6’)-Ib-cr genes was determined by PCR9,10. The presence of 
integrons was determined using the method described by Lévesque et al11.
Molecular typing
Clonal relatedness of all isolates was established using the repetitive sequence-based 
PCR (rep-PCR) DiversiLab® Microbial Typing System (bioMérieux) according to the man-
ufacturer’s instructions. Isolates with >95% identical profiles were considered to be 
closely related.
Results and discussion
During the last decade, treatment failures with ciprofloxacin have been increasingly re-
ported. These failures have been associated with infection with S. Typhi and S. Paratyphi 
A strains that are resistant to nalidixic acid with decreased susceptibility to ciprofloxa-
cin2,3,12. Studies describing mechanisms of fluoroquinolone resistance demonstrate only 
one or two specific mechanisms. However, several mechanisms of resistance can result 
in reduced susceptibility to ciprofloxacin4. Moreover, a combination of resistance mech-
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anisms could also lead to enhancement of each of the separate mechanisms resulting 
in increased MICs. As mentioned previously, studies describing a systematic analysis of 
fluoroquinolone resistance mechanisms in different S. Typhi and S. Paratyphi A isolates 
are rare13. Therefore, we have systematically evaluated the presence and expression 
of different mechanisms of resistance resulting in reduced MICs for ciprofloxacin in 23 
Salmonella isolates.
Of the 23 isolates, 14 (60.9%) were resistant to nalidixic acid (NALR) and displayed re-
duced MICs for ciprofloxacin ranging from 0.25 µg/mL to 2 µg/mL, except for one isolate 
(6838) that had a ciprofloxacin MIC of 32 µg/mL. The remaining nine isolates (39.1%) 
were all nalidixic-acid-susceptible (NALS) and had low MICs for ciprofloxacin (≤0.03 µg/
mL) [Figure 1]. One of the mechanisms resulting in reduced susceptibility to quino-
lones may be the presence of activated efflux pumps. To detect the presence of these 
pumps, a phenotypic method was applied by determining MICs for nalidixic acid and 
ciprofloxacin in the presence and absence of the EPI PAßN. In most isolates, moderate 
efflux activity was determined for nalidixic acid resulting in MIC reductions of 3-4 steps 
in the presence of the EPI. However, the activity of this particular efflux pump(s) does 
not appear to affect the MICs for ciprofloxacin, indicating that the activity of this pump is 
specific, at least for nalidixic acid. As this phenomenon is not exclusively found in NALR 
isolates, it is concluded that this specific efflux pump(s) is not causing the increased 
MICs for ciprofloxacin in the NALR isolates (data not shown). Patients infected with iso-
lates with reduced susceptibility to fluoroquinolones react less favourably on the initi-
ated therapy12. This might be due to the fact that the strains that are already resistant 
to nalidixic acid may require fewer exposures to fluoroquinolones to develop high-level 
resistance to ciprofloxacin than strains that are fully ciprofloxacin-susceptible5.
To check for resistance selection during therapy, a selected number of isolates were 
exposed for two rounds to increasing concentrations of ciprofloxacin. However, this lim-
ited exposure did not result in a significant increase in the MICs of ciprofloxacin. Also, 
efflux pump activity did not change after these two rounds of selection/induction by 
repeated exposure to ciprofloxacin (data not shown). In fact, the same base level efflux 
pump activity was observed for chloramphenicol (efflux indicator antibiotic) as was al-
ready demonstrated for nalidixic acid. Thus, the impaired clinical response is not due to 
resistance selection during antibiotic treatment but may be due to unfavourable phar-
macodynamic parameters resulting in impaired killing.
Resistance or reduced susceptibility for fluoroquinolones is due to the presence of ac-
tive efflux pumps, impaired outer membrane permeability or gyrase mutations. As ef-
flux does not explain the current findings, all isolates were subjected to sequencing of 
the gyrA gene. Mutations in the QRDR region of the gyrA gene resulting in amino acid 
substitutions are given in Figure 1. All NALS isolates show no mutations in the QRDR 
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region. The NALR isolates all had mutations at position 83 resulting in a substitution of 
serine to phenylalanine or tyrosine. Isolate 6838, with a ciprofloxacin MIC of 32 µg/mL, 
had a double mutation. In addition to the mutation at position 83, a substitution of as-
paragine to glycine at position 87 was also demonstrated. Mutations in gyrA outside of 
the QRDR were observed both in NALR and NALS isolates (data not shown). These data 
are in full agreement with the data of Nair et al.14 who demonstrated that a single gyrA 
mutation at ser-83 alone resulted in resistance to nalidixic acid and reduced susceptibil-
ity to ciprofloxacin (MICs of 0.125-0.25 µg/mL). Therefore, it was concluded that Ser-83 
is an important site for determining fluoroquinolone resistance within S. Typhi and S. 
Paratyphi A isolates. Complete resistance to ciprofloxacin (MIC >4 µg/mL) has been re-
ported by Gaind et al.13 and is due to a double mutation in the QRDR region.
In this investigation, the presence of plasmid-encoded qnr genes resulting in reduced 
susceptibility to quinolones in Salmonella spp. Was also studied15. Expression of these 
genes is phenotypically hard to detect as they have a moderate effect on ciprofloxacin 
MICs even in combination with the aac(6’)-Ib-cr gene. In the 23 isolates studied, it was 
not possible to demonstrate the presence of plasmid-encoded qnr genes or aac(6’)-Ib-cr, 
indicating that these qnr bearing plasmids are “host” specific. Therefore, these findings 
confirm other reports that the reduced MICs for ciprofloxacin in S. Typhi and S. Paratyphi 
A are solely due to the amino acid substitution in the QRDR “cluster”. Besides reduced 
susceptibility to quinolones, two S. Typhi isolates demonstrated resistance to ampicillin, 
chloramphenicol, tetracycline and trimethoprim. One S. Paratyphi A isolate was resis-
tant to ampicillin, chloramphenicol and tetracycline. In the two trimethoprim-resistant 
S. Typhi isolates an 800-bp integron cassette was demonstrated, indicating that the gene 
involved is probably the dfrA7 gene encoding for a dihydrofolate reductase16. Integrons 
have been demonstrated in non-typhoidal Salmonella but only occasionally in S. Typhi17.
To study the genetic relationship between the NALR and NALS clusters, all isolates were 
analysed using a commercial rep-PCR system. Results of the rep-PCR [Figure 1] showed 
three different clusters of 8, 2, 11 as well as 2 unique isolates. In the clusters A and D 
consisting of 8 and 11 isolates, respectively, susceptibility to the quinolones was ran-
domly distributed, thereby demonstrating that resistance to nalidixic acid, i.e. reduced 
ciprofloxacin susceptibility, is not linked to a distinct cluster. Isolates belonging to cluster 
A were all S. Typhi isolates, whereas cluster D comprised S. Paratyphi A isolates. The only 
consistent correlation found related to the country of acquisition of the infection, i.e. the 
resistance to nalidixic acid and reduced susceptibility to ciprofloxacin was only found in 
travellers to India and Pakistan, but not in travellers to Indonesia and Cambodia. How-
ever, these geographical differences are not always that clear, as NALR isolates have also 
been reported in Vietnam2. However, based on these data it seems at least indicated to 
treat patients returning from India with an alternative drug instead of ciprofloxacin.
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Figure 1 Genotyping of 23 isolates by repetive sequence-based polymerase chain reaction (rep-PCR)
(DiversiLab®). MIC, minimum inhibitory concentration; QRDR, quinolone resistance-determining 
region.
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Abstract
oBjectives  Infections with typhoidal Salmonella that are resistant to fluoroquinolone 
antibiotics have become very common in several Asian countries. In the majority of 
these cases, resistance to fluoroquinolone-based antibiotics is associated with genetic 
mutations in the quinolone resistance-determining region (QRDR) of the bacterial DNA 
gyrase gene, gyrA. The objective of the present paper is to detect these amino acid sub-
stitutions by high resolution mass spectrometry instead of sequencing of the gyrA gene.
Methods  A liquid chromatography-mass spectrometry (LC-MS) methodology was de-
veloped and evaluated for the detection of amino acid substitutions in the GyrA protein 
of 23 typhoidal Salmonella isolates. These isolates included typhoidal Salmonellae that 
possessed different antibiotic sensitivities to fluoroquinolone antibiotics.
results  The LC-MS methodology correctly identified peptide sequences associated 
with phenotypic QRDR mutations of the GyrA protein in all of the 23 phenotypically 
diverse typhoidal Salmonella isolates tested.
conclusions  A reliable and rapid LC-MS methodology has been developed, which is 
able to identify gyrA QRDR mutations that are involved in the development of fluoroqui-
nolone resistance in typhoidal Salmonella species. Further, this ‘proof of principle’ study, 
indicates the potential usefulness of LC-MS in future detection of antibiotic resistance.
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Introduction
Infections with typhoidal Salmonella that are resistant to fluoroquinolone antibiotics 
(especially ciprofloxacin) have become very common in several Asian countries1-3. For 
example, a very recent phylogeographical analysis showed a single multidrug resistant 
lineage, H58, to be responsible for the emergence of these resistant isolates through-
out Asia and Africa4. In the majority of cases, fluoroquinolone resistance in typhoidal 
Salmonella spp. has been associated with a gyrA mutation in the quinolone resistance-
determining region (QRDR), resulting in a single amino acid substitution in the GyrA pro-
tein5-6. Expression of this mutated gyrA gene (at Ser-83) results in low-level resistance 
to fluoroquinolone antibiotics, as well as resistance to nalidixic acid (a closely related 
‘quinolone’ antibiotic). Importantly, a double mutation in the gyrA gene (at Ser-83 and 
Asp-87) results in a double amino acid mutation in the gyrase protein, which has been 
associated with high-level resistance to fluoroquinolone antibiotics5-6.
Susceptibility testing of micro-organisms is still performed in a classic fashion by 
determining the minimal inhibitory concentration after 18h exposure to different con-
centrations of antibiotic. Further, due to new mechanisms of resistance not only classic 
susceptibility testing is performed but extended by phenotypic screenings assay some-
times in combination with PCR to detect mechanisms of resistance. Due to the delay in 
obtaining susceptibility results and the increase in mechanisms of resistance there is 
a need for alternative techniques which are quicker with the same and perhaps better 
accuracy than current techniques. Currently, the use of mass spectrometry in medical 
microbiology laboratories is limited and mainly applied for microbial identification pur-
poses, for example via matrix-assisted laser desorption ionization-time of flight mass 
spectrometry (MALDI-TOF MS) analysis7. However, the range of mass spectrometry-re-
lated applications in the field of microbiological diagnostics is steadily increasing, with 
current emphasis being related to the detection of antibiotic resistance in clinically rel-
evant bacteria8. Further, in contrast to MALDI-TOF MS, more advanced techniques such 
as liquid chromatography-mass spectrometry (LC-MS), can be used to identify large 
numbers of peptides in complex samples, and could potentially be used to identify non-
synonymous amino-acid substitutions in protein sequences that are associated with 
the development of antimicrobial resistant phenotypes.
In the current study, a targeted LC-MS method for the detection of GyrA amino acid 
substitutions in typhoidal Salmonella isolates on a high resolution mass spectrometer 
using PRM (parallel reaction monitoring) was developed and evaluated. Recently this 
approach has been applied by Lesur and co-workers to identify mutations in oncop-
roteins in eukaryotic cancer cell lines9. Mass spectrometry has to our knowledge not 
been applied to identify mutations in proteins of bacteria before. This ‘proof of principle’ 
methodology demonstrates the feasibility of applying LC-MS-based techniques to the 
diagnosis of antimicrobial resistance in bacteria, as well as pointing to the possible use 
of LC-MS in future medical microbiology applications.
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Materials and methods
Bacterial isolates and antimicrobial susceptibility
An initial set of Salmonella isolates (Set 1) was chosen for use in the development of the 
LC-MS methodology. This set comprised four Salmonella enterica serotype Paratyphi A 
(S. Paratyphi A) isolates selected from a collection of 23 genetically well-characterized 
blood culture-derived typhoidal Salmonella isolates that had been obtained from pa-
tients during the period January 2002 to August 2008 obtained from patients attending 
the Harbour Hospital and Institute for Tropical Diseases, Rotterdam, The Netherlands.
Set 1 isolates comprised: 1) one fluoroquinolone susceptible S. Paratyphi A isolate 
(13471) - which was selected as a wild type isolate; 2) two low-level ciprofloxacin resis-
tant S. Paratyphi A isolates (17109 and 19222); and 3) one S. Paratyphi A isolate (6836) 
possessing high-level ciprofloxacin resistance.
For method validation a second set of isolates (Set 2) was used, which contained 
the remaining 19 typhoidal Salmonella isolates mentioned above, as well as the four 
isolates from Set 1. Therefore, Set 2 contained eleven Salmonella enterica serotype Typhi 
(S. Typhi) and twelve S. Paratyphi A isolates. The results of ciprofloxacin and nalidixic 
acid susceptibility testing for all 23 isolates was previously determined in a separate 
study5. According to EUCAST guidelines (http://www.eucast.org/clinical_breakpoints/), 
the isolates were defined as: 1) ciprofloxacin ‘susceptible’ if their ciprofloxacin MIC was 
≤ 0.06 µg/ml; 2) ‘low-level ciprofloxacin resistant’ if their MIC was 0.125-1.0 µg/ml and 3) 
‘high-level resistant’ if their MIC was >1.0 µg/ml.
Analysis
Sample pre-treatment for LC-MS method
Bacterial isolates were grown in 50 ml Tryptic Soy broth (Becton Dickinson, Sparks, 
Maryland, USA) and incubated overnight at 37oC. The next morning, 1 ml of bacterial 
culture was pelleted by centrifugation (16,000 g, 2 min), washed 3 times using 1 ml of 
Phophate Buffered Saline (PBS). Subsequently, 50 µl of suspension was precipitated us-
ing 950 µl acetone. Pellets were dissolved in SDS-PAGE sample buffer and analyzed on a 
7.5% SDS-PAGE gel for the non-targeted method or dissolved in 100 ul Rapigest 0.2% in 
50 mM NH4HCO3 for the target-method (PRM). The SDS-PAGE non-targeted procedure 
was implemented in order to increase the DNA gyrase protein concentration, which 
was required for proper method development. Both ‘in-gel’ and ‘in-solution’ digestion 
procedures were performed as previously described10. In addition, a digestion using 
immobilized trypsin (Flash digest (Perfinity, West Lafayette, USA) was used. Precipitated 
protein pellets of the bacteria culture were dissolved in 100 ul digestion buffer (Perfinity, 
West Lafayette, USA) vortexed and incubated on a thermo mixer 1000 rpm at 70 ˚C for 4 
hour. Subsequent samples we diluted in water 100 fold and acidified using TFA (pH < 2).
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Non-targeted gel-based LC-MS analysis
Five gel bands of each sample were excised at the approximate molecular weight for GyrA 
(116 kDa). In order to determine if GyrA mutations could be detected, the gel bands were 
digested with trypsin and analyzed by nanoLC LTQ-Orbitrap in a data dependent acquisi-
tion mode as described previously10. Five microliters of digest from the gel bands, were 
injected onto a nanoLC system (nano-LC Ultimate 3000; Thermo Fisher Scientific, Sunny-
vale, CA, USA). After pre-concentration and washing of the sample on a C18 trap column 
(1 mm × 300 µm id), peptides were separated on a C18 PepMap column (250 mm × 75 
µm internal diameter) (Thermo Fisher Scientific) using a linear 90 min gradient (4–40% 
acetonitrile/H20; 0.1% formic acid) at a flow rate of 250 nL/min. The separation of the 
peptides was monitored by a UV detector (absorption at 214 nm). The nano-LC was cou-
pled to the nanospray source of the LTQ-Orbitrap (Orbitrap XL, Thermo Fisher Scientific).
Data-analysis of non-targeted MS measurements
Based on the data obtained, the band with the highest sequence coverage for GyrA 
was selected from all four isolates and the data files from these 4 GyrA bands were re-
analyzed using Mascot, and a separate GyrA database, which contained the different 
known mutational variants of the GyrA protein11,12.
Sequence mutations in the QRDR of the gyrA gene of all Salmonella isolates tested 
had been previously determined using polymerase chain reaction (PCR) amplification 
and gene sequencing analysis4.
Targeted MS analyses
The targeted analysis only includes the GyrA peptides of interest this in contrast to the 
non-targeted analysis in which peptides were selected for MS/MS acquisition based on 
their presence in the MS spectrum13. Two microliters of digested Salmonella protein ex-
tract were injected onto a nanoLC system (nano-LC Ultimate 3000 RSLC; Thermo Fisher 
Scientific, Bremen). After pre-concentration and washing of the sample on a C18 trap 
column (1mm × 300 µm id), peptides were separated on a C18 PepMap column (250 
mm × 75 µm internal diameter) (Thermo Fisher Scientific) using a linear 30 min gradi-
ent (4–38% ACN/H2;0.1% formic acid) at a flow rate of 250 nL/min. The separation of 
the peptides was monitored by a UV detector (absorption at 214 nm). MS analysis was 
performed on a Q-Exactive Plus (Thermo Fisher Scientific) mass spectrometer equipped 
with a nano-spray ion source. A targeted MS/MS method was developed for all peptides 
containing GyrA mutations. In the targeted method we included not only the four possi-
ble tryptic fragments containing phenotypic GyrA mutations, but also included two pep-
tides within the GyrA protein sequence outside the QRDR region. These peptides should 
be present in all samples tested and reflect the total amount of GyrA in a sample. For 
this reason, these peptides were used as a sample control and could also potentially be 
used for normalization. The method allows quantitation if stable isotope labelled pep-
tide standards are included, this quantification step could be included in this method. A 
77
deteCt fluoroquinolone resistanCe usinG hiGh-resolution m ass speCtrometry
quadrupole isolation window of 0.7 m/z units, an automatic gain control target of 2e5 
ions, a maximum fill time of 250 ms and an Orbitrap resolving power of 35000 at 200 
m/z were used. A normalized collision energy of 27 was used for each GyrA peptide pre-
cursor. All different mutational variants of the tryptic peptide in the QRDR region were 
targeted (for each peptide the 2 and 3+ charge states were included), including the two 
additional peptides that are present in all three variants of the GyrA protein tested. Addi-
tional information regarding the different Gyr A peptides targeted are shown in table 1.
Data analyses of targeted MS measurements
The three most intense fragment ions for each targeted mass were extracted using Sky-
line software for each of the typhoidal Salmonella isolates tested. If signals for all three 
fragments with the correct mass (difference <2 ppm) and matching retention times 
were observed, then an isolate was considered positive for the measured peptide and 
based on this information the mutational state of GyrA could be determined.
Results
LC-MS method development
In a first attempt to detect amino acid substitutions in GyrA, trypsin digested extracts 
were used for analysis. However, GyrA specific peptides were not detected using LC-MS, 
which was probably due to the peptide concentration being too low. Therefore, in order 
Table 1 Peptide masses targeted during Q-Exactive Orbitrap measurements
Mass [m/z] CS [z] Polarity (N)CE Peptide sequence
577.28127 3 Positive 27 YHPHGDSAVYDTIVR 
865.41827 2 Positive 27 YHPHGDSAVYDTIVR 
577.95824 3 Positive 27 YHPHGDFAVYGTIVR 
866.43372 2 Positive 27 YHPHGDFAVYGTIVR 
903.43392 2 Positive 27 YHPHGDYAVYDTIVR 
602.62504 3 Positive 27 YHPHGDYAVYDTIVR 
895.43646 2 Positive 27 YHPHGDFAVYDTIVR 
597.29340 3 Positive 27 YHPHGDFAVYDTIVR 
816.35721 2 Positive 27 ETVDFVDNYDGTEK 
845.98358 2 Positive 27 GRPIVNLLPLEANER 
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to specifically enrich the concentration of GyrA proteins, the extracts were first separated 
by SDS-PAGE and the protein band of the expected molecular mass excised and extracted 
[figure 1] before LC-MS. The results of the SDS-PAGE analysis for each of the four Salmo-
nella isolates present in Set 1 were used to optimize the LC-MS method. Individual mass 
spectrometry analysis of all 5 bands for each isolate (n=4) resulted in the identification of 
673 proteins in total. Further, LC-MS sequence coverage for GyrA varied between 54 and 
65% for isolates 13471, 17109, 19222 and 6836 [table 2]. Therefore, by adapting the pre-
treatment steps, the LC-MS methodology correctly identified the protein sequences for 
GyrA gyrases containing the different mutations associated with different fluoroquinolone 
susceptibility phenotypes. All peptides containing these mutations were identified with 
high confidence and Mascot ion scores of 50 and higher (Mascot ion score of >50 relates 
to a p-value of <0.00001) were obtained. The results of GyrA peptide mutation analysis 
was confirmed by nucleotide sequencing of the QRDR-region [table 2].
LC-MS method validation
As the results of the LC-MS approach were in agreement with the sequencing results, the 
number of isolates was extended with an additional 19 Salmonella isolates containing S. 
Typhi and S. Paratyphi isolates, as well as the 4 isolates that were previously used for LC-MS 
method development in Set 1. This resulted in a sequence coverage for GyrA of between 
44 and 68%. Previous sequence analysis of the QRDR of gyrA also showed that the LC-MS 
method correctly identified GyrA mutations in the GyrA protein [table 3] in all isolates.
Figure 1 Five gel bands of approximately 116 kDa were excised from each of 4 Salmonella isolates. Each 
band is indicated by a box. The band contained in the bold box resulted in the highest sequence 
coverage for GyrA and was used in further GyrA mutation analysis.
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Targeted MS analyses
Enrichment by SDS-PAGE is labor intensive and increases the analysis time, consider-
ably. Therefore, in order to further improve the sensitivity and obtain more quantitative 
results, analysis was performed using a Parallel Reaction Monitoring (PRM) method on 
a Q-Exactive Orbitrap instrument14. This PRM is a targeted mass spectrometry method 
that can be performed on the newest generations of high resolution Orbitrap equip-
ment. This quite recently introduced PRM method has the advantage above the more 
regular applied selective reaction monitoring technique that the selectivity is much 
higher because of the high resolution. In this way false positive results can be almost 
eliminated which is of course crucial for this type of analyses. In addition, also the sensi-
tivity of the PRM method is in comparison to the non-targeted method at least an order 
magnitude improved.
For this reason, the SDS-PAGE enrichment step could be omitted, reducing the sample 
preparation and analysis time to 15 hours [table 4], as compared with 48 hours. Figure 2 
shows the qualitative, integration of peak area for the different mutant peptides of GyrA. 
Further, the resulting integrated areas for each Salmonella isolate are displayed for the 
four peptides containing the specific amino acid substitutions and WT-variants within 
the QRDR region. All isolates were only positive for the peptide with the expected mu-
tational profile, as earlier confirmed by the PCR/sequencing analyses. All samples were 
positive for the two control peptides from the non-mutated area of the GyrA protein.
To even further reduce analyses time an experiment was performed using immobilized 
trypsin. In this experiment we were able to reduce the overnight digestion to 4 hours 
without comprising the results (data not shown) reducing the analysis time to 5 hours.
Table 2 S. Paratyphi A isolates used for liquid chromatography mass spectrometry method development 
(Set 1).
Isolate Year / Country MIC of
Ciprofloxacin 
MIC of
Nalidixic 
acid
QRDR 
mutation
Identified peptide 
containing 
mutation sites
Sequence 
Coverage
13471 S. 
Paratyphi A
2005, Indonesia 0.03 8 - YHPH GDSAVYDTIV R 54%
17109 S. 
Paratyphi A
2006, India 1 >128 Ser 83-Tyr YHPH GDYAVYDTIV R 64%
19222 S. 
Paratyphi A
2007, India 1 >128 Ser 83-Phe YHPH GDFAVYDTIV R 62%
6838 S. 
Paratyphi A
2002, India 32 >128 Ser 83-Phe, 
Asp 87-Gly
YHPH GDFAVYGTIV R 65%
Underlined = mutation site
Bold = mutated amino acid
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Table 3 S. Typhi A and S. Paratyphi A isolates used for liquid chromatography mass spectrometry method  
validation (Set 2).
Isolate Year / Country MIC of
Ciprofloxacin 
MIC of
Nalidixic acid
QRDR mutation Identified peptide containing 
mutation sites
Sequence Coverage
13471 S. Paratyphi A 2005, Indonesia 0.03 8 - YHPH GDSAVYDTIV R 56%
17109 S. Paratyphi A 2006, India 1 >128 Ser 83-Tyr YHPH GDYAVYDTIV R 65%
19222 S. Paratyphi A 2007, India 1 >128 Ser 83-Phe YHPH GDFAVYDTIV R 68%
6838 S. Paratyphi A 2002, India 32 >128 Ser 83-Phe, Asp 87-Gly YHPH GDFAVYGTIV R 65%
11169 S. Typhi 2004, India 0.5 >128 Ser 83-Phe YHPH GDFAVYDTIV R 67%
11670 S. Typhi 2004, India 1 >128 Ser 83-Phe YHPH GDFAVYDTIV R 57%
144481 S. Typhi 2007, India 0.25 >128 Ser 83-Phe YHPH GDFAVYDTIV R 56%
18343 S. Typhi 2006, India 0.5 >128 Ser 83-Phe YHPH GDFAVYDTIV R 58%
137765 S. Typhi 2007, Pakistan 0.5 >128 Ser 83-Phe YHPH GDFAVYDTIV R 63%
11117 S. Typhi 2004, Pakistan 0.015 4 - YHPH GDSAVYDTIV R 64%
31985 S. Typhi 2008, India 0.5 >32 Ser 83-Tyr YHPH GDYAVYDTIV R 57%
32994 S. Typhi 2008, Indonesia 0.03 8 - YHPH GDSAVYDTIV R 58%
19254 S. Typhi 2007, India 0.5 32 Ser 83-Phe YHPH GDFAVYDTIV R 63%
121576 S. Typhi 2006, India 0.25 128 Ser 83-Tyr YHPH GDYAVYDTIV R 44%
32857 S. Typhi 2008, Indonesia 0.03 8 - YHPH GDSAVYDTIV R 63%
117304 S. Paratyphi A 2006, Cambodia 0.03 8 - YHPH GDSAVYDTIV R 60%
11220 S. Paratyphi A 2004, Cambodia 0.03 8 - YHPH GDSAVYDTIV R 57%
 9155 S. Paratyphi A 2003, India 2 >128 Ser 83-Phe YHPH GDFAVYDTIV R 61%
15406 S. Paratyphi A 2005, Indonesia 0.03 8 - YHPH GDSAVYDTIV R 44%
143980 S. Paratyphi A 2006, India 1 >128 Ser 83-Phe YHPH GDFAVYDTIV R 62%
117438 S. Paratyphi A 2006, India 1 >128 Ser 83-Phe YHPH GDFAVYDTIV R 52%
17907 S. Paratyphi A 2006, Indonesia 0.03 8 - YHPH GDSAVYDTIV R 50%
10270 S. Paratyphi A 2004, Pakistan 0.03 8 - YHPH GDSAVYDTIV R 60%
Underlined = mutation site
Bold = mutated amino acid
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Table 3 S. Typhi A and S. Paratyphi A isolates used for liquid chromatography mass spectrometry method  
validation (Set 2).
Isolate Year / Country MIC of
Ciprofloxacin 
MIC of
Nalidixic acid
QRDR mutation Identified peptide containing 
mutation sites
Sequence Coverage
13471 S. Paratyphi A 2005, Indonesia 0.03 8 - YHPH GDSAVYDTIV R 56%
17109 S. Paratyphi A 2006, India 1 >128 Ser 83-Tyr YHPH GDYAVYDTIV R 65%
19222 S. Paratyphi A 2007, India 1 >128 Ser 83-Phe YHPH GDFAVYDTIV R 68%
6838 S. Paratyphi A 2002, India 32 >128 Ser 83-Phe, Asp 87-Gly YHPH GDFAVYGTIV R 65%
11169 S. Typhi 2004, India 0.5 >128 Ser 83-Phe YHPH GDFAVYDTIV R 67%
11670 S. Typhi 2004, India 1 >128 Ser 83-Phe YHPH GDFAVYDTIV R 57%
144481 S. Typhi 2007, India 0.25 >128 Ser 83-Phe YHPH GDFAVYDTIV R 56%
18343 S. Typhi 2006, India 0.5 >128 Ser 83-Phe YHPH GDFAVYDTIV R 58%
137765 S. Typhi 2007, Pakistan 0.5 >128 Ser 83-Phe YHPH GDFAVYDTIV R 63%
11117 S. Typhi 2004, Pakistan 0.015 4 - YHPH GDSAVYDTIV R 64%
31985 S. Typhi 2008, India 0.5 >32 Ser 83-Tyr YHPH GDYAVYDTIV R 57%
32994 S. Typhi 2008, Indonesia 0.03 8 - YHPH GDSAVYDTIV R 58%
19254 S. Typhi 2007, India 0.5 32 Ser 83-Phe YHPH GDFAVYDTIV R 63%
121576 S. Typhi 2006, India 0.25 128 Ser 83-Tyr YHPH GDYAVYDTIV R 44%
32857 S. Typhi 2008, Indonesia 0.03 8 - YHPH GDSAVYDTIV R 63%
117304 S. Paratyphi A 2006, Cambodia 0.03 8 - YHPH GDSAVYDTIV R 60%
11220 S. Paratyphi A 2004, Cambodia 0.03 8 - YHPH GDSAVYDTIV R 57%
 9155 S. Paratyphi A 2003, India 2 >128 Ser 83-Phe YHPH GDFAVYDTIV R 61%
15406 S. Paratyphi A 2005, Indonesia 0.03 8 - YHPH GDSAVYDTIV R 44%
143980 S. Paratyphi A 2006, India 1 >128 Ser 83-Phe YHPH GDFAVYDTIV R 62%
117438 S. Paratyphi A 2006, India 1 >128 Ser 83-Phe YHPH GDFAVYDTIV R 52%
17907 S. Paratyphi A 2006, Indonesia 0.03 8 - YHPH GDSAVYDTIV R 50%
10270 S. Paratyphi A 2004, Pakistan 0.03 8 - YHPH GDSAVYDTIV R 60%
Underlined = mutation site
Bold = mutated amino acid
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Figure 2 Bar graph showing the peak area for the different mutant peptides of GyrA. Extracted ion chro-
matographs were generated for the 3 most intense fragment ions for each peptide using Skyline 
open access software. The signals were manually verified for correct retention time (all fragments 
possessed the same retention time, a difference <0.2 min between samples and correct mass of 
fragment ions (<2 ppm). The resulting integrated areas are displayed for the four peptides from 
each Salmonella isolate. All isolates are only positive for the peptide with the expected mutant 
profile as obtained by gyrA gene PCR/sequencing analyses.
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Discussion
In general, antimicrobial resistance is detected phenotypically, or genetically, by making 
use of biochemical susceptibility assays, or DNA gene detection/DNA sequencing by 
means of PCR. Using these methods, decreased susceptibility or resistance to antibi-
otics may be demonstrated for example, by detecting the presence of acquired genes 
encoding, specific antibiotic degrading enzymes e.g. β-lactamases or by detecting the 
presence of genetic mutations that render the target protein insensitive to a particular 
antibiotic e.g. DNA gyrases.
Further, mutations in bacterial antibiotic resistance genes may generate proteins 
containing non-synonymous sequences when compared to the protein translated from 
the original, non-mutated, gene. This occurs when DNA mutations lead to changes in 
triplet codon usage via mutated nucleotide sequences in transcribed messenger RNA. 
Importantly, high resolution mass spectrometry enables the detection and characteriza-
tion of mutant proteins containing non-synonymous amino acid sequence substitutions.
In the present study we demonstrated that a combination of SDS-PAGE based en-
richment of ~116 kDa proteins followed by LC-MS analysis enabled the identification of 
mutations in the QRDR region of GyrA. Frequently, the accuracy of detection of proteins 
Table 4 Estimated time required for the detection of fluoroquinolone resistance using currently available 
methods
Detection Method Estimated 
time
(hours)
Estimated 
costs 
(euro)
Comment
Phenotypic detection
Susceptibility testing 
by minimal inhibitory 
concentration (MIC)
MIC determinations 18 100 information of 
mechanisms of resistance 
is not provided
Genotypic detection
Gene sequences 
determined by nucleotide 
sequencing
Mutations in the QRDR  
of the gyrA gene
10-18 150 All mutations in the QRDR 
region will be detected
Mass spectrometry
Detection of amino-acid 
substitutions
GyrA amino acid mutations 15 300 Up to ~50- 100 mutations 
can be followed
GyrA amino acid mutations,  
and using immobilized  
enzymes for protein digestion
5 300 Process time will decrease 
considerably but cost 
will not decrease (same 
measurement time)
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and peptides by LC-MS is influenced by the expression levels of the target protein/pep-
tide and by the ‘background noise’ levels generated by non-target peptides present in 
the sample. In this publication, we show that the latter problem may be circumvented 
without compromising the sensitivity of the assay by the application of a ‘targeted’ 
LC-MS methodology in which prior enrichment using SDS-PAGE is replaced. Using this 
targeted LC-MS methodology we were able to detect not only the wild type QRDR region 
amino acid sequence in the GyrA protein (fluoroquinolone sensitive), but also QRDR 
amino acid substitutions associated with fluoroquinolone resistance. Further, using the 
targeted LC-MS methodology and using immobilized enzymes for protein digestion, al-
lowed us to perform GyrA peptide analysis within a time-span of 5 hours after initial 
culture of the typhoidal Salmonella isolates being tested. This is much faster compared 
with other currently used fluoroquinolone susceptibility detection methods [table 4]. 
The use of immobilized trypsin has been extensively described in the scientific litera-
ture15,16 and resulted in a significant reduction in digestion time to 3 hours, compared to 
the current approximate 12 hour (overnight) digestion period, decreasing the total time 
required for LC-MS analysis to 5 hours.
At the moment the use of LC-MS technique is limited to research laboratories. How-
ever, future advances in mass spectrometry technology, coupled to the development 
of a multiplex approach (where additional mutated proteins associated with antibiotic 
resistance can be detected) means that LC-MS could potentially become widely used in 
the microbiology clinical laboratory of the future.
The LC-MS methodology described in this publication shows that the detection and 
characterization of amino acid substitutions in the QRDR-region of GyrA is feasible us-
ing high-resolution mass spectrometry (LC-MS). Importantly, this publication shows 
that LC-MS may be used to detect non-synonymous amino acid substitutions that are 
phenotypically and clinically relevant — in this case, relevant for the detection and di-
agnosis of antibiotic resistance. However, in the present paper we only solved part of 
the puzzle. Fluoroquinolone resistance is not only the result of mutations in the gyrA 
protein but can also be due to mutations in the topoisomerase IV (parC) in combina-
tion with decreased permeability and/or activated efflux pumps. Also plasmid encoded 
mechanisms have been described like the Qnr proteins. These additional mechanisms 
of resistance are all related to the absence/presence of specific proteins. So in theory 
detectable by high resolution mass spectrometry. With the current technique in a non-
targeted fashion we are already able to detect 60-70% of the proteins. By optimization 
of the sample pre-treatment protocol and the use of a specific universal antibiotic resis-
tance mechanism database, the accuracy could be significantly further improved. In pi-
lot experiments we already succeeded in the detection of several different β-lactamase 
enzymes as well as aminoglycoside modifying enzymes. However, before translation of 
these data can be used to reliably predict the presence of resistance mechanisms the 
obtained data should be normalized by including an internal reference. With normalized 
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results an algorithm could be developed to predict the presence of resistance mecha-
nisms followed by deduction of the susceptibility to different antibiotics.
Future research based on our findings will show the usefulness of our LC-MS method-
ology for the detection of other clinically relevant antimicrobial resistance phenotypes, 
for example amino acid substitutions in Penicillin-Binding Proteins (PBPs), or amino acid 
substitutions in the active site of β-lactamase enzymes, possibly in a new multiplexed 
methodology. This could eventually lead to major changes in the way that antibiotic 
resistance is detected and diagnosed in the clinical microbiological laboratory.
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Abstract
The emergence of decreased ciprofloxacin susceptibility (DCS) in Salmonella enterica 
serovar Typhi and serovar Paratyphi A, B or C limits treatment options. We studied the 
impact of DCS isolates on the fate of travellers returning with enteric fever and possible 
alternative treatment options. We evaluated the clinical features, susceptibility data and 
efficacy of empirical treatment in patients with positive blood cultures of a DCS isolate 
compared to patients infected with a ciprofloxacin-susceptible (CS) isolate in the period 
from January 2002 to August 2008. In addition, the pharmacokinetic and pharmacody-
namic parameters of ciprofloxacin, levofloxacin and gatifloxacin were determined to as-
sess if increasing the dose would result in adequate unbound fraction of the drug 24-h 
area under the concentration-time curve/minimum inhibitory concentration (ƒAUC0-24/
MIC) ratio. Patients with DCS more often returned from the Indian subcontinent and had 
a longer fever clearance time and length of hospital stay compared to patients in whom 
the initial empirical therapy was adequate. The mean ƒAUC0-24/MIC was 41.3±18.8 in 
the patients with DCS and 585.4±219 in patients with a CS isolate. For DCS isolates, the 
mean ƒAUC0-24/MIC for levofloxacin was 60.5±28.7 and for gatifloxacin, it was 97.9±28.0. 
Increasing the dose to an adequate ƒAUC0-24/MIC ratio will lead to conceivably toxic 
drug levels in 50% of the patients treated with ciprofloxacin. Emerging DCS isolates has 
led to failure of empirical treatment in ill-returned travellers. We demonstrated that, in 
some cases, an adequate ƒAUC0-24/MIC ratio could be achieved by increasing the dose 
of ciprofloxacin or by the use of alternative fluoroquinolones.
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Introduction
Enteric fever (typhoid fever) is caused by Salmonella enterica serovar Typhi (S. Typhi) or 
serovar Paratyphi A, B, or C (S. Paratyphi)1,2. Although most of the burden of the disease 
occurs in developing countries with poor hygiene and sanitation, enteric fever is an im-
ported disease in returning travellers, immigrants or migrant workers in developed coun-
tries3-7. Thirty years ago, many treatment options for enteric fever were available, such as 
ampicillin, chloramphenicol or trimethoprim/sulphamethoxazole. Due to the increased 
occurrence of multidrug resistant (MDR) S. Typhi, these agents were no longer applicable 
for empirical treatment and ciprofloxacin became the first-line drug of treatment. How-
ever, after this switch to ciprofloxacin, isolates with decreased ciprofloxacin susceptibility 
(DCS) or even resistance to ciprofloxacin became evident. Clinical failure due to reduced 
susceptibility to ciprofloxacin has been reported8-11. Therefore, the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) has issued a warning in their guide-
lines that ciprofloxacin susceptibility testing for S. Typhi isolates should be performed 
by quantitative susceptibility methods. Especially, organisms with a minimum inhibitory 
concentration (MIC) greater than 0.06 mg/L may result in failure, while, paradoxically, 
the breakpoint for susceptibility was set at 0.5 mg/L. Therefore, third-generation cepha-
losporins and azithromycin are now recommended as first-line treatment options for 
enteric fever patients from South Asia3,12. However, the first cases of resistance to third-
generation cephalosporins due to the presence of extended-spectrum β-lactamases or 
plasmid encoded AmpC β-lactamases have already been reported13-16.
In the Netherlands, about 30 cases of enteric fever are diagnosed every year17. Fluor-
oquinolones are still recommended by most authorities for the treatment of enteric 
fever. However, in this era of increasing ciprofloxacin resistance among S. Typhi and S. 
Paratyphi, it is not clear whether this still results in optimal empirical antibiotic therapy. 
Here, we evaluated clinical features, susceptibility data and efficacy of empirical treat-
ment in enteric fever patients with positive blood cultures of a DCS isolates compared 
to patients infected with a ciprofloxacin-susceptible (CS) isolate. Additionally, pharma-
cokinetic and pharmacodynamic parameters (PK/PD) of several fluoroquinolones were 
determined to assess if increasing the dose would result in adequate unbound fraction 
of the drug 24-h area under the concentration-time curve/minimum inhibitory concen-
tration (ƒAUC0-24/MIC) ratio.
Materials and methods
Patient characteristics
All travellers diagnosed with blood-culture-confirmed S.Typhi and S. Paratyphi infec-
tions at the Harbour Hospital and Institute for Tropical Diseases, Rotterdam, the Neth-
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erlands, in the period January 2002 to August 2008 were included in this retrospective 
study. These patients were grouped in DCS and CS strains and these groups were com-
pared with respect to sex, age, country of acquisition, symptoms on admission, physical 
findings and laboratory findings on admission and clinical outcome.
Susceptibility testing
The susceptibility for ampicillin, chloramphenicol, ceftazidime, cefotaxime, tetracycline 
and trimethoprim/sulphamethoxazole were determined by the VITEK 2 system. The 
MICs for the fluoroquinolones ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin and 
gatifloxacin were determined by E-test. EUCAST guidelines were applied for category in-
terpretation for the different antibiotics (http://www.eucast.org/clinical_breakpoints/). 
The isolates were defined as DCS if the MIC for ciprofloxacin was 0.125–1.0 mg/l and CS 
if the MIC for ciprofloxacin was < 0.125 mg/l.
Pharmacokinetics
Further, 24-h area under the concentration-time curve (AUC0-24), unbound fraction of 
the drug AUC0-24 (ƒAUC0-24) and ƒAUC0-24/MIC ratios were calculated for individual doses 
of ciprofloxacin. The AUC0-24 of ciprofloxacin were based on the pharmacokinetic data 
from a previous clinical study18. Estimated AUC0-24 for levofloxacin and gatifloxacin were 
calculated with mean AUC0-24 reported in the literature19. The ƒAUC0-24 of ciprofloxacin, 
levofloxacin and gatifloxacin was calculated by correcting the AUC0-24 for the fraction of 
drug bound to serum proteins, respectively 0.3, 0.3 and 0.219. The ƒAUC0-24/MIC was tak-
en as target for optimal fluoroquinolone activity20. Based on an in vitro infection model 
to identify the efficacy of ciprofloxacin, levofloxacin and gatifloxacin against S. Typhi, an 
ƒAUC0-24/MIC ratio of 105 is associated with a 90% maximal drug effect19-21. With this 
assumption, we calculated the individual dose per patient for ciprofloxacin, levofloxacin 
and gatifloxacin to fulfil the critical ratio of ƒAUC0-24/MIC ratio of 105.
Data analysis
For categorical or dichotomized parameters, proportions between groups were com-
pared using the Fisher’s exact test. For continuous parameters with a normal distribu-
tion, t-test was used. Statistical significance was accepted at p-values <0,05. Data were 
analysed using SPSS 20.
Results
Susceptibility of different isolates
A total of 26 patients were identified, which were grouped in DCS and CS strains. DCS 
was found in 17 of 26 isolates (S. Typhi, n=9; S. Paratyphi A, n=8), whereas nine isolates 
were CS (S. Typhi, n=3; S. Paratyphi A, n=6). Only two MDR isolates were found, re-
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Figure 1a Minimum inhibitory concentration (MIC) distribution of fluoroquinolones in enteric fever in 
ciprofloxacin-susceptible (CS) (n=9) isolates.
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Figure 1b MIC distribution of fluoroquinolones in enteric fever in decreased ciprofloxacin susceptibility  
(DCS) (n=14) isolates.
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sistant to amoxicillin, chloramphenicol, trimethoprim/sulphamethoxazole and tetracy-
cline. These two isolates belonged to the DCS group. None of the isolates was resistant 
to third-generation cephalosporins. The DCS isolates also showed increased MICs to 
alternative fluoroquinolones, such as levofloxacin, moxifloxacin or ofloxacin. The only 
fluoroquinolone that did not show increased MICs was gatifloxacin [figure 1].
Clinical features, treatment and outcome
The clinical data of patients included in the study are summarised in table 1. All DCS 
strains were acquired from the Indian subcontinent, whereas CS strains came from 
Southeast Asia in general. From 2002 to 2007, ciprofloxacin was the first-line treat-
ment on admission in all patients who were later diagnosed with enteric fever. During 
these years, 13 patients with a DCS isolate were empirically treated with ciprofloxacin, 
from which only one patient became afebrile within 72 hours of treatment. After the 
demonstration of DCS or resistance or persisting fever, therapy was switched to intra-
venous ceftazidime (n=9) or trimethoprim/sulphamethoxazole (n=3). In the DCS group, 
one of the patients was treated with oral ciprofloxacin and one with oral azithromycin 
monotherapy without relapse. In the CS group, 6 of 9 patients were initially treated with 
oral ciprofloxacin, two received intravenous ceftazidime and one patient was treated 
with oral azithromycin, respectively. After the demonstration of ciprofloxacin suscepti-
bility, follow-up treatment consisted of oral ciprofloxacin (n=7), oral azithromycin (n=1) 
and trimethoprim/sulphamethoxazole (n=1). There was one relapse of enteric fever in 
the DCS group (previous treatment consisted of ciprofloxacin for 3 days, followed with 
intravenous ceftazidime for 10 days) and one in the CS group (previously treated with 
ciprofloxacin and intravenous ceftazidime for 5 days, followed by trimethoprim/sulpha-
methoxazole for 9 days). In addition, DCS was associated with a suggested higher com-
plication rate: an ileal perforation at day 3 after 2 days of ciprofloxacin monotherapy in 
one DCS patient and sudden deafness after ciprofloxacin and ceftazidime in another 
DCS patient, whereas no complications were observed in the CS group22. Patients with 
DCS isolates had significantly longer fever clearance times and were hospitalised longer 
as compared to CS patients. There were no case fatalities.
Pharmacokinetics
The mean ƒAUC0-24 per group showed no significant differences between patients in-
fected with a DCS or CS isolate, respectively, 25.7±7.4 and 30.0±6.3 (p=0.29). However, 
the pharmacodynamics index of efficacy for fluoroquinolones is foremost determined 
by the ƒAUC0-24/MIC ratio. As MICs for ciprofloxacin differed considerably between both 
groups, the ƒAUC0-24/MIC ratios also differed between both patient groups. The mean 
ƒAUC0-24/MIC was 41.3±18.8 in DCS strains and 585.4±219.1 in CS strains (p=0.035). Thus, 
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Table 1 Clinical features and laboratory parameters on admission of 26 patients with imported, blood-
culture-proven enteric fever, grouped into decreased ciprofloxacin susceptible (DCS) and ciproflox-
acin-susceptible (CS) isolates. Data are given as median (range).
Parameter DCS (n = 17) CS (n=9) p-Value 
General features
Serovar Typhi / Paratyphi A
Male / female
Age (yrs) 
9 / 8
12 / 5
32 (18-62)
3 / 6
7 / 2
29 (9-67)
0.21
0.34
0.62
Country of acquisition
Southeast Asiaa/ Indian subcontinentb 0 / 17 7 / 2 0,000055
Symptoms on admission
Anorexia
Abdominal pain
Vomiting
Diarrhoea
Intestinal bleeding
Headache
Cough
Jaundice
4/17
9/17
6/17
10/17
1/17
13/17
7/17
0/17
0 / 8
6 / 8
1 / 8
6 / 8
1 / 8
7 / 8
4 / 8
0 / 8
0.19
0.21
0.21
0.27
0.45
0.36
0.31
1.00
Physical findings on admission
Pulse (beats/min)
Temperature (°C)
Pulse/ temperature ratio
Maximal temperature (°C)
Hepatomegaly
Splenomegaly
99 (64-120)
39,5 (36.9-40.5)
2,50 (1.64-3.37)
40,1 (38.2-41.0)
2/17
2/17
82 (72-120)
39,2 (36.8-40.0)
2,06 (1.69-2.42)
39,8 (38.5-40.5)
1 / 8
2 / 8
0.11*
0.17*
0.16
0.13
0.47
0.30
Laboratory findings on admission
ESR (mm/h)
CRP (mg/L)
Haemoglobin (mmol/L)
Leukocytes (× 109/L)
Platelets (×109/L)
Serum LDH (U/L)
27 (5-68)
115 (25-194)
8.5 (6.1-9.9)
6.3 (3.0-11.9)
168 (33-349)
1034 (500-2764)
31 (17-40)
72 (14-168)
8.4 (7.6-9.4)
7.1 (4.1-9.6)
179 (115-356)
605 (430-1429)
0.69
0.16
0.96
0.45
0.21
0.20**
Follow-up
Fever clearance time (days)
Hospitalisation duration (days)
7 (1-18)
14 (1-24)
4 (3-6)
7 (1-20)
0.041*†
0.034*
* For serovar Typhi: DCS vs. CS (pulse), p=0.001; DCS vs. CS (temperature), p=0,031; DCS vs. CS (fever clearance 
time) P=0,0080; DCS vs CS (hospitalization duration) P=0,0076, DCS vs CS (pulse/ temperature ratio), p=0,0039
** For serovar Paratyphi A: DCS vs. CS (LDH), p=0,049
a = Indonesia, Vietnam, Malaysia, Cambodia, Thailand and Laos
b = India, Pakistan, Bangladesh, Nepal, Sri Lanka and Bhutan
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all the patients infected with a CS isolate fulfilled the condition ƒAUC0-24/MIC >105 and 
those with a DCS isolate fulfilled the condition ƒAUC0-24/MIC <105. As the AUCs for 
ciprofloxacin are not significant different in both groups, the two options to improve the 
ƒAUC0-24/MIC ratio are either to increase the dose or to apply agents with lower MICs. 
So, alternatively, we calculated the ƒAUC0-24/MIC ratios for other fluoroquinolones as 
well. For DCS isolates, the mean ƒAUC0-24/MIC for levofloxacin was 60.5±28.7 and for 
gatifloxacin, it was 97.9±28.0, with half of the isolates even fulfilling the critical ratio of 
ƒAUC0-24/MIC >105 [figure 2].
The option would be to increase the dose to fulfil the critical ratio of 105. For every 
individual, we calculated the dose of ciprofloxacin, levofloxacin and gatifloxacin neces-
sary to achieve this ratio. For our patients with DCS isolates, this would result in a dos-
age in the range of 1134-4240 mg/day for ciprofloxacin, 666–2206 mg/day for levofloxa-
cin and 405–788 mg/day for gatifloxacin. Increasing the dose will lead to conceivably 
toxic drug levels in 50% of the patients treated with ciprofloxacin (>1500 mg/day), in 
87.5% of the patients treated with levofloxacin (>1000 mg/day) and in only 25% of the 
patients in case of treatment with gatifloxacin (>600 mg/day).
Figure 2 Calculated unbound fraction of the drug 24-h area under the concentration-time curve/minimum 
inhibitory concentration (ƒAUC0-24/MIC) ratios of ciprofloxacin and levofloxacin in DCS isolates 
(n=7) and the range in our population
0
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Discussion
Emerging DCS isolates among enteric fever infections in countries of the Indian sub-
continent and Southeast Asia limit treatment options. These infections are not only 
a problem in endemic regions, but may also cause clinical problems in, for instance, 
Western Europe due to travellers who return home ill with imported enteric fever. This 
problem is clearly exemplified in our study, where 17 of 26 (65%) travellers with enteric 
fever were infected with a DCS isolate.
We observed a prolonged fever clearance time and hospital stay for DCS, but this find-
ing may relate to the use of ciprofloxacin as first-line treatment in the early years of 
the 21st century. From the year 2002 onwards, the global emergence of DCS isolates in 
enteric fever became apparent, also in imported cases, resulting in failure of empirical 
treatment with ciprofloxacin in 12 of 13 patients. Since 2007, patients from the Indian 
subcontinent are, therefore, treated upfront with third-generation cephalosporins.
The increase of DCS isolates and upcoming resistance to third-generation cephalospo-
rins in enteric fever necessitates alternative therapies, because, as a result, empirical 
therapy may become ineffective. In case of ciprofloxacin, this is a dose-related effect, 
based on pharmacokinetic and pharmacodynamic principles. The ƒAUC0-24/MIC ratio 
is used as a parameter to evaluate adequate therapy of ciprofloxacin in patients with a 
Gram-negative bacterial infection20. Increasing the dose of ciprofloxacin should theo-
retically result in a better cure rate in enteric fever treatment. Although three patients 
would have achieved an adequate ƒAUC0-24/MIC ratio with 1500 mg of ciprofloxacin 
daily, our study also demonstrates that, for half of the patients with a DCS isolate, the 
ciprofloxacin dosage which should be administered will probably result in toxic levels23. 
Treatment with higher ciprofloxacin doses seems, therefore, not a feasible option.
In countries with a high burden of DCS, other fluoroquinolones have been studied as po-
tential alternative treatment options. The best clinical evidence is available for gatifloxa-
cin24,25. There are no firm clinical data about treatment with levofloxacin or moxifloxacin 
in DCS enteric fever. Based on PK/PD data, the administration of non-toxic doses of 
levofloxacin will likely result in adequate ƒAUC0-24/MICs ratios, so this fluoroquinolone 
may be a possible option for future treatment. However, in the present study, we dem-
onstrated that, theoretically, this could only be achieved in some of the DCS isolates. For 
gatifloxacin, the results looked more promising, but this fluoroquinolone was removed 
from market in 2006 because of its serious side effects. Since mechanisms of resistance 
to different fluoroquinolones are similar, the consequence of usage of higher doses of 
levofloxacin may be a rapid evolution in DCS isolates towards clinical resistance to all 
fluoroquinolones. Also, previous clinical studies with fluoroquinolones show that a sub-
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stantial proportion of hospitalised patients do not reach target ƒAUC0-24/MIC ratios with 
recommended doses26,27. Based on PK/PD principles only, one could argue that, for any 
Enterobacteriaceae organism, the clinical breakpoint should be 0.125 mg/L rather than 
0.5 mg/L19,28,29. If pharmacokinetic variation in the population is taken into account, it 
would be even lower, probably 0.06 mg/L.
In areas with increased use of ciprofloxacin as a first-line drug of choice over more tra-
ditional antimicrobial agents for the treatment of enteric fever, the multidrug resistance 
against ampicillin, chloramphenicol and trimethoprim/sulphamethoxazole is decreas-
ing8. We observed the same trend in our strain collection containing only two MDR 
isolates. Using these antibiotics in an individual is a treatment option when the sus-
ceptibility is proven. It should be borne in mind, however, that widespread use of these 
antibiotics as first-line treatment will likely result in fast re-emergence of resistance.
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Abstract
Antimicrobial susceptibility was analyzed for 354 typhoidal Salmonella isolates collected 
during 1999-2012 in the Netherlands. In 16.1% of all isolates and in 23.8% of all isolates 
that showed increased MICs for ciprofloxacin, the MIC for azithromycin was increased. 
This resistance may complicate empirical treatment of enteric fever.
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Enteric fever caused by Salmonella enterica serotypes Typhi and Paratyphi A, B and C 
is mainly a disease of the developing world, and it is occasionally diagnosed as an im-
ported disease in countries where the disease is not endemic1. Its empirical treatment 
has been hampered by resistance to ampicillin, chloramphenicol, and trimethoprim and 
by decreased ciprofloxacin susceptibility (MIC for ciprofloxacin 0.125-1.0 µg/mL), and 
ciprofloxacin resistance (MIC for ciprofloxacin >1.0 µg/mL)2,3. As a consequence, third-
generation cephalosporins are used as first-line drugs for intravenous treatment, and 
azithromycin is frequently used for empirical treatment of uncomplicated enteric fever.
Although no clinical breakpoints are available to define azithromycin susceptibility or 
resistance, several clinical studies have demonstrated good efficacy of azithromycin for 
the treatment of uncomplicated enteric fever in clinical and in vitro studies4-10. Regard-
ing MIC breakpoints, the European Committee on Antimicrobial Susceptibility Testing 
states that isolates with an MIC <16 µg/mL for azithromycin should be considered as 
wild-type organisms that are responsive to treatment3. The Clinical and Laboratory 
Standards Institute (www.clsi.org/) does not provide clinical breakpoints for macrolides 
for the group of Enterobacteriaceae. In previous studies of typhoidal Salmonella isolates, 
MICs for azithromycin ranged from 4 µg/mL to 64 µg/mL8-13.
The first clinical case for which treatment of illness caused by typhoidal Salmonella 
spp. with azithromycin (MIC 256 µg/mL) failed was reported during 2010, evidenced by 
testing a S. enterica Paratyphi A isolate from Pakistan14. Further, in a study of isolates 
from blood samples collected in India during 2005-2008, MICs ≥16 µg/mL for azithro-
mycin were observed in 34.7% (35/101 isolates) of the Salmonella isolates; clinical non-
response was reported in 19 of 36 patients treated with azithromycin13. Whether this 
problem of increasing MICs for azithromycin is limited to India or is emerging globally is 
not clear. The objective of our study was to investigate azithromycin susceptibility and 
trends in antibacterial drug resistance over time in isolates collected during 1999-2012 
in the Netherlands.
The Study
Enteric fever is a notifiable disease in the Netherlands. During January 1999-December 
2012, a total of 354 isolates were submitted by microbiology laboratories to the Sal-
monella National and Community Reference Laboratory (www.eurlsalmonella.eu/): 177 
(50%) S. enterica Typhi isolates, 98 (27.7%) S. enterica Paratyphi A isolates, 78 (22.0%) S. 
enterica Paratyphi B isolates, and 1 (0.3%) S. Paratyphi C isolate. There was no statistical-
ly significant difference in sex among patients whose tests showed S. enterica Typhi iso-
lates (56.3% male, 43.7% female, p=0.18) and S. enterica Paratyphi isolates (51.6% male, 
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48.4% female, p=0.18). Patients ranged in age from 0 to 92 years. The median ages, 28.4 
and 29.5 years, respectively (p=0.60), did not differ between patients in whose samples 
S. enterica Typhi and Paratyphi were isolated. Trends in cumulative 1-year incidence were 
determined by linear regression analysis; data were weighted on the number of isolates 
collected each year. The cumulative 1-year incidence of enteric fever was relatively sta-
ble during 1999-2012, with an average of 25 isolates (4-39/year) for that period (p=0.42).
All MICs were determined by using the broth microdilution method with Mueller-Hinton 
II cation–adjusted broth (Difco, Franklin Lakes, NJ, USA). We applied European Com-
mittee for Antimicrobial Susceptibility Testing guidelines for category interpretation for 
different antibacterial drugs3. Azithromycin MICs were 2–256 µg/mL among the 354 
isolates and were increased in 57 (16.1%) of the isolates [figure 1]. The distribution of 
azithromycin MICs of S. enterica Typhi and Paratyphi A and B peaked at 8, 16 and 8 µg/
mL, respectively [figure 1]. Trend analysis showed no increased MIC over time for all 
isolates (p=0.21) or for S. enterica Typhi (p=0.35) or Paratyphi (p=0.70). One Paratyphi 
A isolate, from a sample acquired in Malaysia in 2007, required an MIC of 256 µg/mL. 
Decreased susceptibility to ciprofloxacin was observed in 116 (32.8%) and ciprofloxacin 
resistance in 6 (1.7%) of the 354 isolates. Cumulative 1-year incidence of isolates with 
decreased susceptibility or resistance to ciprofloxacin increased significantly from 0% 
(0/12 isolates) in 1999 to 64.3% (18/28 isolates) in 2012 (p<0.001) [figure 2]. Among iso-
lates with decreased susceptibility or resistance to ciprofloxacin, 23.8% (29/122 isolates) 
showed an increased MIC for azithromycin; MICs increased for 12.1% (28/232 isolates) 
Figure 1 MICs of azithromycin of 354 Salmonella enterica serotypes Typhi and Paratyphi A, B, and C  
isolates from samples collected from ill returned travelers in the Netherlands, 1999-2012.  
For wild type isolates, MIC ≤16 µg/mL.
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of the ciprofloxacin-susceptible isolates (p=0.004) [figure 3]. No significant increase in 
amoxicillin, trimethoprim and chloramphenicol resistance was observed (amoxicillin, 
p=0.97; trimethoprim, p=0.95; and chloramphenicol, p=0.99) [figure 2]. For all isolates, 
the MICs for erythromycin ranged from 64 to ≥512 µg/mL. Resistance to third-genera-
tion cephalosporins was not observed in the isolates.
Figure 2 Trends in antimicrobial resistance rates of enteric fever isolates of ill travelers returned to the 
Netherlands, 1999-2012. Trend analysis shows significant increase in decreased ciprofloxacin 
susceptibility or ciprofloxacin resistance (p<0.001).
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Figure 3 MICs of azithromycin in relation to ciprofloxacin susceptibility of 354 Salmonella enterica sero-
types Typhi and Paratyphi isolates. Increased MICs for azithromycin (MIC>16 µg/mL) in isolates 
with decreased ciprofloxacin susceptibility or ciprofloxacin resistance (MIC≥0.125 µg/mL) versus 
ciprofloxacin-susceptible isolates (MIC<0.125 µg/mL) (p=0.004).
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The origins of isolates for which the country of acquisition was known (205 of 354 strains) 
were distributed among geographical regions by using the United Nations geoscheme 
(http://unstats.un.org/unsd/methods/m49/m49regin.htm). Besides imported cases 
from countries in which enteric fever is highly endemic, such as India, Indonesia and 
Pakistan, rates of importation were high for travelers from Turkey and Morocco [table 1].
Percentages of elevated MICs for azithromycin were highest for isolates acquired in 
regions that had concurrent high proportions of isolates with decreased susceptibility 
or resistance to ciprofloxacin [table 1]. In isolates acquired in countries from Southern 
Asia, increased MICs for ciprofloxacin and increased MICs for azithromycin were ob-
served in 21.4% (18/84 isolates) of the isolates.
Conclusions
We found high percentages of elevated azithromycin MICs in typhoidal Salmonella iso-
lates collected in the Netherlands during 1999-2012. MICs >16 µg/mL for azithromycin 
Table 1 Isolates with elevated MICs for ciprofloxacin and isolates with an MIC for azithromycin above wild 
type (>16 µg/mL) in Salmonella enterica serotype Typhi and Paratyphi isolates collected in travel-
ers returning to the Netherlands, 1999–2012. 
Region No. (%) isolates No. (%) isolates 
with elevated MICs
Azithromycin Ciprofloxacin Azithromycin  
and Ciprofloxacin 
All
Asia
Southern Asia*
South-Eastern Asia†
Western Asia‡
Eastern Asia§
Unknown
Africa¶
Europe**
Latin America†† 
205
161 (78.5)
84 (40.0)
44 (21.5)
27 (13.2)
5 (2.4)
1 (0.5)
35 (17.1)
4 (2.0)
5 (2.4)
36 (17.6)
31 (19.3)
21 (25)
5 (12.2)
1 (3.7)
1 (20)
0
5 (14.3)
0
0
83 (40.5)
80 (49.7)
69 (82.1)
3 (6.8)
6 (22.2)
2 (40)
0
1 (2.9)
2 (50)
0
20 (9.8)
20 (12.4)
18 (21.4)
1 (2.3)
1 (3.7)
0
0
0
0
0
* India, Pakistan, Bangladesh, Nepal, Afghanistan, Nepal, Sri Lanka
† Indonesia, Cambodia, Malaysia, Thailand
‡ Turkey, Iraq, Syria
§ China
¶ Morocco, Ghana, Nigeria, Senegal, Tunisia, Malawi, Tanzania
** Gibraltar (Great Britain), Greece, Italy, Romania
†† Peru, Mexico, unknown
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were found in 16.1% of all isolates and in 23.8% of isolates with elevated MICs for cipro-
floxacin. This observation may be explained by increased use of azithromycin in coun-
tries from which samples yielded high rates of typhoidal Salmonella isolates with de-
creased susceptibility or resistance to ciprofloxacin. Moreover, our findings are aligned 
with an alarming report from India on increasing MICs for azithromycin13. Our study 
shows higher MICs than anticipated based on another Western case series11, implying 
that these potentially resistant strains are not confined to India.
Besides treatment with third-generation cephalosporins, empirical treatment options 
may be scarce for patients with potential azithromycin-resistant Salmonella serotypes. 
Reuse of antibacterial drugs, such as ampicillin, chloramphenicol or trimethoprim may 
be a valuable treatment option upon proven susceptibility, but widespread use of these 
antibacterial drugs as first-line treatment will likely result in rapid reemergence of multi-
drug resistance and associated drug-related adverse effects. Further, increasing the dose 
of ciprofloxacin or using alternative fluoroquinolones had been suggested as an effective 
treatment in some cases15. This option will not be feasible for empirical treatment be-
cause it applies only in a minority of cases and may be associated with drug toxicity. The 
danger of losing azithromycin to antimicrobial resistance could be detrimental in coun-
tries faced with endemic or epidemic enteric fever and complicated by poverty; there-
fore, azithromycin should be used with care. The results of this study also implicate the 
importance of developing more effective vaccines as control measures for enteric fever. 
Future research is needed to evaluate clinically relevant breakpoints of azithromycin by 
analyzing the treatment outcome of azithromycin in relation to their MICs.
In conclusion, typhoidal Salmonella isolates in ill returned travelers from the Nether-
lands already show a high percentage of increased MICs for azithromycin. Because the 
highest proportions of increased MICs for azithromycin are found in isolates with in-
creased MICs for ciprofloxacin and in regions where decreased susceptibility or resis-
tance to ciprofloxacin is already widely prevalent among S. enterica Typhi and Paratyphi 
isolates, this resistance may further limit future treatment options for enteric fever.
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Abstract
High rates of quinolone-resistant strains of Shigella sonnei in HIV-infected men who 
have sex with men (MSM) have recently been reported. Patients with a Shigella infection 
are often treated with azithromycin, although no clinical breakpoints are available. We 
would like to describe the first report of treatment failure, due to resistance to azithro-
mycin (MIC >256 mg/L), in a HIV positive patient with a Shigella flexneri bacteremia.
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Dear editor,
We read the paper by Hoffmann et al. on high rates of quinolone-resistant strains of 
Shigella sonnei in human immunodeficiency virus (HIV)-infected men who have sex with 
men (MSM) in Germany1. The authors report that, due to these high rates of resistant 
isolates, the empirical use of quinolones in HIV-infected patients presenting with S. 
sonnei infection is no longer recommended. We fully agree with this statement. Further, 
traditional antibiotics cannot be used as the first-line treatment, because multidrug 
resistance is already widely spread among Shigella isolates. As a consequence of the 
emergence of quinolone resistance in Campylobacter isolates, azithromycin is already 
widely used as empirical treatment of bacterial gastroenteritis. Patients with a gastro-
enteritis caused by a Shigella infection will, therefore, often be treated with azithromy-
cin as first-line treatment. Although, no clinical breakpoints are available, cases of Shi-
gella isolates with increased minimum inhitory concentrations (MICs) for azithromycin 
have already been documented in Asian countries2. Recently, the first observations of 
increased MICs for azithromycin in Shigella isolates have been reported in the United 
States3. Therefore, we would like to describe the first report of treatment failure in a HIV 
positive patient with a Shigella bacteremia which we treated with azithromycin.
Case report
A Dutch untreated HIV-positive man with a CD4 count of 650/ml was hospitalized in 
April 2012 with fever, abdominal pain, and bloody diarrhea. He had a sexual encounter 
with another man in Berlin, Germany 7 days earlier. As clusters of sexually transmitted 
Shigella infections among MSM have been reported previously, we suspected a Shigella 
infection. To cover Campylobacter and Salmonella as well, which are the most frequent 
causes of bacterial gastroenteritis in the Netherlands, we initiated therapy with azithro-
mycin 500 mg per day. 48 h later, Shigella flexneri infection was confirmed in the blood 
and feces cultures. Because, at that time, the patient continued to have diarrhea, ab-
dominal pain, and high fevers, we initiated intravenous therapy with ceftriaxone 2 g 
QD and azithromycin was discontinued. Antimicrobial susceptibility testing showed 
susceptibility to ciprofloxacin (MIC ≤0.25), ceftriaxone (MIC ≤1), and trimethoprim/sul-
phametoxazole (MIC ≤1 mg/L) but the isolates was resistant to azithromycin (MIC >256 
mg/L). To confirm the increased azithromycin MIC, initially obtained by the Etest, the 
MIC was determined by the broth microdilution method with Mueller-Hinton II cation-
adjusted broth (MIC=128 mg/L). Repeated blood cultures after treatment were negative. 
The patient became afebrile 48 h after the initiation of ceftriaxone and he fully recov-
ered without complications.
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Shigella infections among MSM were first reported in San Francisco in 19984 but later 
outbreaks were also reported in other cities, like Berlin, London, Amsterdam, Chicago, 
Montreal and Vancouver. In only one of these reports was susceptibility to azithromycin 
tested and the MIC was 8 to 16 mg/L4. Although no clinical breakpoints are available, 
on epidemiological grounds, it can be suggested that an MIC ≤16 mg/L is comparable to 
the MIC distribution in wild-type Shigella isolates and, therefore, expected to respond to 
treatment5. The frequent use of azithromycin for the treatment of sexually transmitted 
infections among MSM in Europe may have contributed to the azithromycin resistance 
in S. flexneri observed in our patient. Since July 2010, all Shigella isolates from the Eras-
mus Medical Center in Rotterdam have been tested for azithromycin susceptibility by 
the Etest method. All the other 15 consecutive isolates tested during this period showed 
an MIC ≤16 mg/L, compatible with the wild-type distribution. Although increased MICs 
in Shigella isolates are still rare, we advise that MICs for azithromycin should always 
be determined in patients with a Shigella infection. It should be encouraged to report 
MICs for azithromycin in surveillance studies in order to contribute to the establishment 
of clinical breakpoints and to monitor the emergence of resistance. Clinical outcome 
studies are required to establish the clinical breakpoints for azithromycin. In a study 
examining invasive cases of Shigella in South Africa, HIV-infected cases were 4.1 times 
more likely to die than HIV-uninfected cases6. Because the clinical course of a Shigella 
infection may progress faster in HIV-positive patients, a third-generation cephalosporin 
should be considered if the patients presents with severe sepsis and the clinical presen-
tation suggests Shigella infection.
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Introduction
In this thesis, the objective was to study management of antimicrobial resistance in 
gastrointestinal bacteria. This was performed by investigating risk factors, analysing 
mechanisms involved in antimicrobial resistance and developing new diagnostic tools 
to detect resistance in gastrointestinal bacteria. Of all gastrointestinal infections caused 
by the usual bacterial pathogens (Salmonella, Campylobacter, Shigella and Yersinia), ty-
phoidal Salmonella species are the only pathogens requiring antimicrobial treatment 
in immunocompetent patients. Most of the studies in this thesis therefore focus on 
typhoidal Salmonella isolates.
Main findings
Risk factors for gastroenteritis and antimicrobial resistance
An association between proton pump inhibitor (PPI) therapy and bacterial gastroenteri-
tis has been suggested as well as contradicted1-10. As a result, warnings are introduced 
for people using PPIs, such as avoiding raw meat consumption and antibiotic treatment 
on demand for travels to the tropics, to prevent food borne infections. The aim of the 
study in Chapter 2 was to analyse this association in the prospective Rotterdam Study, 
a population-based cohort study among 14 926 subjects aged 45 years and older with 
up to 24 years of follow-up11.
In this study, we found that participants with a bacterial gastroenteritis were more likely 
than controls to be current users of PPIs (adjusted OR, 1.94; 95% CI 1.15-3.25). A consid-
erably higher effect was observed (adjusted OR 6.14; 95% CI 3.81-9.91), using the total 
cohort as a reference in a nested case-control analysis. We showed that current PPI 
therapy is associated with an increased risk of bacterial gastroenteritis. However, by re-
ducing the risk of selection and information bias in our study design, we demonstrated 
that the effect is lower than previously assumed.
International travel is considered to be an important risk factor for acquisition of multi-
resistant Enterobacteriaceae12-22. The aim of the systematic review in Chapter 3 was to 
determine the effect of international travel on the risk of post-travel faecal carriage of 
multidrug-resistant Enterobacteriaceae (MRE). A systematic search for relevant literature 
in seven international databases was conducted according to PRISMA guidelines. Eleven 
studies were identified. In this systematic review, we demonstrated that international 
travel is a major risk factor for acquisition of MRE. This risk is particularly high after travel-
ling to (Southern) Asia and in persons with travel related diarrhoea and antibiotic therapy 
for travellers’ diarrhoea. Further, high percentages of resistance to ciprofloxacin, co-tri-
moxazole and aminoglycosides were observed in travellers with MRE carriage after travel.
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Antimicrobial resistance
Owing to multidrug resistance, and an increase in fluoroquinolones resistance, it be-
comes more problematic to combat Salmonella organisms23. Different bacterial resis-
tance mechanisms may result in reduced ciprofloxacin susceptibility24. In the study in 
Chapter 4, the presence and expression of different resistance mechanisms resulting in 
reduced minimum inhibitory concentrations (MICs) for ciprofloxacin were evaluated in 
23 blood-culture-derived Salmonella enterica serotypes Typhi and Paratyphi A organisms 
from ill-returned travellers to Asia. Reduced ciprofloxacin susceptibility was only found 
in travellers returning from India and Pakistan. All isolates with reduced ciprofloxacin 
susceptibility had a mutation at position 83 in the QRDR region of the gyrA gene. Efflux 
pump inhibition did not appear to affect the MICs of ciprofloxacin and activity of the 
efflux pump appeared to be specific for resistance to nalidixic acid. Repeated exposure 
of the isolates to ciprofloxacin did not result in a significant increase in the MICs for 
ciprofloxacin. Repetitive sequence-based polymerase chain reaction (rep-PCR) profiles 
identified five different genotypes, but no correlation with resistance was observed. 
Plasmid-mediated fluoroquinolone resistance was not found. This study shows that the 
reduced ciprofloxacin MIC in S. Typhi and S. Paratyphi A is solely due to an amino acid 
substitution in the QRDR ‘cluster’ of the gyrA gene.
Though these QRDR mutations are invariably detected by sequencing of the gyrA gene, 
phenotypically important QRDR mutations also result in amino acid substitutions in the 
GyrA protein of typhoidal Salmonellae, which could potentially be detected using high 
resolution mass spectrometry techniques25,26. In Chapter 5 a liquid chromatography-
mass spectrometry (LC-MS) methodology was developed and evaluated for the detec-
tion of amino acid substitutions in the GyrA protein of 23 typhoidal Salmonella isolates, 
with different antibiotic sensitivities to fluoroquinolone antibiotics. PCR sequencing of 
the gyrA gene was used to validate the results. The LC-MS methodology correctly identi-
fied peptide sequences associated with phenotypic QRDR mutations of the GyrA protein 
in all of the 23 phenotypically diverse typhoidal Salmonella isolates tested. A reliable and 
rapid LC-MS methodology has been developed, which is able to identify gyrA QRDR mu-
tations that are involved in the development of fluoroquinolone resistance in typhoidal 
Salmonella species.
In Chapter 6 we studied the impact of decreased ciprofloxacin susceptibility (DCS) iso-
lates (due to changes in EUCAST expert rules currently defined as ciprofloxacin resistant 
isolates; http://www.eucast.org/expert_rules/) on the fate of travellers returning with 
a typhoidal Salmonella infection and possible alternative treatment options. We evalu-
ated the clinical features, susceptibility data and efficacy of empirical treatment in pa-
tients with positive blood cultures of a DCS isolate compared to patients infected with 
a ciprofloxacin-susceptible (CS) isolate in the period from January 2002 to August 2008. 
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In addition, the pharmacokinetic and pharmacodynamic parameters of ciprofloxacin, 
levofloxacin and gatifloxacin were determined to assess if increasing the dose would 
result in adequate unbound fraction of the drug 24-h area under the concentration–time 
curve/minimum inhibitory concentration (ƒAUC0–24/MIC) ratio. DCS was associated with 
a longer fever clearance time and length of hospital stay compared to patients in whom 
the initial empirical therapy was adequate. We demonstrated that, in some cases, an 
adequate ƒAUC0–24/MIC ratio could be achieved by increasing the dose of ciprofloxacin 
or by the use of alternative fluoroquinolones.
Because of the emergence of ciprofloxacin resistance, azithromycin is now often used 
as first line treatment for enteric fever, although clinical breakpoints and epidemiologic 
data are lacking27-34. In Chapter 7 we analysed the incidence and variation in antibiotic 
resistance over time of 354 typhoidal Salmonella isolates collected from January 1999 
to December 2012 in The Netherlands. In 16.1% of all isolates the MIC for azithromycin 
was increased. A significantly higher proportion (23.8%) of isolates with increased MICs 
for azithromycin was found in isolates with decreased susceptibility or resistance to 
ciprofloxacin and in regions where decreased susceptibility or resistance to ciprofloxa-
cin is already widely prevalent among typhoidal Salmonella isolates. This resistance may 
complicate future empirical treatment of enteric fever.
Fortunately, resistance to azithromycine and treatment failure in gastrointestinal 
pathogens is still very uncommon35-38.
Methodological considerations
Study setting and design (The Rotterdam Study)
To study the association between PPIs and the bacterial gastroenteritis in Chapter 2 
The Rotterdam Study was used, a prospective population-based cohort study in 14,926 
people aged ≥45 years, from one district (Ommoord) in the city of Rotterdam, the Neth-
erlands11. In short, from 1990 through 1993, 7983 participants were included (cohort I). 
In 2000, an additional 3011 participants who had become 55 years old or older or who 
had moved into the district, were enrolled (cohort II). In 2006, another 3932 participants, 
aged 45 years and older were included (cohort III) [figure 1]. Follow-up examinations 
are conducted every four to five years. Participants are continuously monitored through 
linkage of records from general practitioners. Results of bacterial pathogens (Salmonella, 
Campylobacter, Shigella and Yersinia species) isolated from stool samples were obtained 
from Star Medisch Diagnostisch Centrum (Star-MDC), a centre for medical diagnostics 
for outpatients in the city of Rotterdam. The majority of all laboratory tests, including 
microbiology tests, of patients from general practitioners within the Ommoord district 
of Rotterdam are performed at Star-MDC. Of all participants of The Rotterdam Study, of 
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whom informed consent was obtained for requesting medical information, positive and 
negative microbiology tests between 1999 and April 2013 were obtained.
Randomized controlled trials are often considered as the golden standard to study ef-
ficacy and effectiveness, and common adverse reactions of drugs39. However, several 
adverse events, such as increased susceptibility to gastrointestinal infections, are rela-
tively rare and therefore other observational study designs are more eligible to inves-
tigate this kind of research questions39. In general, to study a rare outcome (disease), 
a case control design is considered to be the most appropriate design but when a rare 
determinant (risk factor) is expected, a study design using a cohort control study is pre-
ferred39. PPIs are widely used worldwide, and also in our study population. Occurrence 
Figure 1 Design of The Rotterdam Study11
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of a bacterial gastroenteritis is relatively rare (11 cases per 1000 people per year) in terms 
of observational study design, which was also observed in our study40. Based on this in-
formation it is a rational approach of the authors of most of the previous studies to use a 
case control study design to address the association between PPI therapy and bacterial 
gastroenteritis. However, this study design is also prone to selection and information 
bias. Studies considering self-limiting diseases such as gastroenteritis, might select a 
“help seeking” and therefore biased and selected population. As a consequence, people 
using a PPI will be more inclined to consult medical help in case of gastroenteritis com-
pared to randomly selected controls, even if they are matched in a case-control study. 
Recall bias, a well-known example of information bias, is an important problem in case 
control studies in which questionnaires are used to access risk factors. Further, there is 
an increased risk of residual confounding in case-control studies compared to prospec-
tive cohort studies, because relevant information is not systematically and retrospec-
tively collected. For these reasons a prospective population-based cohort study, such as 
The Rotterdam Study, is probably the best study design to address our research ques-
tion and minimize the risk of selection or information bias and residual confounding. 
Within The Rotterdam Study, we were able to investigate the association between PPI 
therapy and bacterial gastroenteritis in a nested case-control study design. Based on 
the previous arguments, the selection of a comparable control group failed in virtually 
all previous studies with a similar research question. As a result, most of these studies 
may have suffered from a “healthy control” bias, because of the use of an incomparable 
healthier control groups (using random samples from population registries, or volun-
teering friends or relatives of the cases as control group). We tried to avoid healthy 
control bias by only using participants with negative stool samples as control group and 
correcting for the use of chronic medication.
Our study may also have suffered from bias and residual confounding. We had no 
data on other important risk factors for bacterial gastroenteritis, such as foreign travel-
ling, eating in a restaurant, or contact with animals. Probably the most important risk 
factor for bacterial gastroenteritis is the dietary pattern, because transmission of the 
pathogen goes by raw meat, especially chicken41,42. An association with dietary data 
was not observed in our study. Unfortunately, the number of missing dietary data in our 
study was rather high with as a consequence a large number of imputed data. Also, the 
dietary data in our study were collected during one week and do therefore not neces-
sarily represent the dietary pattern at the time of infection.
A limitation of our study design, using negative test results, may be underestimation 
of the risk. A number of the controls with negative stool cultures may be false-negatives. 
They can be false-negative either because of low diagnostic sensitivity against the four 
bacterial species (e.g., too little material received, long transportation time, stool collect-
ed many days after onset of gastroenteritis) or because the patient suffered from other 
causes of bacterial gastroenteritis (diarrheagenic Escherichia coli or Clostridium difficile). 
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Clinical cohort
For Chapter 4, 5 and 6 a collection of 23 well-characterized blood culture-derived ty-
phoidal Salmonella isolates was used that had been obtained from patients during the 
period January 2002 to August 2008 obtained from patients attending the Harbour Hos-
pital and Institute for Tropical Diseases, Rotterdam, The Netherlands. All travellers diag-
nosed with blood-culture-confirmed S. Typhi and S. Paratyphi infections in this hospital 
were included and clinical symptoms, physical findings and laboratory findings were 
collected retrospectively. Serotype determination was performed at the Salmonella Na-
tional and Community Reference Laboratory (www.eurlsalmonella.eu/) by the National 
Institute for Public Health and the Environment (RIVM), Bilthoven the Netherlands. All 
travellers did acquire the infection in Asia. Although the majority of endemic cases of 
typhoidal Salmonella infections worldwide are from Asian countries, it is still remark-
able that this cohort of isolates does not include any isolate acquired in Africa23. This is 
probably because the number of Dutch travellers to Asia strongly exceeds the number 
of travellers to Africa. Also high risk countries for enteric fever, such as India, Nepal 
and Indonesia are very popular travel destinations for Dutch travellers. Another possible 
explanation might be that travellers to Africa are more aware of hygiene related health 
risks, compared to travellers to Asia. In Asia eating local food plays an important role 
during travel, whereas this is less the case in Africa. Furthermore, Asia is a more popular 
destination for ‘backpackers’ who are usually more exposed to local food and lesser hy-
giene. The fact that our cohort consists of solely Asian isolates also explains a relatively 
high percentage of resistant Salmonella isolates, because antimicrobial resistance in 
enteric fever is mainly a problem in Asian countries23.
RIVM cohort
Enteric fever is a notifiable disease in the Netherlands (group B2). For Chapter 7 we used 
all available typhoidal isolates detected in the Netherlands during January 1999-Decem-
ber 2012. During this period a total of 354 isolates were submitted by microbiology 
laboratories in the Netherlands to the EURL. It is remarkable that isolates sent to the 
EURL by local laboratories covered only 43% of the overall notifications to the RIVM, 
whereas this is expected to be 100% because a notifiable disease is required by law 
to be reported to government authorities. As a consequence, Chapter 7 could have 
suffered from selection bias. The reason for not sending in the isolate, will probably be 
unawareness off the laboratory and will probably not relate to the determinant (country 
of acquisition) or outcome (antimicrobial resistance) studied in Chapter 3.4 Because all 
isolates were sent anonymously to the EURL, we only had information on gender, age 
and travel destination and a multivariate analysis was not performed. Therefore, there 
might always be a risk of residual confounding. It would have been interesting to include 
some additional covariates to this analysis, such as use of antimicrobial drugs, chronic 
diseases and use of proton pump inhibitors.
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In Chapter 7 an association was observed between increased MICs for ciprofloxacin 
and increased MICs for azithromycin [figure 2]. In a recent phylogeographical analysis, 
a single multidrug resistant lineage, H58, proved to be responsible for the emergence 
of these resistant isolates throughout Asia and Africa34. The phylogenetic agreements 
of these isolates, which have not been analyzed in our study, probably explain this as-
sociation.
Clinical implications
Use of PPIs and bacterial gastroenteritis
Although we found a lower association (odds ratio 1.9) between use of PPIs and bacte-
rial gastroenteritis in Chapter 2 compared to previous studies, this association was not 
rejected by our study. As a result, clinical doctors and patients must be aware of the 
risk and patients should take hygiene precautions into account, such as avoiding to eat 
undercooked eggs. On the other hand, the association concerns a relatively low risk and 
a relatively rare disease. Patients should therefore not be scared and be discouraged to 
participate in barbeques or to travel to countries with lower hygiene standards. For the 
same reason, prescribing prophylactic antibiotics to every traveller using a PPI should be 
discouraged. Antibiotic therapy for travellers’ diarrhoea has even been shown to be one 
of the major risk factors for acquisition of MRE in Chapter 3
Figure 2 MIC distribution for azithromycin of 354 S. Typhi and S. Paratyphi A, B and C isolates, collected from 
1999–2012, from ill returned travellers in the Netherlands. For wild type isolates MIC ≤16 mg/L.
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International travel and acquisition of MRE
In Chapter 3 a very high prevalence of carriage of MRE after international travel was 
found. Routine screening for asymptomatic faecal carriage of MRE seems indicated in 
hospitalized patients with a recent travel history to high risk countries. It is still not clear 
what the duration of carriage is after travel. For infection prevention and control guide-
lines this information will be essential to create new screening strategies.
Diagnostic tools for detecting antimicrobial resistance in typhoidal Salmonella
Susceptibility testing of micro-organisms is still performed in a classic fashion by de-
termining the Minimal Inhibitory Concentration by 18 h exposure to different concen-
trations of the antibiotic. Further, due to new mechanisms of resistance not only clas-
sic susceptibility testing is performed but extended by phenotypic screenings-assays 
sometimes in combination with PCRs to detect/confirm the presence of mechanisms 
of resistance. The reason for performing PCRs is that some mechanisms of resistance 
are not accurately detected by susceptibility testing due to the fact that systems are not 
able to detect small shifts in MICs. With the alternative technique i.e. whole genome 
sequencing, the genetic information is obtained but no information of expression levels 
of the genes is provided. Due to the delay in obtaining susceptibility results and the 
increase in mechanisms of resistance there is a need for alternative techniques which 
are quicker with the same and perhaps better accuracy than current techniques. In the 
study in Chapter 5 we show a proof of principle that with high resolution MS we are 
able to demonstrate the presence of non-synonymous amino-acid substitutions in the 
gyrase enzyme in Salmonella. This methodology can also be used to detect different be-
ta-lactamases and aminoglycoside modifying enzymes. By improving the sample pre-
treatment of samples in combination with the development of a database consisting 
out of adequate information of proteins involved in antibiotic resistance, this technique 
could become a quick and accurate alternative for current resistance determinations.
Treatment
In Chapter 7 it is shown that third generation cephalosporin’s or azithromycin are 
the only empiric antibiotic treatment options in travellers who acquired enteric fever 
in Southern Asia. Based on the results of Chapter 3, in a traveller who very recent-
ly returned from Southern Asia with a severe septicaemia, (combined) resistance to 
cephalosporin’s, aminoglycosides and fluoroquinolones will probably be (much) higher 
than 10% and should be taken into account in the choice of empiric antibiotics. This 
advice seriously conflicts with Dutch guidelines being very restrictive with prescription 
of broad spectrum antibiotics, resulting in the lowest prevalence of antibiotic resistance 
worldwide. Therefore, more research is needed to assess if newly acquired MRE carriage 
also leads to an increase of infections with MRE.
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Future treatment options
In Chapter 6 we demonstrated that, in some cases, a patient infected with a fluoroqui-
nolone resistant Salmonella isolate could potentially be treated with fluoroquinolones 
by increasing the dose of ciprofloxacin or by the use of alternative fluoroquinolones 
and achieving an adequate ƒAUC0–24/MIC ratio. In our study, increasing the dose to an 
adequate ƒAUC0–24/MIC ratio will lead to conceivably toxic drug levels in 50% of the pa-
tients treated with ciprofloxacin. If alternative treatment options are available, increas-
ing the dose of ciprofloxacin or using alternative fluoroquinolones will therefore not be 
an advisable treatment option.
Typhoidal Salmonella infections should be treated with third-generation cephalosporin’s 
or azithromycin empirically. Reuse of antibacterial drugs, such as ampicillin, chloram-
phenicol or trimethoprim may be a valuable treatment option upon proven susceptibility, 
but widespread use of these antibacterial drugs as first-line treatment will likely result in 
rapid reemergence of multidrug resistance and associated drug-related adverse effects.
Azithromycin in the treatment of Salmonella
Good efficacy of azithromycin in the treatment of Salmonella infections have been 
shown in clinical trials. Although cases with treatment failure with azithromycin are 
very uncommon, increased MICs of azithromycin have already been reported35,36. Even 
more worrisome, we demonstrated in Chapter 7 an increased MIC for azithromycin in 
23.8% of the isolates already possessing increased MICs for ciprofloxacin. This highly 
resistant Salmonella strain already emerged from Asian countries to several African 
countries37. The danger of losing azithromycin to antimicrobial resistance could be det-
rimental; therefore, azithromycin should be used with care.
Taken together, emergence of antimicrobial resistance in gastrointestinal bacteria 
should be combated by determining risk factors, analysing mechanisms involved in re-
sistance and developing faster diagnostic tools to detect resistance.
Future research
Use of PPI and travellers’ diarrhoea
It would be interesting to assess the association of PPI use and gastroenteritis in a 
prospective study design. In a normal setting this design would not be possible, be-
cause it concerns a relatively rare disease38. In a population of travellers to the tropics, 
the incidence of travellers’ diarrhoea might be high enough. Travellers’ diarrhoea also 
includes Escherichia coli related diarrhoea. There is no literature about an association 
between PPI use and travellers’ diarrhoea, but diminishing gastric acid and changes 
of microbiota will probably lead to increased survival of diarrheagenic Escherichia coli 
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as well. Participants could be studied using questionnaires during travel about stool 
pattern. Detection bias might be a problem, because people using a PPI will always be 
warned for the risk of gastroenteritis, while visiting a travel clinic. Therefore the control 
group should also be warned for gastroenteritis in a routine way. Multivariate analysis 
should be performed, because there is still a high risk of bias and residual confounding.
International travel and infections with MRE and spread to the community
Two crucial questions still remain unanswered: does increased carriage of MRE results in 
infections with MRE and does increased carriage of MRE results in spread to the commu-
nity? These questions can only be answered by including these analyses in one of the big 
travel studies, such as the French VOYAG-R study or the Dutch COMBAT study20,39. Follow 
up of participants should be performed, monitoring infections including antimicrobial 
susceptibility data. Household contacts should also be screened for carriage of MRE.
International travel and microbiota
There is increasing evidence that the microbiota of the gut plays an important role in 
many diseases. A normal microbiota protects the human body against pathogens [ref]. 
It is interesting to study if the gut microbiota 1. changes during international travel 2. 
Protects against bacterial gastroenteritis and/or travellers’ diarrhoea during travel 3. 
Protects against newly acquisition of MRE?
High-resolution mass spectrometry
We developed and evaluated a “proof-of-principle” methodology using LC-MS for the 
detection of amino acid substitutions in the GyrA protein of typhoidal Salmonella iso-
lates. Future research based on our findings can show the usefulness of our LC-MS 
methodology for the detection of other clinically relevant antimicrobial resistance phe-
notypes, for example amino acid substitutions in Penicillin-Binding Proteins (PBPs), or 
amino acid substitutions in the active site of β-lactamase enzymes, possibly in a new 
multiplexed methodology.
General prospects
Gastrointestinal infections usually not get as much attention as other infectious diseas-
es like for example HIV, tuberculosis or Staphylococcus aureus infections. Maybe because 
serious gastrointestinal infections mainly occur in developing countries. Enteric fever 
is still a neglected disease, resulting in many deaths every year in these countries. Al-
though enteric fever is a quite rare disease among travellers, still a few dozens of Dutch 
travellers acquire this potentially lethal disease every year. This number is not decreas-
ing, although (partially covering) vaccination is available. It is therefore worrisome that 
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the indication of vaccination is now being restricted, driven by shortage of the vaccine 
as a result of manufactory problems. This thesis highlights some other aspects of enter-
ic fever, which goes behind just incidence data. For example, we show that most cases 
of enteric fever in the Netherlands were acquired in Asian countries and these typhoidal 
Salmonella isolates were highly resistant to antibiotics. This fact should be taken into 
account when considering to vaccinate an individual. Vaccination indications for high 
risk Asian countries should therefore not be limited. Studies like ours should be used to 
convince policymakers about the severity of this disease. The vaccine for typhoid fever 
should be improved (to achieve a broader coverage), instead of reduced in production by 
pharmaceutical companies.
In the future different antimicrobial agents might be needed to combat antimicrobial 
resistance in gastrointestinal bacteria. Old antibiotics such as colistin and fosfomycin 
are used again as an ultimate refuge antimicrobial drug in the treatment of infections 
caused by multidrug resistant Gram-negative bacteria43. Worrisome, emergence of plas-
mid-mediated colistin resistance in Enterobacteriaceae have recently been observed in 
China44. Carriage of this colistin resistant Enterobacteriaceae have also been detected in 
healthy Dutch travellers45. These observation further stresses the importance to com-
bine clinical-, epidemiological- and laboratory research, as demonstrated in this thesis.
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In Hoofdstuk 1 wordt een introductie gegeven over bacteriële gastro-intestinale infec-
ties en antibiotica resistentie bij darmbacteriën. Bacteriële gastro-intestinale infecties 
zijn wereldwijd een veel voorkomend probleem. De meest voorkomende bacterie soor-
ten die deze infecties veroorzaken zijn Campylobacter, Salmonella, Shigella en Yersinia 
soorten. Dit zijn allen Gram-negatieve bacteriën die behoren tot de familie van de Ente-
robacteriaceae. Binnen deze bacterie soorten nemen de tyfeuze Salmonella soorten, die 
het ziektebeeld buiktyfus veroorzaken, een bijzondere plek in. Gastro-intestinale infec-
ties hebben, bij personen met een normale afweer, doorgaans een self-limiting beloop. 
Een buiktyfus infectie moet echter wel antibiotisch behandeld worden. Buiktyfus wordt 
in Nederland vooral als importziekte gezien bij reizigers. De afgelopen jaren wordt er 
een toename in antibiotica resistentie waargenomen bij tyfeuze Salmonella bacteriën. 
Dit proefschrift bestaat om die rede voornamelijk uit studies die betrekking hebben op 
tyfeuze Salmonella bacteriën. Naast het bestuderen van antibiotica resistentie mecha-
nismen, hebben we in dit proefschrift ook studies uitgevoerd naar risicofactoren voor 
het krijgen van gastro-intestinale infecties en antibiotica resistentie.
Voorkomen is beter dan genezen. In Hoofdstuk 2 wordt de associatie beschreven tus-
sen het gebruik van maagzuurremmers en bacteriële gastro-enteritis. Deze studie is 
uitgevoerd binnen de Rotterdam Studie, een prospectieve cohortstudie in een algeme-
ne populatie van 14.926 mensen van 45 jaar en ouder. Wij laten zien dat bij gebruikers 
van maagzuurremmers het risico op bacteriële gastro-enteritis significant hoger is dan 
bij vergelijkbare mensen die geen maagzuurremmers gebruiken. Indien wij echter goed 
corrigeren voor informatie en selectie bias, blijkt dit risico een stuk minder hoog te zijn 
dan verwacht op basis van eerdere studies.
Internationaal reizen wordt gezien als risicofactor voor dragerschap van multiresistente 
Enterobacteriaceae in de darm, zoals Escherichia coli (E. coli). Dit zijn normaal gesproken 
geen pathogene bacteriën, maar onder bepaalde omstandigheden kunnen ze wel ern-
stige infecties kunnen veroorzaken, zoals urineweginfecties en sepsis. In Hoofdstuk 3 
laten wij in een systematisch review zien dat het percentage dragerschap in de darm 
van deze multiresistente bacteriën bij net teruggekeerde reizigers ernstig verhoogd is. 
Het hoogste percentage dragerschap werd gezien bij reizigers teruggekeerd uit (zuide-
lijk) Azië, en bij reizigers met gastro-enteritis en/of antibiotica gebruik tijdens de reis. 
Een andere zorgwekkende observatie in het systematisch review was dat deze bacte-
riën, naast resistentie voor 3e generatie cefalosporines ook vaak resistent zijn voor flu-
oroquinolonen, cotrimoxazol en aminoglycosiden.
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Tyfeuze Salmonella bacteriën zijn al ruim 20 jaar multiresistent voor antibiotica (gedefi-
nieerd als resistent voor amoxicilline, chlooramfenicol en cotrimoxazol). Sinds ongeveer 
10 jaar is er in diverse Aziatische landen een toename van ciprofloxacine resistentie, 
wat de behandeling van buiktyfus verder bemoeilijkt. In Hoofdstuk 4 analyseren we 
de verschillende antibiotica resistentie mechanismen die een rol kunnen spelen in ci-
profloxacine resistentie bij 23 tyfeuze Salmonella bacteriën geïsoleerd bij reizigers. In 
alle gevallen blijkt een bekende puntmutatie (positie 83) in het gyrA gen de oorzaak van 
ciprofloxacine resistentie. Er werden geen andere resistentie mechanisme gevonden die 
verantwoordelijk kunnen zijn voor ciprofloxacine resistentie.
Resistentie als gevolg van een gen mutatie kan worden gedetecteerd door middel van 
polymerasekettingreactie (PCR). Een gen mutatie leidt alleen tot antibiotica resistentie 
wanneer de mutatie ook verandering van het bijbehorende aminozuur tot gevolg heeft, 
resulterend in een ander eiwit. In het geval van ciprofloxacine resistentie bij Salmonella 
bacteriën is dat het GyrA eiwit. Eiwitten kunnen worden gedetecteerd door middel van 
massaspectrometrie. In Hoofdstuk 5 tonen wij een studie waarin een methode met 
vloeistofchromatografie met massaspectrometer (LC-MS) wordt ontwikkeld en geëvalu-
eerd om mutaties in het GyrA eiwit te detecteren in dezelfde 23 tyfeuze Salmonella bac-
teriën als gebruikt in Hoofdstuk 3.1. We laten zien dat het in onderzoekssituatie mogelijk 
is om met grote zekerheid en in korte tijd de mutaties te detecteren die tot ciprofloxa-
cine resistentie leiden. Deze methode zou theoretisch ook toegepast kunnen worden 
voor antibiotica resistentie bij andere klassen antibiotica.
Farmacokinetiek is essentieel bij het bepalen van resistentie bij fluorochinolonen. In 
Hoofdstuk 6 tonen wij klinische parameters, antibiotica gevoeligheid en werkzaam-
heid van empirische behandeling van patiënten met een bewezen buiktyfus infectie. In 
deze studie worden patiënten met een ciprofloxacine ongevoelige stam vergeleken met 
een gevoelige stam. Tevens wordt bij deze patiënten de farmacokinetiek ((ƒAUC0–24/MIC) 
ratio) getoond van verschillende fluorochinolonen. Verminderde ciprofloxacine gevoe-
ligheid is geassocieerd met langere tijd tot koortsvrij zijn en een langere ziekenhuis op-
name duur. We laten zien dat in sommige gevallen van buiktyfus met een ciprofloxacine 
ongevoelige stam, toch een adequate behandeling zou kunnen worden bewerkstelligd 
door de dosering van ciprofloxacine te verhogen of door te behandelen met een ander 
fluorochinolon (levofloxacine of gatifloxacine).
Vanwege de forse toename van ciprofloxacine resistentie wordt azitromycine nu dik-
wijls gebruikt als eerstelijns behandeling voor ongecompliceerde buiktyfus infecties. In 
Hoofdstuk7 laten wij zien dat ondanks dat azitromycine resistentie bij tyfeuze Sal-
monella bacteriën zeer zeldzaam is, de MIC (minimum inhibitory concentration) voor 
azitromycine al verhoogd is bij 16.1% van alle Salmonella stammen, geïsoleerd in Neder-
137
samen vattinG
land tussen 1999 en 2012. De MIC voor azitromycine was significant vaker verhoogd bij 
isolaten die ook resistent zijn voor ciprofloxacine.
In Hoofdstuk 9 wordt een overzicht gegeven van de belangrijkste bevindingen van dit 
proefschrift. Ook worden de methodologische overwegingen, klinische implicaties van 
de studies gegeven en wordt stilgestaan bij perspectieven voor de toekomst. Indien 
we nog meer antibiotica gaan verliezen aan resistentie moeten we misschien ook bij 
buiktyfus terug vallen op ouderwetse antibiotica. Chlooramfenicol zou hier een voor-
beeld van kunnen zijn. Er wordt steeds meer bekend over de rol van het microbioom bij 
verschillende ziektebeelden. Mogelijk speelt het microbioom ook een belangrijke rol bij 
het krijgen van infecties en antibiotica resistentie. Er is echter meer onderzoek nodig om 
hier beter inzicht in te krijgen.
Vanwege de vele facetten die invloed hebben op antibiotica resistentie is het belangrijk 
om laboratorium-, klinisch- en epidemiologisch onderzoek te combineren om antibio-
tica resistentie te bestrijden.
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Promoveren was voor mij gelukkig geen vereiste om in opleiding te komen bij de af-
deling Interne Geneeskunde of Infectieziekten. Gemotiveerd door de internisten david 
OvErbOsCH en PErry van gEndErEn in het Havenziekenhuis Rotterdam, werd het voor 
mij als jonge arts-assistent echter al snel een hobby om artikelen te schrijven over bij-
zondere tropische ziektegevallen. Perry had gelukkig al snel door dat het slimmer was 
om je te concentreren op één onderwerp, zodat er later misschien een promotie uit 
zou kunnen volgen. Dit onderwerp werd buiktyfus, één van de meest fascinerende tro-
pische aandoeningen. Zo ligt de basis van dit proefschrift in werkzaamheden die tijdens 
nachtdiensten en vrije uurtjes thuis tijdens mijn opleiding tot internist werden ver-
richt. Toen ik klaar was met mijn opleiding tot internist-infectioloog waren onze hobby 
projecten nog onvoldoende voor een volwaardige promotie. Wil gOEssEns, moleculair 
bioloog, was inmiddels wel volledig geënthousiasmeerd door de resistentie mechanis-
men die voorkomen bij buiktyfus. Nu nog een hoogleraar. PrOFEssOr vErbOn, internist-
infectioloog, was de eerste die geloofde in ons project. Vol met goede ideeën regelde 
zij een samenwerking met de afdeling Epidemiologie van het Erasmus MC waarbij we 
het onderwerp werd uitgebreid naar de epidemiologische aspecten van antimicrobiële 
resistentie in het de Rotterdam Studie onder begeleiding van PrOFEssOr sTriCkEr. Uit-
eindelijk heb ik mij toch beperkt tot de darmbacteriën en is het voor mijn gevoel wel een 
echt eigen proefschrift gebleven, waarbij ik mij ook persoonlijk heb kunnen ontwikkelen 
op epidemiologisch en microbiologisch gebied. Ik wil daarom starten met het bedanken 
van mijn promotie team.
PErry van gEndErEn  Als jonge arts-assistent deden we al veel projecten samen, waarbij 
jij al snel een promotie voor ogen had. Uiteindelijk is dat de basis geweest voor een heel 
mooi promotie traject. Van jou heb ik artikelen leren schrijven, door snelle opbouwende 
kritiek. Jij voorspelde ook al vroeg een carrière voor mij in een groot ambitieus perifeer 
ziekenhuis. Ik ben blij dat ik jouw adviezen heb opgevolgd.
Wil gOEssEns  Als echte resistentie deskundige vanuit het laboratorium heb jij een be-
langrijke rol gehad bij deze promotie. De studies zijn door jou ideeën uiteindelijk zo de 
diepte ingegaan dat we een hoog niveau van de basale microbiologie hebben bereikt. 
Daarbij heb je mij wel regelmatig moeten helpen met achtergrond kennis. Ik zou bijna 
microbioloog willen worden…
PrOF. vErbOn  Beste Annelies, als afdelingshoofd heb je geen moment getwijfeld om 
ons promotie traject verder te begeleiden. Daar was een creatieve oplossing voor nodig 
door mij als internist bij de afdeling Epidemiologie ‘te stallen’. Achteraf is dat voor mij 
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het beste scenario gebleken, waarbij ik mij op wetenschappelijk gebied heb kunnen 
ontwikkelen en heb kunnen wennen aan een rol als internist-infectioloog. Bij proble-
men tijdens deze periode kon ik altijd bij jou terecht.
PrOF. sTriCkEr  Beste Bruno, bedankt voor deze unieke mogelijkheid om mij na mijn 
opleiding tot internist nog op wetenschappelijk gebied te kunnen ontwikkelen. Ik ben 
waarschijnlijk jou eerste en laatste medisch specialist op deze functie, omdat een com-
binatie van internist, promovendus, epidemiologie student, farmacovigilantie inspecteur 
en jonge vader misschien iets te veel was om er het maximale uit te halen. Achteraf ben 
ik echter heel tevreden met de inhoud van dit proefschrift en ben ik blij dat alle andere 
projecten waar we nog mee bezig waren zijn overgenomen door een zeer gemotiveerde 
promovendus marliEs muldEr. Bedankt voor de vrijheid die ik heb gekregen om eigen 
ideeën aan te dragen, waar jij altijd zeer goed commentaar op gaf terwijl het meestal 
niet jouw gebruikelijke onderwerpen betrof.
Graag wil ik PrOF. dr. m.P. grObusCH, PrOF. dr. H.P. EndTz, PrOF. dr. J.H. riCHardus, PrOF 
dr. J.l.C.m. van saasE, PrOF. dr. d.J. mEvius bedanken voor de kritische beoordeling van 
mijn proefschrift en de bereidheid om plaats te nemen in mijn promotie commissie.
Deelnemers van het Rotterdam Studie. Dank aan alle vrijwilligers die als studie popu-
latie het Rotterdam cohort mogelijk maken. Door jullie worden vele nuttige publicaties 
mogelijk gemaakt, waaronder één uit dit proefschrift.
Collega’s van de afdeling Epidemiologie. In het bijzonder mariEkE, TOkE, brEnda, kiki, 
nikkiE, raymOnd, daan en marTEn, bedankt voor de samenwerking en jullie hulp bij 
statistische analyses, waarbij jullie deze oude student moesten helpen.
Inspectie voor de Gezondheidszorg. Collega’s van het programma Geneesmiddelen en 
Medische Technologie, in het bijzonder maris, JudiTH, EdiTH, Janny, raJka en annEJET, 
bedankt voor de samenwerking en het mogelijk maken dit proefschrift.
marian TEn kaTE en aarT van dEr mEiJdEn. Bedankt voor jullie hulp in het laboratorium 
met de resistentie bepalingen. We konden altijd bij jullie terecht om onze Salmonella 
bacteriën uit de vriezer te halen voor aanvullende testen.
dik mEvius, WilFrid van PElT en kEEs vEldman van het RIVM en het Centraal Veterinair 
Instituut Lelystad van Wageningen UR. Dank voor het beschikbaar stellen van jullie Sal-
monella stammen en de samenwerking bij enkele publicaties.
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Collega’s van de afdeling Medische Microbiologie & Infectieziekten en de afdeling In-
wendige Geneeskunde van het Erasmus MC. Bedankt voor de goede opleiding en de 
mogelijkheid om 2 jaar lang mijn infectieziekten kennis op pijl te houden als internist-
infectioloog. Daar was wel enige flexibiliteit voor vereist in de roostering vanwege mijn 
vele andere werkzaamheden.
PrOFEssOr van saasE  Beste Jan, de opleider interne geneeskunde heeft altijd een bij-
zondere plaats. Ik was jou eerste coassistent in het Erasmus MC en een van de laatste 
die van jou het beroemde kunstwerk heeft gekregen als internist. Als coassistent heb 
ik definitief besloten om internist te woorden na jouw woorden ‘everyone is equal, but 
some are more equal than others’. Animal Farm van George Orwell was een van de 
boeken op mijn literatuurlijst. In dit boek heeft deze regel echter wel een hele andere 
betekenis. Tijdens de route van student naar internist is dit echter wel een terugkerend 
thema in het moderne competentie gericht opleiden. Hopelijk slaan we in de toekomst 
niet te veel door op dit gebied.
Collega’s van de afdeling Interne Geneeskunde van Rijnstate Arnhem en van Travel Clinic 
Oost Velp. Sinds januari 2015 ben ik met veel vreugde bij jullie werkzaam. Allemaal heel 
erg bedankt voor de fantastische start. Met jullie samenwerken voelde direct als thuis-
komen, al kom ik niet uit de regio. Hier in het oosten heerst de ambitie van het westen, 
maar ook de gemoedelijkheid van het zuiden. Ik heb het gevoel dat ik al helemaal deel 
uitmaak van jullie team.
‘Vrienden van het voetbal’. Na jaren samen KNVB competitie te hebben gespeeld in 
Rotterdam zijn we nog een paar jaar doorgegaan in een bedrijven competitie bij SDV. 
Dit was altijd een lekkere afwisseling van werk, promotie en gezinsleven. Aangezien de 
meeste voetballers ook studiegenoten waren, zaten er veel in hetzelfde schuitje met 
opleidingen en promoties. Ervaringen konden uitgebreid worden uitgewisseld tijdens de 
warming-up. Dat mis ik wel een beetje.
‘Vrienden uit Venlo’. Na 20 jaar vriendschap blijven we ondanks de afstand een hechte 
groep. Voor HErm, mijn paranimf, geldt dat inmiddels al bijna 30 jaar. Nu consulteren 
we elkaar soms zelfs voor (tropische) huidbeelden en hebben we een leuk stukje samen 
geschreven. Die activiteiten moeten we nu misschien weer eens oppakken.
Schoonfamilie. Lieve Carla, ruud, vinCEnT, WEndy, FElinE en JEns. Bedankt voor alle 
steun. Carla, jij hebt ons heel veel geholpen met oppassen en hulp thuis. Ruud, jij bent 
een goede hulp geweest met het beoordelen van Engelstalige medische teksten, sol-
licitatiebrieven en spontane wijze raad. Altijd handig om met Vincent een familielid bij 
een drukkerij te hebben.
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Familie. Lieve familie, als oudste uit een gezin met zes kinderen en twee artsen als 
ouders is er een hoop ambitieuze en emotionele dynamiek. Ik heb mijn best gedaan 
om een toekomst te zoeken buiten de geneeskunde, maar het plezier van mijn ouders 
in hun werk heeft mij toch doen besluiten dezelfde weg te kiezen. PaP, jouw goedwil-
lende strategische adviezen hebben mij zeker geholpen tijdens mijn loopbaan. mam, 
jij bent een echte internist die voor de kinderen heeft gekozen. Toen ik 11 was en een 
beroepskeuze in moest vullen bij de middelbare school was het ‘internist net als mijn 
moeder’, zonder te weten wat dat inhield. Maar als twee handen op één buik moest dat 
wel een goede keuze zijn. Nu vind ik het heel mooi dat ik jouw ambities als internist door 
kan zetten op mijn eigen manier. Bedankt voor jullie onvoorwaardelijke steun en ver-
trouwen. CarliJnE, mijn paranimf, jij was de eerste die in de familie promoveerde. Dus 
toen moesten er meer gaan volgen. Als enige andere arts onder de kinderen hebben wij 
veel gemeenschappelijke ervaringen om over praten. Al blijft het wel Amsterdam tegen 
Rotterdam. annE-rOOs, jij hebt het andere gezinnetje in de familie met daan, vEsPEr 
en axEl. Ondanks de afstand is het heel leuk dat onze kinderen al echte maatjes aan 
het worden zijn. riannE-FlEur, jij kan met THOm ook al volledig door als een gezin. Voor 
ons altijd een warme plek om te bezoeken. Dan komen we toch weer een beetje thuis 
in Rotterdam. JOriCk, mijn enige broertje, met jou was het leeftijdsverschil te groot om 
vroeger veel samen te doen. Het is daarom ook zo uniek dat we tijdens mijn laatste jaar 
in Rotterdam voor het eerst in hetzelfde voetbalteam hebben gespeeld. Het was voor 
mij een afbouwjaar en jouw fysieke hoogtepunt. JasmiJn, alias ‘mini’, door jouw enorme 
diepgang in de moleculaire microbiologie van gisten ben jij een gevreesde sparringpart-
ner geworden. Mocht je na je studie doorgaan in de microbiologie dan denk ik dat ik het 
snel af ga leggen, maar dan kan ik je nog wel in de maling blijven nemen. 
Tot slot. Lieve laura, met rubEn en CarO hebben wij ons perfecte gezinnetje. Samen 
voor ons gezin zorgen, contact met de familie en allebei als arts werken is voor ons het 
belangrijkste in het leven. Dan blijft er soms weinig tijd over voor andere dingen. Omdat 
wij zo’n goed team samen vormen leidt dat eigenlijk nooit tot problemen. Deze rustige 
stabiele basis is noodzakelijk voor een proefschrift waar ook veel thuis aan is gewerkt. 
Veel dank daarvoor. Nu we onze liefde kunnen delen met onze prachtige kindjes maakt 
dat onze band alleen maar sterker. Op naar een mooie toekomst samen. Ik hou van jullie.
147
about tHe autHoR
rObErT-Jan Hassing was born on the 23rd of September 1980, in Utrecht, the Nether-
lands. He grew up in Venlo and graduated from Secondary School at Thomas College 
Venlo in 1999. That year he started the study Medicine at the Erasmus University of 
 Rotterdam. His finalizing internships were Tropical Medicine in Newala District Hos-
pital in Tanzania and Internal Medicine and Travel Medicine in the Havenziekenhuis 
Rotterdam, before he graduated in 2005. During his internships he generated a great 
interest for Internal Medicine and Infectious Diseases. After one year as a resident in 
Internal Medicine at the Havenziekenhuis, he continued his specialized training Internal 
Medicine and Infectious Diseases at the Havenziekenhuis (dr. P.J. Wismans) and subse-
quently at the Erasmus MC Rotterdam (PrOF.dr. J. l. C. m. van saasE & dr. J. l. nOuWEn) 
from January 2007 until January 2013. In 2013 he worked in Suriname for four months, 
together with his wife, both as a resident. During his specialisation he participated in 
many studies concerning typhoidal Salmonella infections. From January 2013 until Jan-
uary 2015 he worked as a PhD candidate at the department of Epidemiology at the 
Erasmus MC, as a Pharmacovigilance Inspector at the Health Care Inspectorate in The 
Hague (PrOF. dr. b. H. CH. sTriCkEr) and as a Infectious Diseases specialist at the Eras-
mus MC (PrOF. dr. a. vErbOn). In 2014 he obtained the Master of Science degree in Clini-
cal Epidemiology. Since January 2015 he is a staff member of the department of Internal 
Medicine of Rijnstate Hospital in Arnhem. Robert-Jan is married to laura vErmEEr and 
they live in Arnhem together with their beautiful children rubEn and CarO.



